<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Skin care interventions in infants for preventing eczema and food allergy - Kelleher, MM - 2022 | Cochrane Library</title> <meta content="Skin care interventions in infants for preventing eczema and food allergy - Kelleher, MM - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013534.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Skin care interventions in infants for preventing eczema and food allergy - Kelleher, MM - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013534.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013534.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Skin care interventions in infants for preventing eczema and food allergy" name="citation_title"/> <meta content="Maeve M Kelleher" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Rachel Phillips" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Sara J Brown" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Suzie Cro" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Victoria Cornelius" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Karin C Lødrup Carlsen" name="citation_author"/> <meta content="Håvard O Skjerven" name="citation_author"/> <meta content="Oslo University Hospital" name="citation_author_institution"/> <meta content="Eva M Rehbinder" name="citation_author"/> <meta content="Adrian J Lowe" name="citation_author"/> <meta content="University of Melbourne" name="citation_author_institution"/> <meta content="Eishika Dissanayake" name="citation_author"/> <meta content="University of Wisconsin School of Medicine and Public Health" name="citation_author_institution"/> <meta content="Naoki Shimojo&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Chiba University" name="citation_author_institution"/> <meta content="Kaori Yonezawa" name="citation_author"/> <meta content="Graduate School of Medicine, The University of Tokyo" name="citation_author_institution"/> <meta content="Yukihiro Ohya" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Kiwako Yamamoto-Hanada" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Kumiko Morita" name="citation_author"/> <meta content="Keio University School of Medicine" name="citation_author_institution"/> <meta content="Emma Axon" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Michael Cork" name="citation_author"/> <meta content="The University of Sheffield" name="citation_author_institution"/> <meta content="Alison Cooke" name="citation_author"/> <meta content="The University of Manchester" name="citation_author_institution"/> <meta content="Eleanor Van Vogt" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Jochen Schmitt" name="citation_author"/> <meta content="Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden" name="citation_author_institution"/> <meta content="Stephan Weidinger" name="citation_author"/> <meta content="University Hospital Scheswig-Holstein" name="citation_author_institution"/> <meta content="Danielle McClanahan" name="citation_author"/> <meta content="Oregon Health &amp; Science University" name="citation_author_institution"/> <meta content="Eric Simpson" name="citation_author"/> <meta content="Oregon Health &amp; Science University" name="citation_author_institution"/> <meta content="Lelia Duley" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Lisa M Askie" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Hywel C Williams" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Robert J Boyle" name="citation_author"/> <meta content="r.boyle@nhs.net" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013534.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013534.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013534.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013534.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Allergens [therapeutic use]; Cattle; *Eczema [drug therapy, prevention &amp; control]; Emollients [therapeutic use]; *Food Hypersensitivity [prevention &amp; control]; *Milk Hypersensitivity" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013534.pub3&amp;doi=10.1002/14651858.CD013534.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013534\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013534\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","ja","fa","fr","pl","ro"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD013534.pub3",title:"Skin care interventions in infants for preventing eczema and food allergy",firstPublishedDate:"Nov 14, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013534.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013534.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013534.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013534.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013534.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013534.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013534.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013534.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013534.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013534.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13225 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013534.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/appendices#CD013534-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/supinfo/CD013534StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/supinfo/CD013534StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Skin care interventions in infants for preventing eczema and food allergy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0004">Maeve M Kelleher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0005">Rachel Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0006">Sara J Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0007">Suzie Cro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0008">Victoria Cornelius</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0009">Karin C Lødrup Carlsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0010">Håvard O Skjerven</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0011">Eva M Rehbinder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0012">Adrian J Lowe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0013">Eishika Dissanayake</a></li> <li class="author custom-tooltip" title="During the course of the review, Prof. Shimojo retired from Department of Pediatrics, Graduate School of Medicine, and now works at the Center for Preventive Medical Sciences, Chiba University."><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0014">Naoki Shimojo</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0015">Kaori Yonezawa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0016">Yukihiro Ohya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0017">Kiwako Yamamoto-Hanada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0018">Kumiko Morita</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0019">Emma Axon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0020">Michael Cork</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0021">Alison Cooke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0022">Eleanor Van Vogt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0023">Jochen Schmitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0024">Stephan Weidinger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0025">Danielle McClanahan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0026">Eric Simpson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0027">Lelia Duley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0028">Lisa M Askie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0029">Hywel C Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information#CD013534-cr-0030"><i class="icon corresponding-author fa fa-envelope"></i>Robert J Boyle</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information/en#CD013534-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013534.pub3">https://doi.org/10.1002/14651858.CD013534.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013534-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013534-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013534-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013534-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013534-abs-0009">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013534-abs-0001" lang="en"> <section id="CD013534-sec-0001"> <h3 class="title" id="CD013534-sec-0001">Background</h3> <p>Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective for preventing eczema or food allergy. </p> </section> <section id="CD013534-sec-0002"> <h3 class="title" id="CD013534-sec-0002">Objectives</h3> <p><b>Primary objective</b> </p> <p>To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants. </p> <p><b>Secondary objective</b> </p> <p>To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy. </p> </section> <section id="CD013534-sec-0003"> <h3 class="title" id="CD013534-sec-0003">Search methods</h3> <p>We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned conference proceedings to identify further references to relevant randomised controlled trials (RCTs).  </p> </section> <section id="CD013534-sec-0004"> <h3 class="title" id="CD013534-sec-0004">Selection criteria</h3> <p>We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (&gt; 37 weeks) infants (≤ 12 months) without pre‐existing eczema, food allergy, or other skin condition. Eligible comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow‐up was required. </p> </section> <section id="CD013534-sec-0005"> <h3 class="title" id="CD013534-sec-0005">Data collection and analysis</h3> <p>This is a prospective individual participant data (IPD) meta‐analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin (Ig)E‐mediated food allergy by one to three years, both measured at the closest available time point to two years. Secondary outcomes included adverse events during the intervention period; eczema severity (clinician‐assessed); parent report of eczema severity; time to onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen. </p> </section> <section id="CD013534-sec-0006"> <h3 class="title" id="CD013534-sec-0006">Main results</h3> <p>We identified 33 RCTs comprising 25,827 participants. Of these, 17 studies randomising 5823 participants reported information on one or more outcomes specified in this review.  We included 11 studies, randomising 5217 participants, in one or more meta‐analyses (range 2 to 9 studies per individual meta‐analysis), with 10 of these studies providing IPD; the remaining 6 studies were included in the narrative results only.   </p> <p>Most studies were conducted at children's hospitals. Twenty‐five studies, including all those contributing data to meta‐analyses, randomised newborns up to age three weeks to receive a skin care intervention or standard infant skin care. Eight of the 11 studies contributing to meta‐analyses recruited infants at high risk of developing eczema or food allergy, although the definition of high risk varied between studies. Durations of intervention and follow‐up ranged from 24 hours to three years. All interventions were compared against no skin care intervention or local standard care. Of the 17 studies that reported information on our prespecified outcomes, 13 assessed emollients. </p> <p>We assessed most of the evidence in the review as low certainty and had some concerns about risk of bias. A rating of some concerns was most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement but was judged unlikely to have done so. We assessed the evidence for the primary food allergy outcome as high risk of bias due to the inclusion of only one trial, where findings varied based on different assumptions about missing data. </p> <p>Skin care interventions during infancy probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate‐certainty evidence; 3075 participants, 7 trials) or time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate‐certainty evidence; 3349 participants, 9 trials). Skin care interventions during infancy may increase the risk of IgE‐mediated food allergy by one to three years of age (RR 2.53, 95% CI 0.99 to 6.49; low‐certainty evidence; 976 participants, 1 trial) but may not change risk of allergic sensitisation to a food allergen by age one to three years (RR 1.05, 95% CI 0.64 to 1.71; low‐certainty evidence; 1794 participants, 3 trials). Skin care interventions during infancy may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61; low‐certainty evidence; 1171 participants, 1 trial); however, this was only seen for cow’s milk, and may be unreliable due to over‐reporting of milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR 1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate‐certainty evidence; 2728 participants, 6 trials) and may increase the risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low‐certainty evidence; 2538 participants, 4 trials) and stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low‐certainty evidence; 343 participants, 4 trials), although CIs for slippages and stinging/allergic reactions were wide and include the possibility of no effect or reduced risk. </p> <p>Preplanned subgroup analyses showed that the effects of interventions were not influenced by age, duration of intervention, hereditary risk, filaggrin (<i>FLG</i>) mutation, chromosome 11 intergenic variant rs2212434,<b><i> </i> </b>or classification of intervention type for risk of developing eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions influenced the relationship between skin care interventions and eczema or food allergy development. </p> </section> <section id="CD013534-sec-0007"> <h3 class="title" id="CD013534-sec-0007">Authors' conclusions</h3> <p>Based on low‐ to moderate‐certainty evidence, skin care interventions such as emollients during the first year of life in healthy infants are probably not effective for preventing eczema; may increase risk of food allergy; and probably increase risk of skin infection. Further study is needed to understand whether different approaches to infant skin care might prevent eczema or food allergy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013534-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013534-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013534-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013534-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013534-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013534-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013534-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013534-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013534-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD013534-abs-0012">Română</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013534-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013534-abs-0002" lang="en"> <h3>Skin care interventions for preventing eczema and food allergy</h3> <p><b>Does moisturising baby skin prevent eczema or food allergies?</b> </p> <p><b>Key messages</b> </p> <p>Skin care treatments in babies, such as using moisturisers on the skin during the first year of life, probably do not prevent babies from developing eczema; may increase the chance of food allergy; and probably increase the chance of skin infection. This review looked at the prevention of eczema and food allergy only. Skin care treatments are still important to treat eczema.  </p> <p><b>What are allergies?</b> </p> <p>An immune response is how the body recognises and defends itself against substances that appear harmful. An allergy is a reaction of the body's immune system to a particular food or substance (an allergen) that is usually harmless. Different allergies affect different parts of the body, and their effects can be mild or serious. </p> <p><b>Food allergies and eczema</b> </p> <p>Eczema is a common skin condition  that causes dry, itchy, cracked skin. Eczema is common in children, often developing before their first birthday, and may be long‐lasting. </p> <p>Allergies to food can cause itching in the mouth, a raised itchy red rash, swelling of the face, stomach symptoms, or difficulty breathing. They usually happen within two hours after a food is eaten. </p> <p>People with food allergies often have other allergic conditions, such as asthma, hay fever, and eczema. </p> <p><b>Why we did this Cochrane Review</b> </p> <p>We wanted to learn how skin care affects the risk of a baby developing eczema or food allergies. Skin care treatments included: </p> <p>• putting moisturisers on a baby's skin;</p> <p>• bathing babies with water containing moisturisers or moisturising oils;</p> <p>• advising parents to use less soap, or to bathe their child less often;</p> <p>• using water softeners. </p> <p>We also wanted to know if these skin care treatments cause any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies of different types of skin care for healthy babies (aged up to one year) with no previous food allergy, eczema, or other skin condition. </p> <p><b>Search date:</b> we incorporated evidence published up to July 2021. </p> <p>We were interested in studies that reported:</p> <p>• how many children developed eczema, or food allergy, by age one to three years;</p> <p>• how severe the eczema was (according to a researcher and to parents);</p> <p>• how long it took for eczema to develop;</p> <p>• parents' reports of immediate (under two hours) reactions to a food allergen;</p> <p>• how many children developed sensitivity to a particular food allergen;</p> <p>• any unwanted effects.</p> <p>We assessed the strengths and weaknesses of each study to determine how reliable the results might be, and then combined the results of the relevant studies and looked at overall effects.   </p> <p><b>What we found</b> </p> <p>We found 33 studies, involving 25,827 babies, that assessed any type of skin intervention. The included studies took place in Europe, Australia, Japan, and the USA, most often at children's hospitals. Skin care was compared against no skin care or usual skin care for babies in that country. Treatment and follow‐up times ranged from 24 hours to three years. Many studies (13) tested the use of moisturisers; the other studies mainly tested the use of bathing and cleansing products and how often they were used. </p> <p>Of the 33 included studies, only 11 studies had comparable outcomes of eczema, food allergy, or adverse effects and were combined for analysis. All of these studies enrolled babies before they were one month old, and  eight of these studies included babies thought to be at high risk for developing eczema.  </p> <p><b>What are the main results of our review?</b> </p> <p>Compared to no skin care or standard care, moisturisers:</p> <p>• probably do not change the chance of developing eczema by age one to three years (7 studies; 3075 babies), or the time needed for eczema to develop (9 studies; 3349 babies); </p> <p>• may increase the chance of developing a food allergy as judged by a researcher (1 study; 976 babies) by age one to three years; </p> <p>• may slightly increase the number of immediate reactions to a common food allergen at two years, as reported by parents (1 study; 1171 babies); </p> <p>• probably cause more skin infections (6 studies; 2728 babies);</p> <p>• may increase unwanted effects, such as a stinging feeling or an allergic reaction to moisturisers (4 studies; 343 babies); </p> <p>• may increase the chance of babies slipping (4 studies; 2538 babies);</p> <p>• may not affect the chance of developing sensitivity to food allergens (3 studies; 1797 babies) by age one to three years. </p> <p><b>Confidence in our results</b> </p> <p>We are moderately confident in our results for developing eczema and the time needed to develop eczema. We are less confident about our results for food allergy or sensitivity, which are based on small numbers of studies with widely varying results. These results are likely to change when more evidence becomes available. Our confidence in the review findings for skin infections is moderate, but low for stinging or allergic reactions and slipping.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013534-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013534-sec-0098"></div> <h3 class="title" id="CD013534-sec-0099">Implications for practice</h3> <section id="CD013534-sec-0099"> <p>We found, based on low‐ to moderate‐certainty evidence, that skin care interventions such as emollients probably do not influence the development or time to onset of eczema in healthy term infants by age one to three years; may increase risk of food allergy; and probably increase the risk of skin infection. This suggests that regular application of emollients or other similar skin care interventions is probably not beneficial for healthy infants, unless there are other specific reasons for using such products. This information should be taken into account by guideline developers in this field. Given the probable increase in local skin infection risk, it may be important for carers to practise appropriate hygiene measures when applying emollients to the skin of infants. </p> <p>We were unable to draw any firm conclusions about the impact of skin care interventions on immunoglobulin E (IgE)‐mediated food allergy by age one to three years, but the available evidence suggests that they may increase risk of food allergy based on low‐certainty evidence. Low‐certainty evidence from one trial suggests that skin care interventions may slightly increase parent reports of immediate food allergy (to a common allergen) at two years. However, this outcome was only detected for cow’s milk, which may be unreliable as a measure due to the commercially influenced over‐reporting of cow's milk allergy in infants. Evidence suggests that skin care interventions may not change risk of food sensitisation by age one to three years (low‐certainty evidence). The gold standard for diagnosing food allergy is an oral food challenge; however, these are costly and time‐consuming for participants and trialists. Alternative modes of diagnosis of food allergy, by standardised questionnaires and documented sensitisation, or even by more complex methods such as basophil activation test, may be considered in further trials. </p> <p>Infant slippages and stinging/allergic reactions to moisturisers may increase with the use of skin care interventions during infancy (low‐certainty evidence), although confidence intervals for slippages and stinging/allergic reactions were wide and included the possibility of no effect or reduced risk. All results presented here are in comparison to standard care. </p> <p>Subgroup analysis showed that age, hereditary risk, filaggrin (<i>FLG</i>) mutation, duration of intervention, and classification of intervention type did not affect the risk of developing eczema. We could not evaluate these effects for food allergy risk. We do not know if adherence to treatment affects the relationship between skin care interventions and risk of developing eczema or food allergy. </p> <p>The common clinical practice of applying emollients to the skin of people who already have eczema is not directly affected by our findings. </p> </section> <h3 class="title" id="CD013534-sec-0100">Implications for research</h3> <section id="CD013534-sec-0100"> <p>In this review, the trials with eczema as an outcome were mainly emollient trials. Other methods of skin barrier intervention in this review had very short follow‐up and did not measure eczema as an outcome, so their impact on eczema remains unclear. Potential future studies on bathing practices should have longer follow‐up of clinical outcomes and use standard methods of eczema measurement. Trialists may wish to consider using novel interventions that impact skin barrier function, rather than those that have already been evaluated in these trials. </p> <p>We were unable to identify with confidence whether skin care interventions such as emollients affect the risk of developing food allergy. More research is needed to identify whether food allergy risk is influenced by early skin care practices. Future trials should measure food allergy using a robust outcome assessment (<a href="./references#CD013534-bbs2-0231" title="AsaiJ , MartinoD , EiweggerT , NadeauK , KoppelmanGH , ClarkeAE , et al. Phenotype consensus is required to enable large‐scale genetic consortium studies of food allergy. Allergy2020;75:2383-7. [DOI: 10.1111/all.14333]">Asai 2020</a>), and researchers may wish to consider applying published algorithms to evaluate food allergy outcomes in participants who do not undergo oral food challenge (<a href="./references#CD013534-bbs2-0286" title="KelleherMM , JayN , PerkinMR , HainesRH , BattR , BradshawLE , et al. An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge. Clinical and Experimental Allergy2020;50:334-42.">Kelleher 2020b</a>). We can infer from the paucity of oral food challenge‐diagnosed food allergy outcomes in this meta‐analysis that oral food challenges are difficult to conduct and are infrequently attended in prevention studies. We suggest that future studies incorporate Core Outcome Measures for Food Allergy (COMFA). </p> <p>We were unable to draw any conclusions on adherence to intervention, and would suggest that future studies carefully document adherence and compliance with interventions. Also, collaboration between groups regarding future potential studies may allow for larger numbers with less imprecision. </p> <p>This review focused on the primary prevention of eczema and food allergy, preventing the diagnosis of eczema and food allergy in infants. Given the strong links between early‐onset eczema and food allergy, another body of work has begun on secondary prevention of food allergy amongst infants already diagnosed with eczema. These trials, <a href="./references#CD013534-bbs2-0163" title="NCT03742414. Seal, stopping atopic dermatitis and allergy study. clinicaltrials.gov/ct2/show/NCT03742414 (first received 15 November 2018). ">NCT03742414</a> and <a href="./references#CD013534-bbs2-0337" title="UMIN000028043. Early aggressive intervention for infantile atopic dermatitis to prevent development of food allergy: a multicenter, investigator-blinded, randomized, parallel group controlled trial. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031912 (first received 4 July 2017).">UMIN000028043</a>, include infants younger than 13 weeks with diagnosed eczema who are randomised to active eczema management from onset with emollient and topical corticosteroids. Both studies have IgE‐mediated food allergy as a primary outcome and are ongoing. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013534-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013534-sec-0008"></div> <div class="table" id="CD013534-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Skin care intervention compared to standard skin care or no skin care intervention for the prevention of eczema and food allergy</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Patient or population: infants age 12 months or younger</b> </p> <p><b>Setting: prevention</b> </p> <p><b>Intervention: skin care intervention</b> </p> <p><b>Comparison: standard skin care or no skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> <br/> <br/> <br/> <br/> <br/>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema diagnosis by 1 to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000 (122 to 197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (0.81 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3075 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a sensitivity analysis that included studies that measured eczema using Hanifin and Rajka, or UK Working Party methods only, total N = 2919 (6), the pooled treatment effect for eczema by 1 to 2 years was RR 1.02, 95% CI 0.78 to 1.34.  In a separate sensitivity analysis including studies rated as low risk of bias only, total N = 1739 (3), the pooled treatment effect for eczema by 1 to 2 years was RR 0.97, 95% CI 0.81 to 1.17. In sensitivity analysis using a 3‐year eczema outcome instead of a 1‐year eczema outcome from 1 trial, the pooled treatment effect for eczema by 1 to 3 years was RR 1.00, 95% CI 0.88 to 1.14. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IgE‐mediated food allergy (oral food challenge) by 1 to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000 (50 to 335)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (0.99 to 6.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>976 (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a sensitivity analysis that examined IgE‐mediated food allergy as measured by oral food challenge or based on a panel assessment of clinical history and/or allergic sensitisation by 1 to 3 years, total N = 2081 (2), the pooled treatment effect was RR 1.45, 95% CI 0.98 to 2.15. For parent report of a doctor diagnosis of food allergy at 1 to 3 years, total N = 1614 (3), the pooled treatment effect was RR 1.02, 95% CI 0.80 to 1.31. No low risk of bias sensitivity analysis was possible. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slippages (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000 (14 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.42 (0.67 to 2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2538 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin infection (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000 (51 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33 (1.01 to 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2728 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stinging/allergic reactions to moisturisers (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000 (27 to 298) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.24 (0.67 to 7.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 343 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to onset of eczema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27.9 months (21.1 to 36.9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.86 (0.65 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3349 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent report of immediate reaction to common food allergen (at 2 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000 (160 to 258)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (1.00 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1171 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic sensitisation to a food allergen (at 1 to 3 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000 (58 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05 (0.64 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1794 (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI, confidence interval; HR, hazard ratio; IgE, immunoglobulin E; RR risk ratio</p> <p><sup>a</sup>Downgraded one level for heterogeneity driven by one trial (PreventADALL) contributing 21.8% of the weight of the analysis; a clear explanation for this heterogeneity could not be identified. PreventADALL used a bathing intervention, whereas the other trials used direct emollient application to the skin; PreventADALL also initiated treatment later than the other trials. There was no significant heterogeneity in a sensitivity analysis using the 3‐year outcome instead of the 1‐year outcome from the PreventADALL study (Analysis 1.5).<br/><sup>b</sup>Downgraded one level for overall risk of bias due to missing outcome data (29%) and one level for imprecision due to small numbers of events from a single study, with wide confidence intervals including both a harmful effect and no effect. There was increased information for the sensitivity analysis of food allergy diagnosed by oral food challenge or investigator assessment, where overall risk of bias was assessed as 'some concerns' and confidence intervals were narrower. <br/><sup>c</sup>Downgraded by two levels for imprecision due to small numbers of events, with wide confidence intervals including both a harmful effect and a beneficial effect.<br/><sup>d</sup>Downgraded by one level for imprecision due to wide confidence intervals including both a harmful effect and no effect.<br/><sup>e</sup>Downgraded one level for heterogeneity driven by more than one trial, for which a plausible explanation could not be identified.<br/><sup>f</sup>Downgraded two levels for imprecision due to small numbers of events from a single study, with wide confidence intervals including both a harmful effect and no effect.<br/><sup>g</sup>Downgraded one level for heterogeneity, for which a plausible explanation could not be identified, and one level for imprecision due to wide confidence intervals including both a harmful and a beneficial effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013534-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013534-sec-0009"></div> <p>See <a href="#CD013534-tbl-0002">Table 1</a> for explanations of specific terms used in this review. </p> <div class="table" id="CD013534-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adolescence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A period in development, roughly between ages 10 and 19 years, between onset of puberty and acceptance of adult identity and behaviour </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic (atopic) march</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Typical pattern of onset of allergic disease from eczema, to food allergy, to asthma and allergic rhinitis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhinitis is a group of symptoms affecting the nose, typically by sneezing, itching, or congestion. Allergic rhinitis occurs when these symptoms are due to environmental allergies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic sensitisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demonstrated by a positive skin prick test of specific IgE to a known allergen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute, potentially life‐threatening immediate reaction to an allergen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angio‐oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pronounced swelling of the deep dermis, subcutaneous or submucosal tissue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atopic dermatitis</p> <p>(atopic eczema)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema with IgE sensitisation, either by IgE antibody or by skin prick test, is classified as atopic eczema. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genetic predisposition to develop allergic diseases such as eczema, food allergy, asthma, and allergic rhinitis, which is often associated with the production of IgE antibodies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceramides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lipid (fatty) molecules found in the lipid bilayer of the intercellular matrix</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complex chronic skin condition characterised by itch, a form of dermatitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gene encoding for filaggrin, a filament‐binding protein in the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A period of worsening of eczema signs and symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Can be IgE‐mediated or non‐IgE‐mediated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food sensitisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Production of IgE to a food, in the form of a positive skin prick test or immunoglobulin E; may not equate to food allergy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Humectant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or product that draws water towards it</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunoglobulin E (IgE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class of antibody that plays a key role in allergic disease. Signs and symptoms of IgE‐mediated disease include urticaria, angio‐oedema, wheeze, and anaphylaxis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A baby in the first year of life</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhalant allergen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergen that typically enters the immune system via the respiratory tract and is airborne, such as house dust mite or pollen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intergenic locus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A stretch of DNA sequences located between genes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mast cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Granular basophil cell present in connective tissue that releases histamine and other mediators in allergic reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A baby in the first 28 days of life</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observable characteristics from an interaction between genes and the environment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In statistics, refers to the number of cases of a disease, present in a particular population at a given time </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined by the World Health Organization as individuals' perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transepidermal water loss (TEWL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive measurement of water loss across the epidermis used as a measure of skin barrier function </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urticaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash that is a transient erythematous itchy swelling of skin</p> </td> </tr> </tbody> </table> </div> <section id="CD013534-sec-0010"> <h3 class="title" id="CD013534-sec-0010">Description of the condition</h3> <p>Allergic diseases such as eczema and food allergy are some of the most common long‐term health conditions in children and young people (<a href="./references#CD013534-bbs2-0233" title="BaiG , HertenMH , LandgrafJM , KorfageIJ , RaatH . Childhood chronic conditions and health-related quality of life: findings from a large population-based study. PLOS ONE2017;12(6):e0178539.">Bai 2017</a>; <a href="./references#CD013534-bbs2-0338" title="Van CleaveJ , GortmakerSL , PerrinJM . Dynamics of obesity and chronic health conditions among children and youth. JAMA2010;303(7):623-30.">Van Cleave 2010</a>). There is no definitive cure for allergic disease, although treatments can be used to alleviate symptoms. The burden of allergic disease on the individual, the family, and society is significant (<a href="./references#CD013534-bbs2-0270" title="GuptaR , SheikhA , StrachanDP , AndersonHR . Burden of allergic disease in the UK: secondary analyses of national databases. Clinical &amp; Experimental Allergy2004;34(4):520-6.">Gupta 2004</a>; <a href="./references#CD013534-bbs2-0303" title="PawankarR . Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organization Journal2014;7(1):12.">Pawankar 2014</a>). The prevalence of allergic disease appears to have increased; traditionally, higher prevalence was seen in high‐income countries, but prevalence of allergic disease is now increasing in urban cities of low‐ and middle‐income countries (<a href="./references#CD013534-bbs2-0253" title="DeckersIA , McLeanS , LinssenS , MommersM , Van SchayckCP , SheikhA . Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLOS ONE2012;7(7):e39803.">Deckers 2012</a>; <a href="./references#CD013534-bbs2-0309" title="PrescottSL , PawankarR , AllenKJ , CampbellDE , Sinn JKh, FiocchiA , et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organization Journal2013;6(1):21.">Prescott 2013</a>). </p> <p>Eczema is a chronic inflammatory skin disorder, diagnosed clinically based on a collection of symptoms, primarily including itch. Its aetiology is complex and involves interaction between genes, environment, the immune system, and impairment of the skin barrier (<a href="./references#CD013534-bbs2-0287" title="LeungDY , BoguniewiczM , HowellMD , NomuraI , HamidQA . New insights into atopic dermatitis. Journal of Clinical Investigation2004;113(5):651-7.">Leung 2004</a>). Eczema with immunoglobulin (Ig)E sensitisation, either by IgE antibody or by skin prick test, is classified as atopic eczema (<a href="./references#CD013534-bbs2-0284" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. Journal of Allergy and Clinical Immunology2003;113(5):832-6.">Johansson 2003</a>). This review is focused on prevention of eczema and food allergy in infants and children and does not address adult‐onset eczema, which has different associations from childhood atopic eczema (<a href="./references#CD013534-bbs2-0226" title="AbuabaraK , YeM , McCullochCE , SullivanA , MargolisDJ , StrachanDP , et al. Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. Journal of Allergy and Clinical Immunology2019;144(3):710-9.">Abuabara 2019</a>). Likewise, this review did not address adult‐onset food allergy, which accounts for a small proportion of food allergy amongst adults, where there is a loss of tolerance to a food that was previously tolerated (<a href="./references#CD013534-bbs2-0310" title="RameshM , LiebermanJ . Adult-onset food allergies. Annals of Allergy, Asthma &amp; Immunology2017;119(2):111-9. [DOI: 10.1016/j.anai.2017.05.014]">Ramesh 2017</a>). </p> <p>Atopic eczema (atopic dermatitis) is most often associated with other atopic diseases and typically presents in younger children, and may be the first step along the so‐called 'allergic march' (<a href="./references#CD013534-bbs2-0287" title="LeungDY , BoguniewiczM , HowellMD , NomuraI , HamidQA . New insights into atopic dermatitis. Journal of Clinical Investigation2004;113(5):651-7.">Leung 2004</a>). Eczema often occurs in families with atopic diseases such as asthma, allergic rhinitis/hay fever, and food allergy. These diseases share a common pathogenesis and are frequently present in the same individual and family. The word 'atopy' refers to the tendency to produce IgE antibodies in response to small quantities of common environmental proteins such as pollen, house dust mites, and food allergens (<a href="./references#CD013534-bbs2-0326" title="StoneKD . Atopic diseases of childhood. Current Opinion in Pediatrics2002;145(5):634-46.">Stone 2002</a>; <a href="./references#CD013534-bbs2-0331" title="ThomsenSF . Epidemiology and natural history of atopic diseases. European Clinical Respiratory Journal2015;2(1):24642.">Thomsen 2015</a>). Around 30% of people with eczema develop asthma, and 35% develop allergic rhinitis (<a href="./references#CD013534-bbs2-0340" title="van derHulstAE , KlipH , BrandPL . Risk of developing asthma in young children with atopic eczema: a systematic review. Journal of Allergy and Clinical Immunology2007;120(3):565-9. [PMID: 17655920]">van der Hulst 2007 </a>). However, it is understood that atopy does not concurrently occur in all people with atopic eczema. In view of this, it has been proposed that the term 'eczema' should be used to define people both with and without atopy. In agreement with the 'Revised nomenclature for allergy for global use' (<a href="./references#CD013534-bbs2-0284" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. Journal of Allergy and Clinical Immunology2003;113(5):832-6.">Johansson 2003</a>), and similar to other Cochrane Reviews evaluating eczema therapies (<a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a>), we use the term 'eczema' throughout the review<i>.</i> </p> <p>The main mechanism of this disease is the combination of an epidermal barrier function defect and cutaneous inflammation. Barrier dysfunction can be attributed in part to a genetic susceptibility, such as a mutation in the filaggrin gene (<i>FLG</i>). Cutaneous inflammation is demonstrated by inflammatory cell infiltration of the dermis, predominantly by Th2 cells (<a href="./references#CD013534-bbs2-0346" title="WeidingerS , NovakN . Atopic dermatitis. Lancet2016;387(10023):1109-22.">Weidinger 2016</a>). </p> <p>Eczema is diagnosed clinically by its appearance and predilection for certain skin sites, which is age‐dependent (<a href="./references#CD013534-bbs2-0322" title="SpergelJM , PallerAS . Atopic dermatitis and the atopic march. Journal of Allergy and Clinical Immunology2003;112(6 Suppl):S118-27.">Spergel 2003</a>). In a research setting, the most commonly used diagnostic criteria are the UK Working Party Diagnostic Criteria for Atopic Dermatitis (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>). Prevalence of eczema is reported at up to 20% in children, and may be increasing (<a href="./references#CD013534-bbs2-0266" title="FlohrC , MannJ . New insights into the epidemiology of childhood atopic dermatitis. Allergy2014;69(1):3-16.">Flohr 2014</a>). Eczema has a significant impact on the patient and the family. In childhood, eczema is often associated with sleep disturbance and behavioural difficulties. Eczema also significantly impacts the quality of life of parents of affected children. Partaking in their child's treatment can take up to two hours per day, and their own sleep is often disturbed along with their child's, thereby exacerbating the distress experienced (<a href="./references#CD013534-bbs2-0240" title="CarrollCL , BalkrishnanR , FeldmanSR , FleischerAB , ManuelJC . The burden of atopic dermatitis: impact on the patient, family, and society. Pediatric Dermatology2005;22(3):192-9.">Carroll 2005</a>). The impact of moderate to severe eczema on family dynamics is comparable to that of other chronic health conditions such as type 1 diabetes (<a href="./references#CD013534-bbs2-0329" title="SuJC , KempAS , VarigosGA , NolanTM . Atopic eczema: its impact on the family and financial cost. Archives of Disease in Childhood1997;76(2):159-62.">Su 1997</a>). The financial cost of childhood eczema incorporates both the direct cost of the child's care and the indirect costs of parental time off work and decreased productivity due to decreased sleep and increased stress. The total cost of eczema care in the USA has been estimated at over USD 5 billion per annum (<a href="./references#CD013534-bbs2-0257" title="DruckerAM , WangAR , Li W-Q, SevetsonE , BlockJK , QureshiAA . The burden of atopic dermatitis: summary of a report for the National Eczema Association. Journal of Investigative Dermatology2017;137(1):26-30.">Drucker 2017</a>). </p> <p>Eczema often improves during childhood, with more than 50% of childhood eczema resolving by adolescence (<a href="./references#CD013534-bbs2-0350" title="WilliamsHC , StrachanDP . The natural history of childhood eczema: observations from the British 1958 birth cohort study. British Journal of Dermatology1998;139(5):834-9.">Williams 1998</a>). Recent studies suggest that some aspects of skin barrier and immune dysfunction may persist into adulthood (<a href="./references#CD013534-bbs2-0225" title="AbuabaraK , YuAM , OkhovatJP , AllenIE , LanganSM . The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies. Allergy2018;73(3):696-704.">Abuabara 2018</a>). Adult eczema is estimated at approximately 5% in the USA and 2% in Japan (<a href="./references#CD013534-bbs2-0234" title="BarbarotS , AuziereS , GadkariA , GirolomoniG , PuigL , SimpsonEL , et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy2018;73(6):1284-93.">Barbarot 2018</a>). Adults with eczema have significantly decreased social functioning and greater psychological distress than both the general population and adults with some other long‐term conditions (<a href="./references#CD013534-bbs2-0240" title="CarrollCL , BalkrishnanR , FeldmanSR , FleischerAB , ManuelJC . The burden of atopic dermatitis: impact on the patient, family, and society. Pediatric Dermatology2005;22(3):192-9.">Carroll 2005</a>). In a recent systematic review, a positive association was seen between eczema and suicidal ideation in adults and adolescents. It was proposed that chronic itch, sleep disturbance, and the social stigma of a visible disease contribute to mental health effects (<a href="./references#CD013534-bbs2-0316" title="RønnstadAT , Halling-Overgaard A-S, HamannCR , SkovL , EgebergA , ThyssenJP . Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. Journal of the American Academy of Dermatology2018;79(3):448-56.e30.">Ronnstad 2018</a>). </p> <p>As seen in most disease prevalence studies, the reported prevalence of eczema may vary depending on the location of the trial and variation in measurements used for classification and diagnosis. Using consistent measurements, the International Study of Asthma and Allergies in Childhood (ISAAC) has shown an increase in the reporting of eczema across different settings and in different populations apart from those with already high prevalence (<a href="./references#CD013534-bbs2-0232" title="AsherMI , MontefortS , BjörksténB , LaiCK , StrachanDP , WeilandSK , et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet2006;368(9537):733-43.">Asher 2006</a>). Admittedly, the youngest children in this cohort were six to seven years old ‐ not preschool age, at which eczema prevalence can be higher. This variation in reported prevalence between different regions and over time suggests that environmental influences may contribute significantly to disease prevalence. Eczema has been associated with smaller families, higher social class, and urban living. Children of immigrants moving from a country with low eczema prevalence to a country with higher eczema prevalence have a relatively higher prevalence of eczema, providing support for a role of environmental factors acting during early life (<a href="./references#CD013534-bbs2-0291" title="MartinPE , KoplinJJ , EckertJK , LoweAJ , PonsonbyAL , OsborneNJ , et al. The prevalence and socio-demographic risk factors of clinical eczema in infancy: a population-based observational study. Clinical and Experimental Allergy2013;43(6):642-51.">Martin 2013</a>). Family history of eczema, that is genetics, is the strongest determinant of eczema, and it cannot be modified (<a href="./references#CD013534-bbs2-0229" title="ApfelbacherCJ , DiepgenTL , SchmittJ . Determinants of eczema: population-based cross-sectional study in Germany. Allergy2011;66(2):206-13.">Apfelbacher 2011</a>). However, interaction of genes with environmental factors may be influenced by skin barrier interventions. </p> <p>Food allergy has been defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food (<a href="./references#CD013534-bbs2-0237" title="BoyceJA , Assa'adA , BurksAW , JonesSM , SampsonHA , WoodRA , et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. Journal of Allergy and Clinical Immunology2010;126(6):S1-58.">Boyce 2010</a>). Food allergy can further be classified into IgE‐mediated, non‐IgE‐mediated, and mixed types. IgE‐mediated food allergy typically occurs within two hours of exposure to the offending food, and symptoms are well characterised, ranging from minor oral or gastrointestinal symptoms, urticaria, or angioedema, to more severe symptoms such as anaphylaxis, which can occasionally result in death (<a href="./references#CD013534-bbs2-0237" title="BoyceJA , Assa'adA , BurksAW , JonesSM , SampsonHA , WoodRA , et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. Journal of Allergy and Clinical Immunology2010;126(6):S1-58.">Boyce 2010</a>). IgE‐mediated reactions involve degranulation of mast cells, and the condition is diagnosed by a clinical history supported by skin prick or serum‐specific IgE testing. A positive test alone indicates sensitisation to the food but does not always predict clinical reactivity. The titre of IgE or the size of the skin prick test wheal is a predictor of clinical reactivity, although not an indication of the severity of a reaction. Oral food challenges ‐ either open or blinded, placebo‐controlled challenges ‐ are used to confirm the diagnosis in cases where clinical history and test results are inconclusive (<a href="./references#CD013534-bbs2-0320" title="SichererSH , SampsonHA . Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. Journal of Allergy and Clinical Immunology2018;141(1):41-58.">Sicherer 2018</a> ). Non‐IgE‐mediated food allergy and mixed food allergies have a slower onset and less specific symptoms. Diagnosis is more difficult and relies on clinical history supported by exclusion or reintroduction of suspected foods, or both (<a href="./references#CD013534-bbs2-0284" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. Journal of Allergy and Clinical Immunology2003;113(5):832-6.">Johansson 2003</a>). It is unclear whether non‐IgE‐mediated allergies have the same association with skin barrier function and eczema, therefore we did not consider non‐IgE‐mediated food allergies in this review.  </p> <p>Exact prevalence rates for food allergy are difficult to ascertain and are largely dependent on the method used to diagnose food allergy and the population studied. Self‐reported food allergy rates are generally higher than those confirmed by specific allergy testing (<a href="./references#CD013534-bbs2-0351" title="WoodsRK , StoneyRM , RavenJ , WaltersEH , AbramsonM , ThienFC . Reported adverse food reactions overestimate true food allergy in the community. European Journal of Clinical Nutrition2002;56(1):31-6.">Woods 2002</a>). Previous population‐based studies have suggested that IgE‐mediated food allergy affects around 3% to 10% of children (<a href="./references#CD013534-bbs2-0285" title="KelleherMM , Dunn-GalvinA , GrayC , MurrayDM , KielyM , KennyL , et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. Journal of Allergy and Clinical Immunology2016;137(4):1111-6.e8.">Kelleher 2016</a>; <a href="./references#CD013534-bbs2-0301" title="OsborneNJ , KoplinJJ , MartinPE , GurrinLC , LoweAJ , MathesonMC , et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. Journal of Allergy and Clinical Immunology2011;127(3):668-76 e1-2.">Osborne 2011</a>; <a href="./references#CD013534-bbs2-0342" title="VenterC , PereiraB , VoigtK , GrundyJ , ClaytonCB , HigginsB , et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy2008;63(3):354-9.">Venter 2008</a>). For some people, food allergy can resolve spontaneously during childhood, particularly for foods such as milk and egg. However, a recent US survey study identified a history suggestive of IgE‐mediated food allergy in over 10% of adults, demonstrating that it is not just a disease of childhood (<a href="./references#CD013534-bbs2-0272" title="GuptaRS , WarrenCM , SmithBM , JiangJ , BlumenstockJA , DavisMM , et al. Prevalence and severity of food allergies among US adults. JAMA Network Open2019;2(1):e185630.">Gupta 2019</a>). Like eczema, food allergy is thought to have increased in prevalence in recent decades, although epidemiological data from the 1990s onwards in England and Australia suggest that food allergy prevalence in young children may be stable (<a href="./references#CD013534-bbs2-0307" title="PetersRL , KoplinJJ , AllenKJ , LoweAJ , LodgeCJ , TangML , et al. The prevalence of food sensitization appears not to have changed between 2 Melbourne cohorts of high-risk infants recruited 15 years apart. Journal of Allergy and Clinical Immunology In Practice2018;6(2):440-8. [DOI: 10.1016/j.jaip.2017.11.018]">Peters 2018</a> ; <a href="./references#CD013534-bbs2-0309" title="PrescottSL , PawankarR , AllenKJ , CampbellDE , Sinn JKh, FiocchiA , et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organization Journal2013;6(1):21.">Prescott 2013</a>; <a href="./references#CD013534-bbs2-0319" title="SichererSH , Muñoz-FurlongA , SampsonHA . Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. Journal of Allergy and Clinical Immunology2003;112(6):1203-7.">Sicherer 2003</a>; <a href="./references#CD013534-bbs2-0342" title="VenterC , PereiraB , VoigtK , GrundyJ , ClaytonCB , HigginsB , et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy2008;63(3):354-9.">Venter 2008</a>). Food allergy also varies in prevalence across different regions, with lower prevalence in areas with lower overall rates of allergic disease, such as rural settings in Asia and Africa (<a href="./references#CD013534-bbs2-0236" title="BothaM , BaseraW , Facey-ThomasHE , GauntB , GrayCL , RamjithJ , et al. Rural and urban food allergy prevalence from the South African Food Allergy (SAFFA) study. Journal of Allergy and Clinical Immunology2019;143(2):662-8. [DOI: 10.1016/j.jaci.2018.07.023]">Botha 2019</a>; <a href="./references#CD013534-bbs2-0309" title="PrescottSL , PawankarR , AllenKJ , CampbellDE , Sinn JKh, FiocchiA , et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organization Journal2013;6(1):21.">Prescott 2013</a>). </p> <p>Food allergy is a considerable burden on the individual, family, and wider society. Acute reactions can cause significant anxiety and when severe may rarely result in a fatal outcome within minutes of food ingestion (<a href="./references#CD013534-bbs2-0336" title="UmasuntharT , Leonardi-BeeJ , HodesM , TurnerPJ , GoreC , HabibiP , et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clinical and Experimental Allergy2013;43(12):1333-41.">Umasunthar 2013</a>). The continuous vigilance required to avoid potential triggers has an adverse impact on quality of life of allergic children and adults and their families (<a href="./references#CD013534-bbs2-0250" title="CummingsAJ , KnibbRC , KingRM , LucasJS . The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy2010;65(8):933-45. [DOI: 10.1111/j.1398-9995.2010.02342.x]">Cummings 2010</a>). People with food allergy and their carers report a negative impact of dietary restrictions, limitations to social activities, and an emotional and financial burden of living with food allergy. For example, in the USA, the financial cost of food allergy for affected families and healthcare providers has been estimated as at least USD 25 billion per annum (<a href="./references#CD013534-bbs2-0271" title="GuptaR , HoldfordD , BilaverL , DyerA , HollJL , MeltzerD . The economic impact of childhood food allergy in the United States. JAMA Pediatrics2013;167(11):1026-31.">Gupta 2013</a>). In recent decades, numbers of hospital admissions for food‐related anaphylaxis have increased. It is unclear, however, whether this represents a true increase in incidence or a greater recognition of the potential for acute food allergy as a cause of symptoms, as there reassuringly has not been a concomitant increase in fatal anaphylaxis (<a href="./references#CD013534-bbs2-0283" title="JerschowE , LinRY , ScaperottiMM , McGinnAP . Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. Journal of Allergy and Clinical Immunology2014;134(6):1318-28 e7.">Jerschow 2014</a>; <a href="./references#CD013534-bbs2-0308" title="Poulos LM, Waters A-M, Correll PK, Loblay RH, MarksGB . Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. Journal of Allergy and Clinical Immunology2007;120(4):878-84.">Poulos 2007</a>; <a href="./references#CD013534-bbs2-0335" title="TurnerPJ , GowlandMH , SharmaV , IerodiakonouD , HarperN , GarcezT , et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. Journal of Allergy and Clinical Immunology2015;135(4):956-63.e1.">Turner 2015</a>). </p> <p>Eczema and food allergy are closely associated. Both conditions typically begin during the first year of life. Genetic variations that damage skin barrier function are associated with both eczema and food allergy (<a href="./references#CD013534-bbs2-0302" title="PalmerCN , IrvineAD , Terron-KwiatkowskiA , ZhaoY , LiaoH , LeeSP , et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics2006;38(4):441-6.">Palmer 2006</a>; <a href="./references#CD013534-bbs2-0339" title="Van den OordRA , SheikhA . Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ2009;339:b2433.">Van den Oord 2009</a>). In particular, <i>FLG</i> is the most widely studied of the genes associated with atopy. <i>FLG</i> codes for filaggrin, a filament aggregating protein that contributes to the structure and function of the outer epidermis. Those with one or more <i>FLG</i> loss‐of‐function mutations have significantly increased prevalence of eczema and food allergy (<a href="./references#CD013534-bbs2-0282" title="IrvineAD , McLeanWH , LeungDY . Filaggrin mutations associated with skin and allergic diseases. New England Journal of Medicine2011;365(14):1315-27.">Irvine 2011</a>). An intergenic locus on chromosome 11q13.5 has non‐coding variants associated with multiple atopic disorders including eczema (<a href="./references#CD013534-bbs2-0263" title="Esparza-GordilloJ , WeidingerS , Fölster-HolstR , BauerfeindA , RuschendorfF , PatoneG , et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. Nature Genetics2009;41(5):596-601. [DOI: 10.1038/ng.347 A]">Esparza‐Gordillo 2009</a>), allergic sensitisation (<a href="./references#CD013534-bbs2-0239" title="BønnelykkeK , MathesonMC , PersTH , GranellR , StrachanDP , AlvesAC , et al. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. Nature Genetics2013;45(8):902-6. [DOI: 10.1038/ng.2694]">Bønnelykke 2013</a>), and food allergy (<a href="./references#CD013534-bbs2-0230" title="AsaiY , EslamiA , vanGinkelCD , AkhabirL , WanM , EllisG , et al. Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy. Journal of Allergy &amp; Clinical Immunology2018;141(3):991-1001. [DOI: 10.1016/j.jaci.2017.09.015.]">Asai 2018</a>). Animal studies demonstrate that exposure to food allergen across a damaged skin barrier predisposes to food sensitisation (<a href="./references#CD013534-bbs2-0327" title="StridJ , HourihaneJ , KimberI , CallardR , StrobelS . Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. European Journal of Immunology2004;34(8):2100-9.">Strid 2004</a>; <a href="./references#CD013534-bbs2-0328" title="StridJ , HourihaneJ , KimberI , CallardR , StrobelS . Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clinical and Experimental Allergy2005;35(6):757-66.">Strid 2005</a>). Human observational studies support an onset, timing, and severity‐dependent relationship between childhood eczema and risk of food allergy. In <a href="./references#CD013534-bbs2-0292" title="MartinPE , EckertJK , KoplinJJ , LoweAJ , GurrinLC , DharmageSC , et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clinical and Experimental Allergy2015;45(1):255-64.">Martin 2015</a>, over 50% of infants who needed prescription topical steroids before three months of age for treatment of eczema were IgE‐sensitised to one or more of egg white, peanut, or sesame. This study was included in a systematic review, which demonstrated a strong dose‐dependent relationship between eczema, food sensitisation, and food allergy, and suggested that eczema may be an important cause of food allergy (<a href="./references#CD013534-bbs2-0333" title="TsakokT , MarrsT , MohsinM , BaronS , du ToitG , TillS , et al. Does atopic dermatitis cause food allergy? A systematic review. Journal of Allergy and Clinical Immunology2016;137(4):1071-8.">Tsakok 2016</a>). </p> <p>With regard to the primary prevention of eczema, some studies have suggested that maternal supplementation with a probiotic supplement during pregnancy and breastfeeding may reduce the risk of eczema (<a href="./references#CD013534-bbs2-0268" title="Garcia-LarsenV , IerodiakonouD , JarroldK ,  Cunha S, Chivinge J, RobinsonZ , et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. PLOS Medicine2018;15(2):e1002507. [DOI: 10.1371/journal.pmed.1002507]">Garcia‐Larsen 2018</a>). However, the mechanism of action of such an intervention is unclear; findings are inconsistent between trials; and few relevant studies have published protocols that confirm the absence of selective reporting. </p> <p>With regard to the primary prevention of food allergy, it has been shown that the early introduction of allergenic foods such as egg and peanut can decrease the risk of allergy to those foods (<a href="./references#CD013534-bbs2-0258" title="Du ToitG , RobertsG , SayrePH , BahnsonHT , RadulovicS , SantosAF , et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. New England Journal of Medicine2015;372(9):803-13.">Du Toit 2015</a>; <a href="./references#CD013534-bbs2-0280" title="IerodiakonouD , Garcia-LarsenV , LoganA , Groome A,  Cunha S,  Chivinge J, et al. Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA2016;316(11):1181-92. [DOI: 10.1001/jama.2016.12623]">Ierodiakonou 2016</a>; <a href="./references#CD013534-bbs2-0296" title="NatsumeO , KabashimaS , NakazatoJ , Yamamoto-Hanada K,  Narita M,  Kondo M, et al. Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial. Lancet2017;389(10066):276-86. [DOI: 10.1016/S0140-6736(16)31418-0]">Natsume 2017</a>; <a href="./references#CD013534-bbs2-0305" title="Perkin K, LoganK , Tseng A,  Raji B,  Ayis S, PeacockJ , et al. Randomized trial of introduction of allergenic foods in breast-fed infants. New England Journal of Medicine2016;374:1733-43. [DOI: 10.1056/NEJMoa1514210]">Perkin 2016</a>). However, it is unclear whether this approach will reduce the prevalence of food allergy at a population level because applying the intervention to multiple foods is likely to be too onerous for parents (<a href="./references#CD013534-bbs2-0344" title="Voorheis P, BellS ,  Cornelsen L. Challenges experienced with early introduction and sustained consumption of allergenic foods in the Enquiring About Tolerance (EAT) study: a qualitative analysis. Journal of Allergy and Clinical Immunology2019;144(6):1615-23.">Voorheis 2019</a>), and some children already have allergy to the food before the age when complementary foods are usually introduced (<a href="./references#CD013534-bbs2-0258" title="Du ToitG , RobertsG , SayrePH , BahnsonHT , RadulovicS , SantosAF , et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. New England Journal of Medicine2015;372(9):803-13.">Du Toit 2015</a>).   </p> <p>New approaches are therefore required for the prevention of eczema and food allergy; simple interventions designed to promote skin barrier function represent one potential approach.  </p> </section> <section id="CD013534-sec-0011"> <h3 class="title" id="CD013534-sec-0011">Description of the intervention</h3> <p>In this review we included all interventions designed to improve the skin barrier in infants, either by enhancement or by promotion of the barrier through hydration via directly applied topical products, such as emollients or moisturisers, or through the reduction of potential damage to the skin barrier and consequent dryness through various means such as avoiding soaps or reducing water hardness. We expected that promotion of the skin barrier and skin hydration through topical emollients would be the most widely used intervention. Emollients are described as mainly lipid‐based products that smooth the skin, whereas moisturisers give water and moisture to the skin (<a href="./references#CD013534-bbs2-0304" title="PenzerR . Best practice in emollient therapy: a statement for healthcare professionals December 2012. Dermatological Nursing2012;11(4):60-79.">Penzer 2012</a>). However, sometimes 'emollient' is referred to as an ingredient of 'moisturisers' (<a href="./references#CD013534-bbs2-0289" title="LodénM . Effect of moisturizers on epidermal barrier function. Clinics in Dermatology2012;30(3):286-96.">Lodén 2012</a>). There is not yet a clear nomenclature for topical preparations for the skin. The terms 'moisturiser' and 'emollient' are used interchangeably in different settings to describe directly applied topical products. Several different 'classes' or 'formulations' of emollients and moisturisers are available, including oil‐in‐water creams, water‐in‐oil creams, ointments, lotions, oils, gels, sprays, and emulsions (<a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a>). However, these may not accurately reflect the format, ingredient, and effects of the product. Further complicating this is the fact that many skin care products are classed as cosmetics and are therefore not subjected to the same regulations as medicines. A recently proposed classification includes considering the vehicle, formulation, and active ingredients (<a href="./references#CD013534-bbs2-0330" title="SurberC , KottnerJ . Skin care products: what do they promise, what do they deliver. Journal of Tissue Viability2017;26(1):29-36.">Surber 2017</a>). </p> <p>Emollients themselves may be categorised by their mode of use, as leave‐on emollients that are directly applied to the skin and allowed to dry in; as soap substitutes whereby an emollient may be used instead of a soap to clean; and as bath oils or emollients by which a product is added to the bath water (<a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a>). We expected most intervention trials to use leave‐on emollients, although the characteristics of emollients may vary. </p> <p>As part of treatment for established eczema, emollients are recommended to be applied two to three times a day, at up to 150 g to 200 g per week in young children and up to 500 g in adults (<a href="./references#CD013534-bbs2-0260" title="EichenfieldLF , TomWL , BergerTG , KrolA , PallerAS , SchwarzenbergerK , et al. Guidelines of care for the management of atopic dermatitis: Part 2: Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology2014;71(1):116-32.">Eichenfield 2014</a>; <a href="./references#CD013534-bbs2-0315" title="RingJ , AlomarA , BieberT , DeleuranM , Fink-WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045-60.">Ring 2012</a>). Overall, emollients are regarded as safe, with few adverse effects. However, daily application of sufficient emollient can be time‐consuming and unpleasant, potentially having a negative impact on the child and the family (<a href="./references#CD013534-bbs2-0240" title="CarrollCL , BalkrishnanR , FeldmanSR , FleischerAB , ManuelJC . The burden of atopic dermatitis: impact on the patient, family, and society. Pediatric Dermatology2005;22(3):192-9.">Carroll 2005</a>). Certain emollients can cause stinging, especially to skin with established eczema (<a href="./references#CD013534-bbs2-0300" title="OakleyR , LawtonS . Views on unwanted effects of leave-on emollients and experiences surrounding their incidence. Dermatological Nursing2016;15(4):38-43.">Oakley 2016</a>). There is concern that emollients can actively sensitise to their individual components, leading to cutaneous reactions (<a href="./references#CD013534-bbs2-0251" title="DanbySG , Al-EneziT , SultanA , ChittockJ , KennedyK , CorkMJ . The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. British Journal of Dermatology2011;165(2):329-34.">Danby 2011</a>), and even systemic allergic reactions (<a href="./references#CD013534-bbs2-0345" title="VoskampAL , ZubrinichCM , AbramovitchJB , RollandJM , O’HehirRE . Goat's cheese anaphylaxis after cutaneous sensitization by moisturizer that contained goat's milk. Journal of Allergy and Clinical Immunology2014;2(5):629-30.">Voskamp 2014</a>). Slippage of infants covered in emollient from the hands of carers is a stated potential adverse reaction in emollient prevention studies such as the Barrier Enhancement for Eczema Prevention (BEEP) study (<a href="./references#CD013534-bbs2-0242" title="ChalmersJR , HainesRH , MitchellEJ , ThomasKS , BrownSJ , RiddM , et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343.">Chalmers 2017</a>). </p> <p>Protection of the skin barrier could also be achieved by limiting water loss across the skin, or by limiting skin contact with potentially harmful substances or irritants. Activities and substances that may harm the skin barrier, at least in people with established eczema, include excessive bathing, wash products, and hard water (<a href="./references#CD013534-bbs2-0247" title="CorkMJ , MurphyR , CarrJ , ButtleD , WardS , BåvikC , et al. The rising prevalence of atopic eczema and environmental trauma to the skin. Dermatology in Practice2002;10(3):22-6.">Cork 2002</a>). Ameliorating any of these factors in the first months of life may thus potentially improve hydration and skin barrier function, thereby reducing subsequent eczema prevalence. </p> <p>Neonatal skin is different from the skin of children and adults, as it takes time to adjust to the dry extrauterine environment during the postnatal period (<a href="./references#CD013534-bbs2-0060" title="CookeA , Bedwell C, CampbellM , McGowanL , Ersser SJ, LavenderT . Skin care for healthy babies at term: a systematic review of the evidence. Midwifery2018;56:29-43. [PMID: 29055852]">Cooke 2018</a>). Postnatal maturation of skin structure and physiology can take up to a year, with regional differences in maturation, with cheek skin maturing more slowly than skin at other sites (<a href="./references#CD013534-bbs2-0293" title="McAleerMA , JakasaI , RajN , O'DonnellCP , LaneME , RawlingsAV , et al. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. British Journal of Dermatology2018;179(2):431-41.">McAleer 2018</a>). However, very early neonatal skin has decreased water permeability compared to the skin of older children and adults, along with decreased surface pH and stratum corneum formation, demonstrating an effective skin barrier in the first two days of life, which changes rapidly (<a href="./references#CD013534-bbs2-0352" title="YosipovitchG , Maayan-MetzgerA , MerlobP , SirotaL . Skin barrier properties in different body areas in neonates. Pediatrics2000;106(1):105-8.">Yosipovitch 2000</a>). It was previously thought that infant skin beyond the first few weeks following birth was structurally and functionally equivalent to the skin of adults; however, skin undergoes a maturation process that can last for several years after birth (<a href="./references#CD013534-bbs2-0244" title="ChiouYB ,  Blume-PeytaviU . Stratum corneum maturation. A review of neonatal skin function. Skin Pharmacology &amp; Physiology2004;17(2):57-66. [DOI: 10.1159/000076015]">Chiou 2004</a>; <a href="./references#CD013534-bbs2-0324" title="StamatasGN , NikolovskiJ , MackMC , KolliasN . Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies. International Journal of Cosmetic Science2011;33(1):17-24. [PMID: 20807257]">Stamatas 2011</a>; <a href="./references#CD013534-bbs2-0343" title="VisscherMO , BurkesSA , AdamsDM , HammillAM , WickettRR . Infant skin maturation: preliminary outcomes for color and biomechanical properties. Skin Research &amp; Technology2017;23(4):545-51. [PMID: 28303612]">Visscher 2017</a>). This process involves higher keratinocyte proliferation and desquamation rates with impaired keratinocyte differentiation compared to adults (<a href="./references#CD013534-bbs2-0288" title="LiuQ , ZhangY , DanbySG , CorkMJ , StamatasGN . Infant skin barrier, structure, and enzymatic activity differ from those of adult in an East Asian cohort. BioMed Research International2018;12:1-8. [DOI: 10.1155/2018/1302465]">Liu 2018</a>; <a href="./references#CD013534-bbs2-0323" title="StamatasGN , NikolovskiJ , LuedtkeMA , KolliasN , WiegandBC . Infant skin microstructure assessed in vivo differs from adult skin in organization and at the cellular level. Pediatric Dermatology2010;27(2):125-31. [DOI: 10.1111/j.1525-1470.2009.00973.x]">Stamatas 2010</a>). The increased keratinocyte cell turnover results in smaller corneocytes and a thinner stratum corneum (<a href="./references#CD013534-bbs2-0323" title="StamatasGN , NikolovskiJ , LuedtkeMA , KolliasN , WiegandBC . Infant skin microstructure assessed in vivo differs from adult skin in organization and at the cellular level. Pediatric Dermatology2010;27(2):125-31. [DOI: 10.1111/j.1525-1470.2009.00973.x]">Stamatas 2010</a>). These changes in  the stratum corneum create a shorter path for penetration of irritants and allergens through the skin of normal babies. The increased permeability of a baby's stratum corneum compared to that of an adult is reflected in higher transepidermal water loss (TEWL) rates (<a href="./references#CD013534-bbs2-0298" title="NikolovskiJ , StamatasGN , KolliasN , WiegandBC . Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. Journal of Investigative Dermatology2008;128(7):1728-36. [DOI: 10.1038/sj.jid.5701239]">Nikolovski 2008</a>). This higher stratum corneum permeability is likely to be an important factor in the development of eczema early in life. Infants, with their thinner skin and an increased body surface area‐to‐volume ratio compared with adults, may be more susceptible to percutaneous uptake of any potentially harmful substances (<a href="./references#CD013534-bbs2-0290" title="ManciniA , LawleyL . Structure and function of newborn skin. In: Neonatal Dermatology. 2nd edition. Philadelphia: Elsevier Saunders, 2008:19-31.">Mancini 2008</a>).  </p> <p>Standard care for neonatal and infant skin differs internationally and is affected by cultural factors. The World Health Organization (WHO) recommends not bathing newborn infants in the first 24 hours after birth, but does not recommend any specific method of infant skin care beyond this time (<a href="./references#CD013534-bbs2-0348" title="World Health Organization. Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice. www.ncbi.nlm.nih.gov/books/NBK326678/ (accessed prior to 11 March 2019).">WHO 2015</a>). In the UK, standard skin care advice given to parents of newborns is to wash in plain water for the first month, and to use a mild non‐perfumed soap if one is required. What constitutes a 'mild soap' is not described, and there is no set recommendation for bathing frequency or use of moisturisers (<a href="./references#CD013534-bbs2-0297" title="National Institute for Health and Care Excellence. Postnatal care up to 8 weeks after birth. www.nice.org.uk/guidance/cg37 (accessed prior to 24 January 2019).">NICE 2006</a>). Few emollient studies have included term infants; most have incorporated premature infants, whose skin is different from the skin of term infants (<a href="./references#CD013534-bbs2-0281" title="IrvinEJ , MillerHD . Emollient use in the term newborn: a literature review. Neonatal Network2015;34(4):227-30.">Irvin 2015</a>). Application of an emollient or oil to the skin of newborn infants is practised in some regions and cultures for a variety of reasons often unrelated to allergy prevention (<a href="./references#CD013534-bbs2-0227" title="AmareY , ShambaDD , ManziF , BeeMH , OmotaraBA , IganusRB , et al. Current neonatal skin care practices in four African sites. Journal of Tropical Pediatrics2015;61(6):428-34. [DOI: 10.1093/tropej/fmv053]">Amare 2015</a>). </p> <p>Timing of the first bath in neonates may be important. In some areas of the world, infants are washed immediately after birth, but the WHO recommends leaving the vernix caseosa intact and allowing it to wear off with normal handling (<a href="./references#CD013534-bbs2-0348" title="World Health Organization. Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice. www.ncbi.nlm.nih.gov/books/NBK326678/ (accessed prior to 11 March 2019).">WHO 2015</a>). When modes of washing were compared, a comparison of infant bathing with water versus washing with a cotton wash cloth did not demonstrate a significant difference in skin barrier properties after four weeks, but did show regional differences in skin barrier properties and demonstrated dynamic adaption of the skin barrier over the first four weeks of life (<a href="./references#CD013534-bbs2-0087" title="Garcia Bartels N, Mleczko A, Schink T, Proquitte H, Wauer RR,  Blume-Peytavi U. Influence of bathing or washing on skin barrier function in newborns during the first four weeks of life. Skin Pharmacology &amp; Physiology2009;22(5):248-57. ">Garcia Bartels 2009</a>). Amongst neonates bathed twice weekly, those washed in age‐appropriate liquid cleanser with added cream had lower TEWL than those washed with water only, whereas stratum corneum hydration was similar. Whether this shows improvement in the skin barrier is unclear (<a href="./references#CD013534-bbs2-0011" title="Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,  Proquitté H,  Wauer RR, et al. Effect of standardized skin care regimens on neonatal skin barrier function in different body areas. Pediatric Dermatology2010;27(1):1‐8. [DOI: 10.1111/j.1525-1470.2009.01068.x]">Garcia Bartels 2010</a>). Although specific wash products or moisturiser ingredients such as sodium laureth sulfate are thought to be harmful, plain water or wash products without known skin irritants are thought to be safe, other than the risk of slippages with oil‐based products (<a href="./references#CD013534-bbs2-0235" title="Blume-PeytaviU , LavenderT , JenerowiczD , RyuminaI , StalderJF , TorreloA , et al. Recommendations from a European roundtable meeting on best practice healthy infant skin care. Pediatric Dermatology2016;33(3):311-21.">Blume‐Peytavi 2016</a>). Some groups recommend pharmaceutical‐grade oils or specially formulated baby skin products over locally produced oils that are traditionally used in many parts of the world (<a href="./references#CD013534-bbs2-0235" title="Blume-PeytaviU , LavenderT , JenerowiczD , RyuminaI , StalderJF , TorreloA , et al. Recommendations from a European roundtable meeting on best practice healthy infant skin care. Pediatric Dermatology2016;33(3):311-21.">Blume‐Peytavi 2016</a>). However, such recommendations sometimes come from industry‐funded groups, and there is little direct evidence to suggest that traditional local oils are inferior to commercial products. Frequency and timing of infant bathing may vary by culture and region, and although excessively frequent infant bathing is thought to harm skin barrier function and physiology, the optimal frequency of infant washing or bathing is not known. </p> <p>Hard water is relatively rich in calcium and magnesium, and water hardness varies depending on geographical location. Water of a certain hardness will cause limescale and may corrode pipes (<a href="./references#CD013534-bbs2-0264" title="EwenceA , RumsbyP , DanbyS , CorkMJ , WilliamsHC . A review of skin irritation and tap water. www.dwi.defra.gov.uk/research/completed-research/reports/dwi70-2-257.pdf (accessed prior to 24 January 2019).">Ewence 2011</a>). Hard water is associated with increased eczema prevalence (<a href="./references#CD013534-bbs2-0262" title="EngebretsenKA , BagerP , WohlfahrtJ , SkovL , ZachariaeC , Nybo AndersenAM , et al. Prevalence of atopic dermatitis in infants by domestic water hardness and season of birth: cohort study. Journal of Allergy and Clinical Immunology2017;139(5):1568-74.e1.">Engebretsen 2017</a>). It is thought that the skin barrier disruption associated with hard water is due to the interaction between surfactants in wash products and hard water itself (<a href="./references#CD013534-bbs2-0252" title="DanbySG , BrownK , WigleyAM , ChittockJ , PyaePK , FlohrC , et al. The effect of water hardness on surfactant deposition after washing and subsequent skin irritation in atopic dermatitis patients and healthy control subjects. Journal of Investigative Dermatology2018;138(1):68-77.">Danby 2018</a>). </p> <p>This review covers all potential skin care interventions designed to promote, or reduce damage to, the skin barrier and to enhance skin hydration for the primary prevention of eczema and food allergy.  </p> </section> <section id="CD013534-sec-0012"> <h3 class="title" id="CD013534-sec-0012">How the intervention might work</h3> <p>Emollients, as one intervention, are the mainstay of treatment for those with already established eczema, as detailed in a Cochrane Review (<a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a>), because dry skin (xerosis) is a key feature of eczema, and topical moisturisers have an integral role in the standard treatment of eczema of all severities (<a href="./references#CD013534-bbs2-0260" title="EichenfieldLF , TomWL , BergerTG , KrolA , PallerAS , SchwarzenbergerK , et al. Guidelines of care for the management of atopic dermatitis: Part 2: Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology2014;71(1):116-32.">Eichenfield 2014</a>). Emollients can decrease TEWL, increase stratum corneum hydration, improve comfort, and reduce itch when used on skin that already has active eczema (<a href="./references#CD013534-bbs2-0289" title="LodénM . Effect of moisturizers on epidermal barrier function. Clinics in Dermatology2012;30(3):286-96.">Lodén 2012</a>; <a href="./references#CD013534-bbs2-0311" title="RawlingsAV , CanestrariDA , DobkowskiB . Moisturizer technology versus clinical performance. Dermatologic Therapy2004;17(Suppl 1):49-56.">Rawlings 2004</a>), and are therefore a key component in the treatment of eczema (<a href="./references#CD013534-bbs2-0315" title="RingJ , AlomarA , BieberT , DeleuranM , Fink-WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045-60.">Ring 2012</a>). They may be more effective than interventions such as less frequent bathing or use of water softeners for eczema prevention. </p> <p>All moisturisers contain varying amounts of active ingredients such as humectant or ceramide, as well as excipient ingredients such as emulsifiers (<a href="./references#CD013534-bbs2-0289" title="LodénM . Effect of moisturizers on epidermal barrier function. Clinics in Dermatology2012;30(3):286-96.">Lodén 2012</a>). Humectants, such as glycerol or urea, aid retention and attraction of water by the stratum corneum. Ceramides are intracellular lipids found in the stratum corneum that are reduced in lesional eczematous skin (<a href="./references#CD013534-bbs2-0294" title="MeckfesselMH , BrandtS . The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. Journal of the American Academy of Dermatology2014;71(1):177-84.">Meckfessel 2014</a>). Occlusives such as petrolatum form a layer on the skin surface that may prevent TEWL across the stratum corneum and can soften the skin (<a href="./references#CD013534-bbs2-0260" title="EichenfieldLF , TomWL , BergerTG , KrolA , PallerAS , SchwarzenbergerK , et al. Guidelines of care for the management of atopic dermatitis: Part 2: Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology2014;71(1):116-32.">Eichenfield 2014</a>; <a href="./references#CD013534-bbs2-0311" title="RawlingsAV , CanestrariDA , DobkowskiB . Moisturizer technology versus clinical performance. Dermatologic Therapy2004;17(Suppl 1):49-56.">Rawlings 2004</a>). Moisturisers can be hydrophilic or lipophilic. Hydrophilic moisturisers attract water and are important for skin hydration, whereas lipophilic moisturisers tend to stay on the surface to aid the skin barrier (<a href="./references#CD013534-bbs2-0241" title="CaussinJ , RozemaE , GoorisGS , WiechersJW , PavelS , BouwstraJA . Hydrophilic and lipophilic moisturizers have similar penetration profiles but different effects on SC water distribution in vivo. Experimental Dermatology2009;18(11):954-61.">Caussin 2009</a>). </p> <p><a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a> showed that regular use of emollients for those with eczema can prolong time to eczema flare and reduce the number of flares and need for topical corticosteroids. In infants, skin barrier dysfunction is seen before the development of clinical eczema (<a href="./references#CD013534-bbs2-0251" title="DanbySG , Al-EneziT , SultanA , ChittockJ , KennedyK , CorkMJ . The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. British Journal of Dermatology2011;165(2):329-34.">Danby 2011</a>; <a href="./references#CD013534-bbs2-0265" title="FlohrC , EnglandK , RadulovicS , McLeanWH , CampbellLE , BarkerJ , et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. British Journal of Dermatology2010;163(6):1333-6.">Flohr 2010</a>). Applying moisturisers before eczema is noted may therefore offer a route for the primary prevention of eczema. Three published pilot studies suggest that applying moisturisers to infant skin might reduce the prevalence of eczema during the application period (<a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>). These pilot studies were small‐scale studies testing the feasibility of the intervention or looking for signals of a preventative effect, or both. They were insufficiently powered for confirming a preventative effect. It is not known whether applying moisturisers could lead to a programming effect on the skin, causing longer‐term effects on skin physiology, immunology, or clinical manifestations of eczema. </p> <p>The strong association between eczema and food allergy would suggest that reduced clinical manifestations of eczema could potentially reduce the risk of food allergy, even if it were just to delay the onset of eczema from early infancy, where the association with development of food allergy is strongest (<a href="./references#CD013534-bbs2-0292" title="MartinPE , EckertJK , KoplinJJ , LoweAJ , GurrinLC , DharmageSC , et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clinical and Experimental Allergy2015;45(1):255-64.">Martin 2015</a>). In a small pilot study of a ceramide‐dominant emollient with an action described as a lipid replacement, evidence suggests reduced allergic sensitisation to foods in the per‐protocol analysis of the intervention group (<a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>). </p> <p>Mechanistic studies within the clinical trials suggest that emollients can increase stratum corneum hydration when used in healthy infants; however, trials have not consistently identified changes in skin pH or TEWL (<a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). It is unclear whether this increase in stratum corneum hydration will lead to reduced skin inflammation and associated allergic sensitisation. </p> </section> <section id="CD013534-sec-0013"> <h3 class="title" id="CD013534-sec-0013">Why it is important to do this review</h3> <p>The first version of this Cochrane Review (<a href="./references#CD013534-bbs2-0354" title="Kelleher  MM, Cro  S, Cornelius  V, Lodrup Carlsen  KC, Skjerven  HO, Rehbinder  EM. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013534. [DOI: 10.1002/14651858.CD013534.pub2]">Kelleher 2021</a>), published in February 2021, found that skin barrier interventions probably do not prevent eczema. For the co‐primary outcome of food allergy, only one study was included with food allergy outcome (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). The review found weak evidence that skin care interventions may slightly increase food allergy rates, but without significant evidence to support or refute this from other included trials. The largest included trial was affected by the COVID‐19 pandemic (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), resulting in delays to data sharing and publication for the food allergy outcomes. It is important to clarify whether or not skin care interventions may cause harm by increasing food allergy, so that appropriate advice can be given to carers of young infants. Observational data published since the first version of this Cochrane Review have reported an association between frequency of emollient application during early infancy and risk of food allergy (<a href="./references#CD013534-bbs2-0306" title="PerkinMR , LoganK , MarrsT , RadulovicS , CravenJ , BoyleRJ , et al. Association of frequent moisturizer use in early infancy with the development of food allergy. Journal of Allergy and Clinical Immunology2021;147(3):967-76. [PMID: 33678253]">Perkin 2021</a>). The potential mechanism for this association is the facilitation of transcutaneous passage of environmental food allergens, leading to food sensitisation and food allergy. The purpose of this update was to include food allergy and food sensitisation data from <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> in order to provide increased information about the relationship between skin care interventions during infancy and the risk of developing IgE‐mediated food allergy. In this update, we also incorporated subgroup analyses using new information from trials that had undertaken <i>FLG</i> genotyping or genotyping of the non‐coding variants in the intergenic locus on chromosome 11q13.5 subsequent to the first version of this Cochrane Review (<a href="./references#CD013534-bbs2-0354" title="Kelleher  MM, Cro  S, Cornelius  V, Lodrup Carlsen  KC, Skjerven  HO, Rehbinder  EM. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013534. [DOI: 10.1002/14651858.CD013534.pub2]">Kelleher 2021</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013534-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013534-sec-0014"></div> <section id="CD013534-sec-0015"> <h3 class="title" id="CD013534-sec-0015">Primary objective</h3> <p>To assess the effects of skin care interventions such as emollients for the primary prevention of eczema and food allergy in infants. </p> </section> <section id="CD013534-sec-0016"> <h3 class="title" id="CD013534-sec-0016">Secondary objective</h3> <p>To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013534-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013534-sec-0017"></div> <section id="CD013534-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013534-sec-0019"> <h4 class="title">Types of studies</h4> <p>Parallel‐group or factorial randomised controlled trials (RCTs), including both individual and cluster‐randomised trials. We excluded quasi‐RCTs and controlled clinical trials. We also excluded cross‐over trials, as the design is inappropriate to the clinical context. </p> </section> <section id="CD013534-sec-0020"> <h4 class="title">Types of participants</h4> <p>Infants (age 12 months or younger). As this is a primary prevention review, we did not include studies on infants who already had diagnosed eczema or food allergy at the time of randomisation. We excluded study populations defined by a pre‐existing health state in the infant, such as preterm birth (less than 37 weeks' gestation) or congenital skin conditions, because findings in these populations may not be generalisable. </p> <p>We attempted to obtain individual participant data (IPD) for all included studies. If IPD were not available, we obtained aggregate data instead. For studies with only aggregate data, we excluded the whole study if some participants were not eligible, unless ineligible participants made up an insignificant proportion of the total group, that is less than 5%. In trials with IPD, we planned to include only data on participants who met our eligibility criteria; however, no exclusions were necessary, as all obtained IPD were eligible. </p> </section> <section id="CD013534-sec-0021"> <h4 class="title">Types of interventions</h4> <p>All skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation. These include: </p> <p> <ol id="CD013534-list-0001"> <li> <p>moisturisers/emollients;</p> </li> <li> <p>bathing products (these may include oils or emollients);</p> </li> <li> <p>advice regarding reducing soap exposure and bathing frequency; and</p> </li> <li> <p>use of water softeners.</p> </li> </ol> </p> <p>Interventions could be simple single interventions, or complex interventions that utilised a combination of measures to protect or promote skin barrier function and hydration or to reduce subclinical inflammation. Comparators were no treatment intervention or advice, or standard care, in the study setting. We excluded multifaceted interventions, whereby the skin care component was only a small part of the study, if the skin care component was likely trivial or irrelevant to the outcome. We also planned to separately assess those interventions that primarily aimed to enhance the skin barrier through direct application of emollient or moisturiser (skin care intervention A) and those that aimed to protect the skin barrier from irritation, that is through the use of water softeners (skin care intervention B). However, we did not find any eligible studies for skin care intervention B. </p> </section> <section id="CD013534-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>No minimum follow‐up was required. However, we separately analysed outcomes that related to symptoms during the intervention period and outcomes that occurred and were reported after the intervention period, when appropriate and feasible. </p> <section id="CD013534-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013534-list-0002"> <li> <p>Eczema. When multiple measures were reported, the hierarchy of diagnosis was investigator assessment as described by the Hanifin and Rajka criteria in their original form (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>), or by the UK Working Party refinement of them (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), other modifications of the Hanifin and Rajka criteria, doctor diagnosis of eczema, then patient or parent report of eczema. </p> </li> <li> <p>Food allergy. When multiple measures of food allergy were reported, the hierarchy of diagnosis was confirmed IgE‐mediated food allergy diagnosed via oral food challenge, with eligibility for oral food challenge decided as per study protocol, although ideally based on current recommendations (<a href="./references#CD013534-bbs2-0269" title="GrabenhenrichLB , ReichA , BellachJ , TrendelenburgV , SprikkelmanAB , RobertsG , et al. A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research. Allergy2017;72(3):453-61.">Grabenhenrich 2017</a>). If oral food challenge was not available, then food allergy was as diagnosed by investigator assessment using a combination of clinical history and allergy testing: skin prick testing and serum‐specific IgE. We defined IgE sensitisation as skin test to a food of 3 mm or more, or specific IgE of 0.35 kUa/L or higher. The primary foods of interest were milk, egg, and peanut; however, we collected data on any foods that were available from each study. </p> </li> </ol> </p> <p>The time point for all food allergy and eczema outcome analyses was by age one to three years, using the closest available time point to two years, from each included trial. Adverse event outcomes were measured during the intervention period only. When pooling data from different trials, we considered the relationship between timing of the intervention and timing of the outcome measure, for example we separately pooled measures of eczema taken during the intervention period and measures of eczema taken after the intervention period had ceased. </p> <p>As we identified multiple measures of eczema across trials, we conducted sensitivity analysis to look separately at eczema measured using the Hanifin and Rajka criteria in their original form (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>), or the UK Working Party refinement of them (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), and other modifications of the Hanifin and Rajka criteria only. We planned to look separately at food allergy measured using secure diagnosis of food allergy by oral food challenge in a sensitivity analysis, if necessary. </p> </section> <section id="CD013534-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013534-list-0003"> <li> <p>Adverse events, including skin infection during the intervention period; stinging or allergic reactions to moisturisers; or slippage accidents around the time of bathing or application of emollient. We planned to report all serious adverse events. </p> </li> <li> <p>Eczema severity: clinician‐assessed using EASI (Eczema Area and Severity Index) or a similarly validated method (<a href="./references#CD013534-bbs2-0274" title="HanifinJM , ThurstonM , OmotoM , CherillR , TofteSJ , GraeberM , et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology2001;10(1):11-8.">Hanifin 2001</a>). </p> </li> <li> <p>Parent‐reported eczema severity using POEM (Patient‐Orientated Eczema Measure) or a similarly validated patient‐reported measure (<a href="./references#CD013534-bbs2-0243" title="CharmanCR , VennAJ , WilliamsHC . The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Archives of Dermatology2004;140(12):1513-9.">Charman 2004</a>). </p> </li> <li> <p>Time to onset of eczema.</p> </li> <li> <p>Parent report of immediate (less than two hours) reaction to a known food allergen: milk, soya, wheat, fish, seafood, peanut, tree nut, egg, or local common food allergen. </p> </li> <li> <p>Allergic sensitisation to foods and inhalants via skin prick test (or, if not available, via serum‐specific IgE). </p> </li> </ol> </p> <p>We analysed any relevant core outcomes identified as part of the Cochrane Skin Core Outcomes Set Initiative (CS‐COUSIN) and Harmonising Outcome Measures for Eczema (HOME) initiatives when this information was available from each trial (<a href="http://www.homeforeczema.org/" target="_blank">www.homeforeczema.org</a>). Relevant HOME domains include clinician signs measured using the Eczema Area and Severity Index (EASI) instrument, patient‐reported symptoms using the POEM instrument, long‐term disease control, and quality of life. These outcomes were designed for trials involving those with established eczema. There is not yet a set of core outcomes for defining eczema or food allergy in prevention studies; however, for eczema, a modified version of the UK Hanifin and Rajka criteria has been proposed to differentiate between an incident diagnosis of eczema and transient eczematous rashes of infancy (<a href="./references#CD013534-bbs2-0321" title="SimpsonEL , KeckLE , ChalmersJR , WilliamsHC . How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. Journal of Allergy and Clinical Immunology2012;130(1):137-44.">Simpson 2012</a>). When feasible, we contacted trial authors early in the design or set‐up of their trial to encourage sharing of outcome assessment methods, instruments used, and timing. We did not include long‐term disease control or quality of life outcomes in this review. </p> </section> </section> </section> <section id="CD013534-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD013534-sec-0026"> <h4 class="title">Electronic searches</h4> <p>For this update Cochrane Skin Information Specialist Liz Doney searched the following databases up to 16 September 2021, using strategies created for the previous version of this review (<a href="./references#CD013534-bbs2-0354" title="Kelleher  MM, Cro  S, Cornelius  V, Lodrup Carlsen  KC, Skjerven  HO, Rehbinder  EM. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013534. [DOI: 10.1002/14651858.CD013534.pub2]">Kelleher 2021</a>). </p> <p> <ol id="CD013534-list-0004"> <li> <p><a href="./references#CD013534-bbs2-0245" title="Cochrane Skin. More about the Cochrane Skin Specialised Register. skin.cochrane.org/search-methods (accessed 12 October 2021).">Cochrane Skin Specialised Register 2021</a> (<a href="./appendices#CD013534-sec-0104">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 8), in the Cochrane Library (<a href="./appendices#CD013534-sec-0105">Appendix 2</a>). </p> </li> <li> <p>MEDLINE via Ovid (from 1946 to 16 September 2021) (<a href="./appendices#CD013534-sec-0106">Appendix 3</a>). </p> </li> <li> <p>Embase via Ovid (from 1974 to 16 September 2021) (<a href="./appendices#CD013534-sec-0107">Appendix 4</a>). </p> </li> </ol> </p> <section id="CD013534-sec-0027"> <h5 class="title">Trials registers</h5> <p>For this update, two review authors (MK and RJB) searched the following trials registers on 31 July 2021.  </p> <p> <ol id="CD013534-list-0005"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (<a href="./appendices#CD013534-sec-0108">Appendix 5</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (<a href="./appendices#CD013534-sec-0109">Appendix 6</a>). </p> </li> </ol> </p> </section> <section id="CD013534-sec-0028"> <h5 class="title">Retractions and errata</h5> <p>We undertook a search to identify retraction statements or errata related to the studies included in the review in MEDLINE and Embase on 13 October 2021. No new relevant records were retrieved.  </p> </section> </section> <section id="CD013534-sec-0029"> <h4 class="title">Searching other resources</h4> <section id="CD013534-sec-0030"> <h5 class="title">Conference proceedings</h5> <p>We reviewed the proceedings of the Asia Pacific Association of Pediatric Allergy, Respirology &amp; Immunology Conferences (APAPARI) for 2018, 2019, and 2020. </p> </section> <section id="CD013534-sec-0031"> <h5 class="title">Searching reference lists</h5> <p>We checked the bibliographies of included trials and identified relevant systematic reviews to obtain further references to relevant RCTs. </p> </section> <section id="CD013534-sec-0032"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of interventions used for the prevention of eczema and food allergy. We only considered adverse effects described in the included trials. </p> </section> </section> </section> <section id="CD013534-sec-0033"> <h3 class="title" id="CD013534-sec-0033">Data collection and analysis</h3> <p>We undertook the review according to the methods recommended in Chapter 26 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013534-bbs2-0332" title="TierneyJF , StewartLA , ClarkeM . Chapter 26: Individual participant data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Tierney 2021</a>). A summary record of prospectively planned components of the meta‐analysis was registered on PROSPERO (reference 42017056965; registered 10 February 2017) (<a href="./references#CD013534-bbs2-0238" title="BoyleR , WilliamsH , AskieL , Lodrup-CarlsenK , MontgomeryA , ChalmersJ , et al. Prospectively planned meta-analysis of skin barrier studies for the prevention of eczema and associated health conditions. www.crd.york.ac.uk/prospero/display_record.php?RecordID=56965 (first received 10 February 2017).">Boyle 2017</a>). </p> <section id="CD013534-sec-0034"> <h4 class="title">Selection of studies</h4> <p>For this update of the review, two review authors (from MK, SC, and RJB) independently carried out title, abstract, and full‐text screening, with arbitration by a third review author (RP) when necessary. We combined both retrospective and prospectively acquired data in the meta‐analysis. Retrospective data are outcome data acquired, analysed, unblinded, and known to the trial investigators before registration of the systematic review protocol (PROSPERO reference 42017056965; registered 10 February 2017) (<a href="./references#CD013534-bbs2-0238" title="BoyleR , WilliamsH , AskieL , Lodrup-CarlsenK , MontgomeryA , ChalmersJ , et al. Prospectively planned meta-analysis of skin barrier studies for the prevention of eczema and associated health conditions. www.crd.york.ac.uk/prospero/display_record.php?RecordID=56965 (first received 10 February 2017).">Boyle 2017</a>). Prospectively acquired data are those data known to the trial investigators, in analysed and unblinded form, before 10 February 2017. We used participant‐level data from all trials when possible. We invited the authors of each included trial to collaborate in accordance with Chapter 26 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013534-bbs2-0332" title="TierneyJF , StewartLA , ClarkeM . Chapter 26: Individual participant data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Tierney 2021</a>). We asked all trial authors to provide IPD. One review team member (MK or SC) sent a data request email to the first and corresponding authors of the associated trial listing the variables required for the analysis (<a href="./appendices#CD013534-sec-0110">Appendix 7</a>). Following completion of a data sharing agreement, selected variables, or full data sets when appropriate permissions were obtained, were exchanged between researchers along with a data dictionary. If study authors were unable to provide participant‐level data, we accepted appropriate summary data. </p> </section> <section id="CD013534-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We conducted data collection and handling in accordance with the guidance provided in Chapter 26 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013534-bbs2-0332" title="TierneyJF , StewartLA , ClarkeM . Chapter 26: Individual participant data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Tierney 2021</a>). We extracted descriptive data on trial setting, methods, participants, interventions, comparator, length of follow‐up, instruments used for measuring outcomes, funding source, and conflicts of interest for each included trial. Two review authors (MK, SC, RP, or VC) independently extracted data using a standardised data collection form. Any disagreements were resolved through discussion or by consulting a third review author (RJB) when necessary. We requested that trial authors who agreed to provide information or data beyond those available in the public sphere share protocol and statistical analysis plan details, along with details of available data fields. For a trial in which MK and RJB were investigators (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), SC or VC performed data extraction, and RP acted as arbiter. </p> <p>All IPD data used in the review were de‐identified. The list of variables that we requested from each trial is provided in <a href="./appendices#CD013534-sec-0110">Appendix 7</a>. We transferred specific data fields and then cleaned and coded data for analysis for those trials willing to provide IPD. Data sources from previously published trials were provided as anonymised whole databases when trial authors preferred. We carried out range and consistency checks for all data. Any missing data, obvious errors, inconsistencies between variables, or extreme values were queried and rectified with individual trial authors as necessary. We also cross‐checked summaries of provided data with those in published reports of the trial and contacted original trial authors to resolve identified inconsistencies. We kept a secure record of all correspondence, agreements and data transfers with trial authors, and the review database. </p> <p>For included trials that were unable to provide IPD, we recorded the reason for data unavailability and requested aggregate data on our outcomes. If aggregate data could not be obtained directly from the trial authors, two review authors assessed whether any relevant appropriate aggregate‐level data were available in the trial publication or other sources (e.g. clinical trials registries). We recorded aggregate data on a standardised data extraction form. Two review authors (MK, RP or SC) independently extracted data. Any disagreements on extracted aggregate data were discussed and resolved by consensus, with no requirement for a third review author to arbitrate. </p> <p>The detailed statistical analysis plan for this review was written when data to be collected for the trials providing IPD were known, but before any grouped outcome data from prospective trials had been evaluated (<a href="./references#CD013534-bbs2-0248" title="CroS , BoyleR , KelleherM , TranL , CorneliusV . Skin care interventions for preventing eczema and food allergy: a statistical analysis plan for a systematic review and individual participant data meta-analysis. zenodo.org/record/3610604#.XiGKU8j7SUk (accessed 16 January 2020). [DOI: 10.5281/zenodo.3610604]">Cro 2020a</a>). The statistical analysis plan was therefore written with consideration of the nature and limitations of the data recorded in trials known to be eligible for inclusion, and the statistician remained blind to intervention and control group outcomes for each data field, so that bias was not introduced by exploring the possible impact of different data analyses and coding decisions on findings. </p> </section> <section id="CD013534-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias using version 2 of the Cochrane tool for assessing risk of bias in randomised trials (RoB 2) (<a href="./references#CD013534-bbs2-0277" title="HigginsJP , SavovicJ , PageMJ , SterneJA , ROB2 development group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 5 February 2019).">Higgins 2018</a>; <a href="./references#CD013534-bbs2-0279" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021b</a>), which is designed specifically for RCTs and assesses bias based on the following five domains. </p> <p> <ol id="CD013534-list-0006"> <li> <p>Bias arising from the randomisation process.</p> </li> <li> <p>Bias due to deviations from intended interventions.</p> </li> <li> <p>Bias due to missing outcome data.</p> </li> <li> <p>Bias in measurement of the outcome.</p> </li> <li> <p>Bias in selection of the reported result.</p> </li> </ol> </p> <p>We assessed risk of bias separately for eczema (by age one to three years using the closest time point to two years), food allergy (by age one to three years using the closest time point to two years), slippage accidents (during the intervention period), skin infection (during the intervention period), allergic reactions (during the intervention period), time to onset of eczema, parent report of food allergy reaction (at age one to three years using the closest time point to two years), and allergic sensitisation (at age one to three years using the closest time point to two years). The RoB 2 tool is outcome‐specific, and we rated each domain as 'low risk of bias', 'some concerns', or 'high risk of bias'. For bias due to deviations from intended interventions, we were interested in the effects of assignment to the interventions at baseline, regardless of whether interventions were received as intended, by an intention‐to‐treat analysis that included all randomised participants. Bias in selection of the reported result was low risk for all prospectively identified studies, as we obtained the full data set for these trials. We did not perform risk of bias assessments for qualitative narrative information. </p> <p>At the time of writing of this review, the RoB 2 tool for cluster‐RCTs was under development. For cluster‐RCTs, we therefore similarly assessed risk of bias using RoB 2 as outlined above (<a href="./references#CD013534-bbs2-0277" title="HigginsJP , SavovicJ , PageMJ , SterneJA , ROB2 development group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 5 February 2019).">Higgins 2018</a>), but included an additional cluster‐RCT‐specific domain from the archived version of the RoB 2 tool for cluster‐RCTs (<a href="./references#CD013534-bbs2-0261" title="EldridgeS , CampbellM , CampbellM , DrahotaA , GiraudeauB , HigginsJ , et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. www.riskofbias.info/welcome/rob-2-0-tool/archive-rob-2-0-cluster-randomized-trials-2016 (accessed 14 October 2020).">Eldridge 2016</a>): 'Domain 1b ‐ Bias arising from the timing and identification and recruitment of participants'. </p> <p>We used the following criteria to reach an overall risk of bias judgement for a specific outcome. </p> <p> <ol id="CD013534-list-0007"> <li> <p>Overall low risk of bias: all domains considered at low risk for the specific result.</p> </li> <li> <p>Some concerns: some concerns have been raised in at least one domain for the specific result, but no domains are considered at high risk of bias. </p> </li> <li> <p>High risk of bias: at least one domain is considered at high risk for the specific result, or there are some concerns for multiple domains, which substantially lowers confidence in the result. </p> </li> </ol> </p> <p>Two review authors (MK, SC, VC, or RP) independently conducted risk of bias assessments, with any disagreements resolved through discussion or through arbitration with a third review author (RJB). For a trial in which MK and RJB were investigators (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), SC and VC independently conducted risk of bias assessments with RP acting as arbiter. </p> </section> <section id="CD013534-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes when meta‐analysis was considered appropriate, we calculated risk ratios (RRs). For continuous outcomes when trials used the same measurement scale, we calculated mean differences (MDs); when trials used different measurement scales, we calculated standardised mean differences (SMDs). For time‐to‐event outcomes, we expressed the intervention effect as a hazard ratio (HR). We computed a 95% confidence interval (CI) for each outcome. </p> </section> <section id="CD013534-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>This review included RCTs only. As discussed below (see <a href="#CD013534-sec-0042">Data synthesis</a>), we adopted a two‐stage approach for this IPD meta‐analysis. In stage 1, we separately estimated the treatment effect of interest for each included trial. In stage 2, we pooled treatment effects using methods for meta‐analyses of aggregate data. </p> <p>We included factorial RCTs and cluster‐RCTs. For factorial randomised trials, if we noted a significant interaction between the two active interventions with respect to our primary outcome, we included only the arms ‘skin care intervention/control’ versus ‘control/control’. We explored through sensitivity analysis the impact of including data from all arms of factorial trials when an interaction was present, with adjustment for non‐skin care interventions. </p> <p>For other trials with more than two treatment arms (excluding factorial trials, which were handled as described above), which could have multiple intervention groups in a particular meta‐analysis, we combined all relevant intervention groups into a single intervention group and all relevant control groups into a single control group.  </p> <p>For all stage 1 analyses for cluster‐RCTs providing IPD, we used mixed models that permit analysis at the level of the individual whilst accounting for clustering in the data. Treatment effects from cluster‐RCTs were therefore appropriately adjusted for correlation within clusters before inclusion in the stage 2 (pooled) analysis, following recommendations for the analysis of cluster‐RCTs (<a href="./references#CD013534-bbs2-0278" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021a</a>). </p> <p>For cluster‐RCTs providing non‐IPD, we planned to extract data from trial reports that had taken into account the clustering in these data, and then analyse the data using the generic inverse‐variance method in Review Manager Web (<a href="./references#CD013534-bbs2-0313" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). If data were not adjusted for clustering, we would attempt to estimate the intervention effect by calculating an intracluster correlation coefficient (ICC), whilst following the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013534-bbs2-0278" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021a</a>).  </p> </section> <section id="CD013534-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data according to the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013534-bbs2-0254" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Deeks 2021</a>). We contacted trial authors to resolve missing information about methodological properties of identified trials. When trial authors were unable to provide the required information, we rated the relevant risk of bias criterion using the Cochrane RoB 2 tool (<a href="./references#CD013534-bbs2-0277" title="HigginsJP , SavovicJ , PageMJ , SterneJA , ROB2 development group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 5 February 2019).">Higgins 2018</a>). We did not anticipate substantial quantities of missing data for the primary outcomes. For trials providing IPD, we naturally handled missing participant data under the assumption of missing‐at‐random within each trial analysis. </p> <p>We planned that for trials that did not provide IPD and reported an MD but no standard deviation (SD) or other statistic that could be used to derive the SD, we would use imputation (<a href="./references#CD013534-bbs2-0267" title="FurlanAD , PennickV , BombardierC , Van TulderM , Editorial Board, Cochrane Back Review Group. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine2009;34(18):1929-41.">Furlan 2009</a>). Specifically, we planned to impute SDs for each outcome using the pooled SD across all other trials within the same meta‐analysis by treatment group. This is an appropriate method of analysis if a majority of the trials do not have missing SDs in the meta‐analysis. If a large proportion of trials (e.g. ≥ 20%) were missing data on parameter variability for a particular outcome, imputation would not have been appropriate, and we would have conducted analysis using only trials providing complete data, and discussed the implications of this alongside the results. However, such imputation did not prove necessary. </p> <p>In risk of bias assessments, to address the impact of non‐negligible missing data (≥ 5%) on individual trial outcomes, we conducted sensitivity analyses using IPD and best‐case/worst‐case scenarios, that is we conducted analysis by imputing a best‐case scenario of response in both treatment groups, followed by analysis under a worst‐case scenario of no response in both treatment groups. Results of sensitivity analyses under these scenarios were compared to primary complete‐case analyses (conducted under the missing‐at‐random assumption) to assess risk of bias due to missing data. </p> <p>We included trials with substantial quantities of missing data (e.g. rated as high risk of bias or some concerns due to missing data) in meta‐analysis, but to investigate the robustness of pooled results, we performed sensitivity analysis whilst excluding trials rated overall at high risk of bias or with some concerns, which included excluding trials rated at high risk of bias or some concerns due to missing data.  </p> </section> <section id="CD013534-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined both clinical and statistical heterogeneity, combining data in meta‐analysis only when we judged that evaluation would yield a meaningful summary. We assessed clinical heterogeneity by examining the characteristics of included participants, types of interventions, primary and secondary outcomes, and follow‐up period. We used the I² statistic and the Chi² test to quantify the degree of statistical heterogeneity of trials judged as clinically homogeneous (<a href="./references#CD013534-bbs2-0276" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). We interpreted the I² statistic as follows: </p> <p> <ul id="CD013534-list-0008"> <li> <p>0% to 40%: might not be important heterogeneity; </p> </li> <li> <p>30 to 60%: may represent moderate heterogeneity; </p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; </p> </li> <li> <p>greater than 75%: indicative of considerable heterogeneity (<a href="./references#CD013534-bbs2-0254" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Deeks 2021</a>).  </p> </li> </ul> </p> <p>The observed I² value was judged against this guide in combination with its 95% CI, the P value from the Chi² test, and the magnitude and direction of effect. When the magnitude and direction of effects and the strength of evidence for heterogeneity based on the P value from the Chi² confidence intervals for I² revealed heterogeneity, or if we observed considerable heterogeneity, we explored reasons for heterogeneity, and when appropriate conducted sensitivity analysis whilst excluding any trials identified as outlying. </p> </section> <section id="CD013534-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>By including as many prospective trials as possible in this review, as well as IPD, the risks of reporting bias and publication bias should have been reduced. However, we planned that if at least 10 trials were included in the meta‐analysis, we would formally assess reporting bias using funnel plots to explore the likelihood of any reporting bias or small‐study effects. We planned to assess funnel plot asymmetry visually and to use formal tests for funnel plot asymmetry. For continuous outcomes, we planned to use the test proposed by Egger (<a href="./references#CD013534-bbs2-0259" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). For dichotomous outcomes, we planned to use the test proposed by Rucker when estimated between‐study heterogeneity variance of log odds ratios, Tau², was greater than 0.1 (<a href="./references#CD013534-bbs2-0317" title="RuckerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine2008;27(5):746-63.">Rucker 2008</a>). Otherwise, when the heterogeneity variance Tau² was less than 0.1, we would use one of the tests proposed by Harbord (<a href="./references#CD013534-bbs2-0275" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57.">Harbord 2006</a>). We planned that if asymmetry was detected in any of these tests or was suggested by a visual assessment, we would explore and discuss possible explanations. However, we did not conduct a meta‐analysis including 10 or more trials, therefore we did not undertake any formal assessment of reporting bias. </p> </section> <section id="CD013534-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We conducted an IPD meta‐analysis of both prospective and retrospectively acquired data. Primary meta‐analysis used IPD only. We did not use aggregate data in the primary meta‐analysis when IPD could not be provided, as the total proportion of participants that made up aggregate data was less than 10% of the overall number of participants across all trials (i.e. total aggregate data represented a negligible proportion of the data set). We performed a sensitivity analysis by adding in the aggregate data, as described below, to explore the impact of data availability bias. We undertook a prospectively planned meta‐analysis (PPMA) of a more limited number of trials as a sensitivity analysis. PPMA was limited to those trials in which trial authors were not aware of trial outcomes at the time of PPMA protocol registration on PROSPERO (<a href="./references#CD013534-bbs2-0238" title="BoyleR , WilliamsH , AskieL , Lodrup-CarlsenK , MontgomeryA , ChalmersJ , et al. Prospectively planned meta-analysis of skin barrier studies for the prevention of eczema and associated health conditions. www.crd.york.ac.uk/prospero/display_record.php?RecordID=56965 (first received 10 February 2017).">Boyle 2017</a>). </p> <p>The main analyses estimated the effect of being assigned to receive the intervention, according to the intention‐to‐treat principle. We retained all eligible participants in the treatment group to which they had originally been assigned who had an outcome, irrespective of the treatment they actually received. To understand the effect of compliance, we included pre‐planned secondary supplementary analysis to estimate the complier average causal effect. </p> <p>We planned to perform all analyses stratified by type of intervention group. Our planned comparisons were therefore: </p> <p> <ol id="CD013534-list-0009"> <li> <p>skin care intervention versus no treatment or standard care;</p> </li> <li> <p>skin care intervention 'A' versus no treatment or standard care;</p> </li> <li> <p>skin care intervention 'B' versus no treatment or standard care.</p> </li> </ol> </p> <p>We planned to consider interventions in two broad categories: A interventions promoting hydration and skin barrier mainly through emollients, and B interventions that would protect from harm, such as water softeners or avoidance of irritants. Because our search did not reveal any completed eligible trials of B‐type skin care interventions, it did not prove necessary to stratify comparisons by type of skin care intervention, therefore we undertook only comparisons of type A. For each outcome, when we judged a sufficient number of trials (two or more) to be clinically similar, we pooled results in a meta‐analysis. When we did not undertake meta‐analyses owing to clinical heterogeneity or to insufficient data, we discussed the results from individual trials narratively. </p> <p>We adopted a two‐stage approach to analysis for all primary and secondary analyses. In the first stage, we derived individual trial treatment effect estimates from IPD. For analyses of binary outcomes, including both primary outcomes (eczema and food allergy), the stage 1 model, fitted to each trial providing IPD separately, was a binomial regression model. For analyses of continuous outcomes, the stage 1 model fitted to each trial providing IPD was a linear regression model. For time‐to‐event outcomes, the stage 1 model fitted to each trial providing IPD was a binomial regression model with a complementary log‐log link, where follow‐up time was split into appropriate intervals for the obtained data (3 months, 6 months, 12 months, 18 months, and 24 months). This model was appropriate for time‐to‐event data of a discrete nature. In addition to the treatment group variable indicating use of a skin care intervention, we included the important prognostic factors of sex and family history of atopic disease within the stage 1 models. </p> <p>In the second stage, we combined derived treatment effects using methods for meta‐analyses of aggregate data. We used random‐effects models in stage 2 to derive the pooled treatment effect (<a href="./references#CD013534-bbs2-0255" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>; <a href="./references#CD013534-bbs2-0314" title="RileyRD , LambertPC , Abo-ZaidG . Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ2010;340: c221. [PMID: 20139215]">Riley 2010</a>). We planned to use random‐effects models because we anticipated some level of variability across trials, for example by types of interventions, length of follow‐up, and methods of measurement. A random‐effects model incorporates heterogeneity amongst trials and allows the true treatment effect to be different in each trial. In sensitivity analysis, the second stage also included aggregate data from trials whose authors did not provide IPD. </p> <p>We performed residual analysis for all IPD meta‐analyses and PPMAs to assess model assumptions and fit. Meta‐analyses also included trial sequential analysis, using two‐sided 5% significance and 80% power to estimate optimum heterogeneity‐adjusted information sizes needed to identify relative risk reductions of 20% and 30% (<a href="./references#CD013534-bbs2-0347" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>). We estimated control event rates using random‐effects meta‐analyses of pooled proportions from the largest trials included in the meta‐analyses and compared them with event rates from large population‐based studies. We used trial sequential analysis to identify when the optimum information size or futility boundaries for predefined effect sizes in relation to primary outcomes would be reached. We performed stage 1 of the IPD meta‐analysis in Stata 15 or above (<a href="./references#CD013534-bbs2-0325" title="Stata. Version 15. College Station, TX, USA: StataCorp, 2017. Available at www.stata.com.">Stata</a>), with summary results of these analyses added to <a href="./references#CD013534-bbs2-0313" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>. </p> <p>To explore the impact of compliance, we estimated the effect of complying with the intended intervention. For the subgroup of trials providing compliance data, we estimated the complier average causal effect (CACE) for each primary outcome. As in the primary analysis, we followed a two‐stage approach to analysis. For each trial, we estimated the CACE using instrumental variable (IV) analysis. We used randomisation as an instrumental variable for intervention received, and we estimated the CACE using a two‐stage residual inclusion estimator approach (2SRI) (<a href="./references#CD013534-bbs2-0246" title="CookJA , MacLennanGS , PalmerT , LoisN , EmsleyR . Instrumental variable methods for a binary outcome were used to informatively address noncompliance in a randomized trial in surgery. Journal of Clinical Epidemiology2018;96:126-32.">Cook 2018</a>). Randomisation meets the criteria for an adequate instrument in that (i) randomisation predicts the treatment receipt; (ii) randomisation is unconfounded with the outcome; and (iii) we assume no direct effect of randomisation on the outcome (other than via treatment receipt): 'the exclusion restriction'. Here, we initially defined a ‘complier’ as an individual who used the prescribed intervention for three or more days a week over the intervention period. When interventions and the quality of compliance data were sufficiently comparable, we used random‐effects models in stage 2 to derive the pooled CACE effect. We repeated the primary analysis for each of the trials in the subgroup of trials with compliance data to compare pooled CACE estimates against the primary treatment effect (RR) whilst estimating the effect of being assigned to the intervention for the subgroup of trials for which compliance data were available. Subsequently, we explored the impact of different threshold values for defining compliance (≥ 5 days a week over the intervention period, 7 days over the intervention period, ≥ 3 days a week over the first 3 months of the intervention period, ≥ 5 days a week over the first 3 months of the intervention period, and 7 days a week over the first 3 months of the intervention period). </p> <p>The detailed statistical analysis plan, which set out all comparisons to be made and the precise model forms and fitting strategy to be used, may be consulted for additional information (<a href="./references#CD013534-bbs2-0248" title="CroS , BoyleR , KelleherM , TranL , CorneliusV . Skin care interventions for preventing eczema and food allergy: a statistical analysis plan for a systematic review and individual participant data meta-analysis. zenodo.org/record/3610604#.XiGKU8j7SUk (accessed 16 January 2020). [DOI: 10.5281/zenodo.3610604]">Cro 2020a</a>). For trials providing only narrative information, or incomplete measures of effect (i.e. no denominators available) when meta‐analysis could not be performed, we summarised available effect estimates or narrative information alongside meta‐analyses for the same groupings of populations, interventions, outcomes, and study design as were used in the quantitative meta‐analysis. </p> </section> <section id="CD013534-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We identified the following subgroups of interest a priori for analysis in this update.</p> <p> <ol id="CD013534-list-0010"> <li> <p>By participant‐level characteristics</p> <ol id="CD013534-list-0011"> <li> <p>Comparing effects of the intervention on 'high' or 'not high' genetic risk for atopy based on <i>FLG</i> genotype or the chromosome 11 intergenic variant rs2212434, or both. </p> </li> <li> <p>Comparing effects of the intervention on 'high' or 'not high' risk for atopy based on family history of allergic disease. </p> </li> </ol> </li> <li> <p>By study‐level characteristics</p> <ol id="CD013534-list-0012"> <li> <p>Comparing effects of interventions aimed at preventing damage to the skin (e.g. reduced exposure to soaps, wipes, bathing, hard water) versus interventions aimed at promoting skin hydration or barrier function (e.g. emollient cream, lotion, ointment, oil) versus combined treatment. </p> </li> <li> <p>Intervention timing: comparing effects of intervention on participants advised to commence the skin care intervention within the first four weeks of life versus those who commenced intervention after four weeks. </p> </li> <li> <p>Intervention duration: comparing duration of intended treatment, when 'short' is regarded as up to six months of treatment, and 'longer' is six months' duration or longer. When feasible, we planned to undertake modelling to assess the relationship between study outcome and timing or duration of intervention. </p> </li> </ol> </li> </ol> </p> <p>We calculated subgroup effects for participant‐level characteristics on the two primary outcomes by first estimating treatment by covariate interaction terms within studies using IPD. We then combined interaction terms across studies in the same way as for the main intervention effects, using a random‐effects meta‐analysis. For study‐level characteristics, we pooled treatment effects separately for each characteristic, and performed a test for subgroup differences using a Chi² test. </p> </section> <section id="CD013534-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted the following a priori planned sensitivity analyses for the co‐primary outcomes when relevant. </p> <p> <ol id="CD013534-list-0013"> <li> <p>By overall risk of bias: in primary analysis, we included all trials regardless of overall risk of bias, and undertook a sensitivity analysis of trial outcomes assessed as having an overall low risk of bias. The 'low risk of bias' sensitivity analysis excluded trial outcomes at overall high risk or those with some concerns, as assessed via the Cochrane RoB 2 tool (<a href="./references#CD013534-bbs2-0277" title="HigginsJP , SavovicJ , PageMJ , SterneJA , ROB2 development group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 5 February 2019).">Higgins 2018</a>). This included omitting trial outcomes with high risk of bias and those with some concerns due to missing data, because inclusion would have led to the trial receiving an overall rating that was not low risk of bias. </p> </li> <li> <p>By outcome measures: we explored the impact of using different definitions of outcome measures by undertaking sensitivity analyses of outcomes that had previously been validated. For the primary outcome of eczema, in the absence of agreed‐upon core outcomes, we undertook sensitivity analysis of eczema evaluated using only the UK Working Party Criteria (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), or other variations of the Hanifin and Rajka criteria (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>). For the primary outcome of food allergy, we undertook sensitivity analysis for secure diagnosis of food allergy by oral food challenge or investigator decision using an algorithm developed for the Barrier Enhancement for Eczema Prevention (BEEP) study. </p> </li> <li> <p>Including aggregate data from trials that did not provide IPD: as aggregate data made up less than 10% of the total number of participants across all trials, our primary analysis included IPD only, and we conducted a sensitivity analysis <i>including</i> aggregate data from trials that did not provide IPD. </p> </li> <li> <p>Excluding any data that were not prospectively acquired: prospectively acquired data are data that were not known to the study chief investigator, in analysed and unblinded form, before 10 February 2017. PPMA reduces bias related to the knowledge of existing trial outcomes, which might influence trial selection in a retrospective study, because trials are included without any knowledge of outcome. Additionally, outcomes across prospectively planned trials were more closely aligned due to awareness of being included in this IPD meta‐analysis. We conducted sensitivity analysis of prospectively acquired data using the same approach to the primary analysis (i.e. using IPD only; see <a href="#CD013534-sec-0042">Data synthesis</a>). </p> </li> <li> <p>To explore heterogeneity: when considerable statistical heterogeneity was observed (I² &gt; 75%), we explored reasons for heterogeneity, and when appropriate conducted sensitivity analysis whilst excluding any trials identified as outlying. Outlying trials are those with very different trial findings from others reporting comparable interventions/outcomes. We identified outliers from inspection of individual trial treatment estimates and 95% CIs in forest plots. </p> </li> <li> <p>Including data from all arms of factorial trials with a significant interaction: for factorial trials, when there was a significant interaction between the two active interventions with respect to our primary outcome, we included only the arms ‘skin care intervention/control’ versus ‘control/control’. In such scenarios, we performed an additional sensitivity analysis exploring the impact of including data from all arms of factorial trials, with adjustment for the non‐skin barrier intervention in stage 1 of the analysis. </p> </li> </ol> </p> </section> <section id="CD013534-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We planned to include the following summary of findings tables.</p> <p> <ol id="CD013534-list-0014"> <li> <p>Summary of findings table 1: Skin care intervention versus no treatment or standard care only. </p> <ol id="CD013534-list-0015"> <li> <p>This table includes primary estimates of treatment effects in addition to key sensitivity analyses for primary outcomes. </p> </li> </ol> </li> <li> <p>Summary of findings table 2: Skin care intervention A versus no treatment or standard care only. Intervention A = skin care interventions that aim to promote hydration or barrier function. </p> <ol id="CD013534-list-0016"> <li> <p>This table would include subgroup analyses of low risk of eczema and food allergy versus high risk of eczema and food allergy, either by <i>FLG</i> mutation or by family history of allergic disease. </p> </li> </ol> </li> <li> <p>Summary of findings table 3: Skin care intervention B versus no treatment or standard care only. Intervention B = skin care interventions that aim to prevent damage. </p> <ol id="CD013534-list-0017"> <li> <p>This table would include subgroup analyses of low risk of eczema and food allergy versus high risk of eczema and food allergy, either by <i>FLG</i> mutation or by family history of allergic disease. </p> </li> </ol> </li> </ol> </p> <p>It did not prove necessary to stratify comparisons by types of skin care interventions because we did not identify any eligible trials of skin care intervention type B. We therefore included only <a href="./full#CD013534-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013534-sec-0046"> <h5 class="title">Outcomes for summary of findings tables</h5> <section id="CD013534-sec-0047"> <h6 class="title">Primary outcomes</h6> <p> <ol id="CD013534-list-0018"> <li> <p>Eczema diagnosis</p> </li> <li> <p>IgE‐mediated food allergy</p> </li> </ol> </p> </section> <section id="CD013534-sec-0048"> <h6 class="title">Key secondary outcomes</h6> <p> <ol id="CD013534-list-0019"> <li> <p>Adverse events during the intervention period, such as slippage, skin infection, stinging, or allergic reaction to moisturiser </p> </li> <li> <p>Time to onset of eczema</p> </li> <li> <p>Parental report of immediate reaction to a common food allergen</p> </li> <li> <p>Allergic sensitisation to a food allergen</p> </li> </ol> </p> <p>We included outcomes for sensitivity analyses by method of outcome assessment and by risk of bias in the 'Comments' section of <a href="./full#CD013534-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> <section id="CD013534-sec-0049"> <h5 class="title">Certainty of the evidence</h5> <p>We applied the GRADE approach to our main comparisons listed above (<a href="./references#CD013534-bbs2-0228" title="AndrewsJC , SchunemannHJ , OxmanAD , PottieK , MeerpohlJJ , CoelloPA , et al. GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology2013;66(7):726-35. [DOI: 10.1016/j.jclinepi.2013.02.003]">Andrews 2013</a>; <a href="./references#CD013534-bbs2-0318" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021</a>). The outcomes included in our summary of findings table are the primary outcomes of eczema and food allergy, along with key secondary outcomes of adverse events, time to onset of eczema, parental report of immediate food allergy, and allergic sensitisation to a food allergen. Two review authors (MK, SC, VC, or RJB) independently assessed each outcome for risk of bias, imprecision, inconsistency, indirectness, and publication bias, downgrading the certainty of evidence when appropriate. For assessing a trial for which MK and RJB were investigators (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), SC and VC independently performed GRADE assessment for that study. We graded each outcome as high, moderate, low, or very low certainty. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013534-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013534-sec-0050"></div> <section id="CD013534-sec-0051"> <h3 class="title">Description of studies</h3> <p>We included 33 RCTs in the review. </p> <section id="CD013534-sec-0052"> <h4 class="title">Results of the search</h4> <p>For this update, we re‐ran our searches of four databases and two trials registers (see <a href="#CD013534-sec-0026">Electronic searches</a>). Across this update and the previous version of this review, we retrieved a total of 10,884 records from these sources. Our searches of other resources (conference proceedings, scanning bibliographies) identified no further relevant records. After de‐duplication, 9964 records remained. We excluded 9676 records based on title and abstract and obtained the full texts of the remaining 288 records. We excluded 191 studies reported in 194 references, of which 15 were duplicates. Reasons for excluding the 176 studies are provided in <a href="./references#CD013534-sec-0124" title="">Characteristics of excluded studies</a>. We identified 11 ongoing studies reported in 14 references (see <a href="./references#CD013534-sec-0126" title="">Characteristics of ongoing studies</a>), and 4 studies reported in 5 references are awaiting classification (see <a href="./references#CD013534-sec-0125" title="">Characteristics of studies awaiting classification</a>). We included 33 studies reported in 75 references in the review (see <a href="./references#CD013534-sec-0123" title="">Characteristics of included studies</a>). Our screening process is illustrated in a study flow diagram (<a href="#CD013534-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013534-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013534-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013534-sec-0053"> <h4 class="title">Included studies</h4> <p>We included 33 studies involving a total of 25,827 participants in the review. For details on each trial, see <a href="./references#CD013534-sec-0123" title="">Characteristics of included studies</a>. Of the 33 included studies, 17 trials randomising 5823 participants reported outcome data relevant to eczema, food allergy, or the adverse events of interest; these data were IPD, either aggregate or narrative. Of the 17 studies, 11 studies randomising 5217 participants (of which 10 studies provided IPD) were included in one or more meta‐analysis.  </p> <p>The remaining 16 included studies did not report any outcome data relevant to the review (<a href="./references#CD013534-bbs2-0001" title="Abraham D,  Ravindran V,  Joseph M. Effectiveness of chlorhexidine bath, saline bath and standard bath on skin health status. Indian Journal of Public Health Research and Development2019;10(8):563-8. [DOI: 10.37506/ijphrd.v10i8.7446]">Abraham 2019</a>; <a href="./references#CD013534-bbs2-0003" title="BaldwinS ,  Odio MR,  Haines SL, O'ConnorRJ ,  Englehart JS, LaneAT . Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. Journal of the European Academy of Dermatology and Venereology2001;15(s1):5-11. [DOI: 10.1046/j.0926-9959.2001.00002.x]">Baldwin 2001</a>; <a href="./references#CD013534-bbs2-0010" title="Duan Y, MaL ,  Galzote C, KongFQ ,  Shen CP. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clinical, Cosmetic and Investigational Dermatology2019;12:895-909. [DOI: 10.2147/CCID.S204216]NCT02981056. A clinical assessment of the efficacy and effects of different skincare regimens on infants. clinicaltrials.gov/ct2/show/NCT02981056 (first received 2 December 2016). ">Duan 2019</a>; <a href="./references#CD013534-bbs2-0011" title="Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,  Proquitté H,  Wauer RR, et al. Effect of standardized skin care regimens on neonatal skin barrier function in different body areas. Pediatric Dermatology2010;27(1):1‐8. [DOI: 10.1111/j.1525-1470.2009.01068.x]">Garcia Bartels 2010</a>; <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a>; <a href="./references#CD013534-bbs2-0013" title="Garcia Bartels N,  Massoudy L,  Scheufele R, DietzE ,  Proquitté H,  Wauer R, et al. Standardized diaper care regimen: a prospective, randomized pilot study on skin barrier function and epidermal IL-1α in newborns. Pediatric Dermatology2012;29(3):270‐6. [DOI: 10.1111/j.1525-1470.2011.01590.x]NCT01131403. Clinical analysis of the influence of using the skin care products on the diaper area in comparison with using a cotton wool cloth, moistened with clear water on the skin physiology of the newborns from the 1st day to the 4th week of life. clinicaltrials.gov/ct2/show/NCT01131403 (first received 27 May 2010). ">Garcia Bartels 2012</a>; <a href="./references#CD013534-bbs2-0014" title="Garcia Bartels N,  Lunnemann L,  Stroux A,  Kottner J, SerranoJ ,  Blume-Peytavi U. Effect of diaper cream and wet wipes on skin barrier properties in infants: a prospective randomized controlled trial. Pediatric Dermatology2014;31(6):683-91. [DOI: 10.1111/pde.12370]">Garcia Bartels 2014</a>; <a href="./references#CD013534-bbs2-0017" title="ISRCTN72285670. Baby Skin Care Trial: a study comparing an infant skin-cleansing product with water. www.isrctn.com/ISRCTN72285670 (first received 17 March 2009). [DOI: 10.1186/ISRCTN72285670]LavenderT ,  Bedwell C, O'BrienE , CorkMJ , TurnerM , HartA . Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial. BMC Pediatrics2011;11:35. [DOI: 10.1186/1471-2431-11-35]">Lavender 2011</a>; <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>; <a href="./references#CD013534-bbs2-0019" title="LavenderT ,  Bedwell C, RobertsSA , HartA , TurnerMA , CarterLA , et al. Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates. Journal of Obstetric, Gynaecologic, and Neonatal Nursing2013;42(2):203‐14. [DOI: 10.1111/1552-6909.12015]">Lavender 2013</a>; <a href="./references#CD013534-bbs2-0021" title="LundC ,  Kuller J, DurandDJ . Baby's first bath: changes in skin barrier function after bathing full-term newborns with water vs liquid baby cleanser. Pediatric Dermatology2019;37:115-9. [DOI: 10.1111/pde.14037]">Lund 2020</a>; <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a>; <a href="./references#CD013534-bbs2-0026" title="RushJ . Does routine newborn bathing reduce Staphylococcus aureus colonization rates? A randomized controlled trial. Birth1986;13(3):176‐80. ">Rush 1986</a>; <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a>; <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a>; <a href="./references#CD013534-bbs2-0033" title="Zhao S,  Xie L, HuH , Xia J, ZhangW , YeN , et al. A study of neonatal swimming (water therapy) applied in clinical obstetrics. Journal of Maternal-Fetal &amp; Neonatal Medicine2005;17(1):59‐62. [DOI: 10.1080/14767050400028782]">Zhao 2005</a>). Ten of these studies assessed the impact of short‐term application of skin care products in term infants in the first few weeks of life on physiological skin outcomes (<a href="./references#CD013534-bbs2-0001" title="Abraham D,  Ravindran V,  Joseph M. Effectiveness of chlorhexidine bath, saline bath and standard bath on skin health status. Indian Journal of Public Health Research and Development2019;10(8):563-8. [DOI: 10.37506/ijphrd.v10i8.7446]">Abraham 2019</a>; <a href="./references#CD013534-bbs2-0010" title="Duan Y, MaL ,  Galzote C, KongFQ ,  Shen CP. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clinical, Cosmetic and Investigational Dermatology2019;12:895-909. [DOI: 10.2147/CCID.S204216]NCT02981056. A clinical assessment of the efficacy and effects of different skincare regimens on infants. clinicaltrials.gov/ct2/show/NCT02981056 (first received 2 December 2016). ">Duan 2019</a>; <a href="./references#CD013534-bbs2-0011" title="Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,  Proquitté H,  Wauer RR, et al. Effect of standardized skin care regimens on neonatal skin barrier function in different body areas. Pediatric Dermatology2010;27(1):1‐8. [DOI: 10.1111/j.1525-1470.2009.01068.x]">Garcia Bartels 2010</a>; <a href="./references#CD013534-bbs2-0013" title="Garcia Bartels N,  Massoudy L,  Scheufele R, DietzE ,  Proquitté H,  Wauer R, et al. Standardized diaper care regimen: a prospective, randomized pilot study on skin barrier function and epidermal IL-1α in newborns. Pediatric Dermatology2012;29(3):270‐6. [DOI: 10.1111/j.1525-1470.2011.01590.x]NCT01131403. Clinical analysis of the influence of using the skin care products on the diaper area in comparison with using a cotton wool cloth, moistened with clear water on the skin physiology of the newborns from the 1st day to the 4th week of life. clinicaltrials.gov/ct2/show/NCT01131403 (first received 27 May 2010). ">Garcia Bartels 2012</a>; <a href="./references#CD013534-bbs2-0014" title="Garcia Bartels N,  Lunnemann L,  Stroux A,  Kottner J, SerranoJ ,  Blume-Peytavi U. Effect of diaper cream and wet wipes on skin barrier properties in infants: a prospective randomized controlled trial. Pediatric Dermatology2014;31(6):683-91. [DOI: 10.1111/pde.12370]">Garcia Bartels 2014</a>; <a href="./references#CD013534-bbs2-0017" title="ISRCTN72285670. Baby Skin Care Trial: a study comparing an infant skin-cleansing product with water. www.isrctn.com/ISRCTN72285670 (first received 17 March 2009). [DOI: 10.1186/ISRCTN72285670]LavenderT ,  Bedwell C, O'BrienE , CorkMJ , TurnerM , HartA . Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial. BMC Pediatrics2011;11:35. [DOI: 10.1186/1471-2431-11-35]">Lavender 2011</a>; <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>; <a href="./references#CD013534-bbs2-0019" title="LavenderT ,  Bedwell C, RobertsSA , HartA , TurnerMA , CarterLA , et al. Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates. Journal of Obstetric, Gynaecologic, and Neonatal Nursing2013;42(2):203‐14. [DOI: 10.1111/1552-6909.12015]">Lavender 2013</a>; <a href="./references#CD013534-bbs2-0021" title="LundC ,  Kuller J, DurandDJ . Baby's first bath: changes in skin barrier function after bathing full-term newborns with water vs liquid baby cleanser. Pediatric Dermatology2019;37:115-9. [DOI: 10.1111/pde.14037]">Lund 2020</a>; <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a>). <a href="./references#CD013534-bbs2-0026" title="RushJ . Does routine newborn bathing reduce Staphylococcus aureus colonization rates? A randomized controlled trial. Birth1986;13(3):176‐80. ">Rush 1986</a> evaluated the impact of daily bathing on <i>Staphylococcus aureus</i> colonisation levels. <a href="./references#CD013534-bbs2-0003" title="BaldwinS ,  Odio MR,  Haines SL, O'ConnorRJ ,  Englehart JS, LaneAT . Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. Journal of the European Academy of Dermatology and Venereology2001;15(s1):5-11. [DOI: 10.1046/j.0926-9959.2001.00002.x]">Baldwin 2001</a> assessed diaper products to prevent diaper dermatitis. <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a> assessed the effects of swimming and lotion on infant skin, whilst <a href="./references#CD013534-bbs2-0033" title="Zhao S,  Xie L, HuH , Xia J, ZhangW , YeN , et al. A study of neonatal swimming (water therapy) applied in clinical obstetrics. Journal of Maternal-Fetal &amp; Neonatal Medicine2005;17(1):59‐62. [DOI: 10.1080/14767050400028782]">Zhao 2005</a> evaluated the impact of swimming alone on neonatal skin barrier. <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a> was a cluster‐randomised trial including more than 17,000 participants that evaluated the effects of chlorhexidine wipes on neonatal mortality and infection in rural Nepal. <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a> evaluated the effects of coconut and mineral oil on weight velocity. The longest follow‐up period for these trials was four weeks, and outcomes were physiological skin measures or non‐skin‐related outcomes. These trials met the criteria for inclusion; however, they did not include eczema or food allergy outcomes, or any useable adverse event outcomes.  </p> <section id="CD013534-sec-0054"> <h5 class="title">Participant characteristics</h5> <p>For studies included in the meta‐analysis, almost all participants were enrolled in the study before 14 days of age. </p> <p>Female sex ranged from 43% of participants in <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a> to 56% in <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>. Vaginal delivery ranged from 26% in <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a> to 83% in <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>. </p> </section> <section id="CD013534-sec-0055"> <h5 class="title">Design</h5> <p>As per the inclusion criteria, all trials were RCTs comparing a skin barrier intervention versus standard care or no skin care intervention. Most trials (25/33) recruited infants before one month of age and randomised them to a 'control' group, which provided standard care for infant skin in the locality, or an 'intervention' group. Both intervention and control groups were then followed up at specified intervals for assessment of outcomes. Because the most common intervention was the application of emollients or changes to skin care, in almost all studies participants were not blinded to their allocation status. All trials apart from <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> and <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a> were individually randomised. </p> <p>Two studies were factorial RCTs: <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> was a cluster‐randomised trial evaluating both a skin barrier intervention and early introduction of solid foods. Due to significant interaction between interventions, only the skin care and control arms of the study were used for IPD analysis. <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> was an individually randomised factorial trial evaluating both a skin barrier intervention and an oral synbiotic. Eight studies had more than two arms but included a control arm (<a href="./references#CD013534-bbs2-0001" title="Abraham D,  Ravindran V,  Joseph M. Effectiveness of chlorhexidine bath, saline bath and standard bath on skin health status. Indian Journal of Public Health Research and Development2019;10(8):563-8. [DOI: 10.37506/ijphrd.v10i8.7446]">Abraham 2019</a>; <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0010" title="Duan Y, MaL ,  Galzote C, KongFQ ,  Shen CP. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clinical, Cosmetic and Investigational Dermatology2019;12:895-909. [DOI: 10.2147/CCID.S204216]NCT02981056. A clinical assessment of the efficacy and effects of different skincare regimens on infants. clinicaltrials.gov/ct2/show/NCT02981056 (first received 2 December 2016). ">Duan 2019</a>; <a href="./references#CD013534-bbs2-0011" title="Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,  Proquitté H,  Wauer RR, et al. Effect of standardized skin care regimens on neonatal skin barrier function in different body areas. Pediatric Dermatology2010;27(1):1‐8. [DOI: 10.1111/j.1525-1470.2009.01068.x]">Garcia Bartels 2010</a>; <a href="./references#CD013534-bbs2-0014" title="Garcia Bartels N,  Lunnemann L,  Stroux A,  Kottner J, SerranoJ ,  Blume-Peytavi U. Effect of diaper cream and wet wipes on skin barrier properties in infants: a prospective randomized controlled trial. Pediatric Dermatology2014;31(6):683-91. [DOI: 10.1111/pde.12370]">Garcia Bartels 2014</a>; <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a>; <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a>). </p> <p><a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a> was the pilot study for <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>. <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> was the pilot study for an ongoing study, <a href="./references#CD013534-bbs2-0218" title="ACTRN12617001380381. The PEBBLES Study - testing a strategy for preventing eczema and food allergy in high risk infants. www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617001380381 (first received 28 September 2017). Lowe A, SuJ , TangM , LodgeCJ , Matheson M, AllenKJ ,  et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open2019;9(3):e024594. [DOI: 10.1136/bmjopen-2018-024594]">Lowe 2019</a>. </p> </section> <section id="CD013534-sec-0056"> <h5 class="title">Sample sizes</h5> <p>The three largest studies contributing to data analysis were <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> (n = 2397), <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> (n = 1394), and <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> (n = 549). Eight studies enrolled between 100 and 250 participants (<a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>), and six studies included fewer than 100 participants (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>).  </p> </section> <section id="CD013534-sec-0057"> <h5 class="title">Setting</h5> <p>In most of the included trials, women were approached during pregnancy or in the first few weeks after birth and were offered participation. Most studies were conducted from tertiary referral hospitals. All studies that contributed to the meta‐analysis were conducted in well‐resourced settings. Visits mainly took place at children's hospitals, apart from <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>, which was a pragmatic study, and a majority of end‐of‐study assessments were conducted in participants' homes. <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> recruited from multiple sites across England. <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> recruited mainly in Oslo, Norway, but also in Sweden. Four studies were based in Japan (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). The remaining trials were based in Australia, France, Germany, and the United States. </p> </section> <section id="CD013534-sec-0058"> <h5 class="title">Participants</h5> <p>All trials set their own inclusion and exclusion criteria. The review protocol set inclusion criteria as infants under the age of one year; however, the vast majority of studies in the review that contributed data to meta‐analyses enrolled newborns up to three weeks of age. The exceptions to this were <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a> (infants 3 to 6 months), <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a> (mean age approximately 5.4 months), <a href="./references#CD013534-bbs2-0010" title="Duan Y, MaL ,  Galzote C, KongFQ ,  Shen CP. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clinical, Cosmetic and Investigational Dermatology2019;12:895-909. [DOI: 10.2147/CCID.S204216]NCT02981056. A clinical assessment of the efficacy and effects of different skincare regimens on infants. clinicaltrials.gov/ct2/show/NCT02981056 (first received 2 December 2016). ">Duan 2019</a> (mean age 3 months), and <a href="./references#CD013534-bbs2-0014" title="Garcia Bartels N,  Lunnemann L,  Stroux A,  Kottner J, SerranoJ ,  Blume-Peytavi U. Effect of diaper cream and wet wipes on skin barrier properties in infants: a prospective randomized controlled trial. Pediatric Dermatology2014;31(6):683-91. [DOI: 10.1111/pde.12370]">Garcia Bartels 2014</a> (infants enrolled at 9 months of age). As this was a primary prevention review, infants who already had eczema diagnosed were excluded, along with infants with a known skin condition. Studies that focused on a prespecified population such as preterm infants were excluded, as their findings may not be generalisable. Most studies contributing to meta‐analyses enrolled participants with a family history of allergy, although this was defined in different ways across studies. <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a> included infants with high risk of atopic dermatitis from family history, and <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a> included infants with "family history of AD in second degree of kinship". Four studies included infants with at least one first‐degree relative with eczema, hay fever, or asthma (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>). <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> and <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a> included infants with a self‐reported family history in parent or sibling of any allergic disease, whereas <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a> required two atopic first‐degree relatives. <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>, <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>, and <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a> did not require family history of atopy for enrolment. Key baseline characteristics of participants included in the meta‐analyses are summarised in <a href="#CD013534-tbl-0003">Table 2</a> and <a href="#CD013534-tbl-0004">Table 3</a>. </p> <div class="table" id="CD013534-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]"><b>Chalmers 2020</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]"><b>Cooke 2015</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). "><b>Dissanayake 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]"><b>Horimukai 2014</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]"><b>Lowe 2018a</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]"><b>Migacheva 2018</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). "><b>McClanahan 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]"><b>Simpson 2014</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]"><b>Skjerven 2020</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gestational age: mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (1.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1134 (47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight: mean grams (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3405 (452)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3048 (322)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3054 (363)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3356 (442)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3577 (480)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal delivery: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 (83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age intervention began: mean days (SD)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All &lt; 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Family history atopy: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1394 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 (83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1814 (78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) (1/2 mutations): n (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1394</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>549</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>118</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>80</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>124</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2396</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </div> <div class="table" id="CD013534-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis (continued)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b><a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). "><b>NCT03376243</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]"><b>Yonezawa 2018</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gestational age: mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4 (1.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight: mean grams (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3547 (497)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3017 (362)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal delivery: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age intervention began: mean days (SD)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Family history atopy: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) (1/2 mutations): n (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </div> </section> <section id="CD013534-sec-0059"> <h5 class="title">Interventions</h5> <p>The included studies evaluated any skin barrier intervention that could alter the skin barrier in the infant. We did not identify any completed trials of interventions to reduce exposure to substances that might damage the skin barrier, although we did identify one ongoing trial of a water softener with this aim (<a href="./references#CD013534-bbs2-0217" title="Jabbar-LopezZK , Gurung N,  Greenblatt D,  Briley A, ChalmersJR , ThomasKS , et al. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]NCT03270566. Softened water for eczema prevention pilot trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1 September 2017). ">Jabbar‐Lopez 2019</a>). Some included trials used a single intervention, whilst others used a package of skin care interventions, and two studies were factorial trials. The intervention was compared to standard infant care in the country of the study setting.  </p> <section id="CD013534-sec-0060"> <h6 class="title">i. Emollients</h6> <p>The most common intervention, used in 13 of 33 trials, was emollient with standard care. The type of emollient and the treatment regimen varied across trials. </p> <p>Five trials compared a commercial daily emollient for a treatment duration of three to six months with standard care (<a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a> compared the use of a "French cosmetic brand" emollient in neonates twice daily for the first six months of life versus control, with outcomes measured at six months of age. <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a> randomised newborn infants to an unspecified daily emollient "more than once a day", or to control, for six months, with outcome measured at six months of age. <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> randomised 80 newborn infants to a ceramide dominant emollient (EpiCeram; PuraCap Pharmaceutical LLC, South Plainfield, NJ, USA) or control (no intervention); participants were advised to apply the emollient all over twice a day for six months. Outcomes were measured at 12 months of age. <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a> was the pilot study for <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> and randomised 124 infants to once‐daily all‐over emollient or standard care for six months, starting within three weeks of birth, with outcomes measured at 24 weeks. The emollient was chosen from sunflower oil, Doublebase Gel, or paraffin in UK‐based participants, and from sunflower oil, Aquaphor, or Cetaphil in US‐based participants. In <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>, newborn infants were randomised to an emollient one or more times per day and reduced bathing to every second day or standard care for the control group. Soap for washing was provided by the team. The intervention period lasted from week 1 to week 12 after birth; outcomes were measured at three months of age. </p> <p>Five trials compared the use of commercial emollients with standard care over a longer intervention period, between 32 weeks and 12 months (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>). <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> was a pragmatic RCT of all‐over body, once‐daily emollient from enrolment to one year, with outcome assessment one year after end of treatment. This trial used Doublebase Gel or Diprobase Cream, with participants being able to choose between them and to swap during the study. In <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>, infants younger than one week were randomised to an all‐over, once‐daily emulsion‐type emollient (2e (Douhet) Emulsion; Shiseido, Tokyo, Japan) or to control for 32 weeks. Participants in the control group were allowed to use petroleum jelly if they wished. Outcomes were measured at 32 weeks. <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a> randomised 100 infants under three weeks of age to Cetaphil Restoraderm emollient or to an emollient of choice on an as‐needed basis. The intervention group was advised to apply the emollient all over the baby once daily until 12 months of age, with outcomes recorded at two years of age. <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a> randomised 54 infants less than 10 weeks old to once‐daily, all‐over‐body cold cream or control. The skin outcome was assessed at nine months of age; however, it was unclear when the intervention period was completed. <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a> randomised newborn infants to once‐daily all‐over Lipikaur Baume or control. Both groups received general skin care advice for infants. The intervention was given for 12 months, and outcome was assessed at two years of age. </p> <p><a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> evaluated skin care intervention and early introduction of allergenic food. As <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> reported a significant interaction between interventions for the primary eczema outcome, we only used data from the skin care and control arms for our primary analysis, where infants were bathed using an oil emulsion and had cream applied to the face once daily from age two weeks to eight months. Eczema outcome was measured at 12 months of age, and food allergy was assessed at three years of age. </p> <p>Two trials compared the use of emollient and synbiotic with standard care (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>). <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> was a factorial trial of skin care intervention plus a synbiotic versus normal care for the prevention of eczema in infants. The skin care intervention was a lipid‐based emollient, which was advised to be put on the cheeks twice daily and on the body if wished. The synbiotic was a combination of 0.5 g (7 × 109 colony‐forming units (CFUs)/g) of <i>Bifidobacterium bifidum</i> and fructo‐oligosaccharides twice a day. The intervention period lasted from birth to six months, with outcome assessment at 12 months of age. <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a> compared an emollient and an oral synbiotic versus control. Sixty‐three infants younger than three weeks of age were randomised to twice‐daily all‐over emollient for six months and two supplements of synbiotic at three and six months, or control. </p> </section> <section id="CD013534-sec-0061"> <h6 class="title">ii. Topical oils </h6> <p><a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a> was a three‐armed trial evaluating the effect of sunflower oil or olive oil versus control on neonatal skin. Parents were advised to apply 4 drops of oil to their baby's left forearm, left thigh, and abdomen, twice a day. All groups were advised not to use any other skin care products. The intervention period lasted four weeks, with outcomes measured at four weeks. <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a> randomised 120 infants who were 10 to 15 days old to massage with sunflower oil, sesame oil, or no oil. Mothers were advised to massage the oil into infants twice daily for 28 days, with outcomes measured at the end of the 28 days. <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a> randomised 224 babies to coconut oil, mineral oil, or control with four times daily oil massage from birth until 31 days of age; outcomes were measured at 31 days of age. </p> </section> <section id="CD013534-sec-0062"> <h6 class="title">iii. Bathing products and frequency </h6> <p>In <a href="./references#CD013534-bbs2-0001" title="Abraham D,  Ravindran V,  Joseph M. Effectiveness of chlorhexidine bath, saline bath and standard bath on skin health status. Indian Journal of Public Health Research and Development2019;10(8):563-8. [DOI: 10.37506/ijphrd.v10i8.7446]">Abraham 2019</a>, 102 children were randomly assigned to bathing with one of chlorhexidine, saline, or standard bath, with outcomes assessed up to 24 hours after the intervention. In <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>, children younger than one year were randomly assigned to one of three groups to be bathed for two weeks: Group I: Johnson's Baby Top‐to‐Toe Wash, Group II: Sebamed Baby Liquid Cleanser, or Group III: clear water. Assessment was done at one and two weeks of treatment. In <a href="./references#CD013534-bbs2-0010" title="Duan Y, MaL ,  Galzote C, KongFQ ,  Shen CP. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clinical, Cosmetic and Investigational Dermatology2019;12:895-909. [DOI: 10.2147/CCID.S204216]NCT02981056. A clinical assessment of the efficacy and effects of different skincare regimens on infants. clinicaltrials.gov/ct2/show/NCT02981056 (first received 2 December 2016). ">Duan 2019</a>, 150 infants were randomised to Group I commercial baby wash (Johnson's Baby Wash) and commercial baby lotion (Johnson's Baby Lotion), and Group II water wash and commercial baby lotion, or water only. Parents were asked to wash their infant daily in the wash and apply the lotion, or to wash their infant daily with water and apply the lotion daily, or to wash their infant daily with water only. This intervention was administered for 12 weeks, with outcomes assessed at the end of the 12‐week period. In <a href="./references#CD013534-bbs2-0011" title="Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,  Proquitté H,  Wauer RR, et al. Effect of standardized skin care regimens on neonatal skin barrier function in different body areas. Pediatric Dermatology2010;27(1):1‐8. [DOI: 10.1111/j.1525-1470.2009.01068.x]">Garcia Bartels 2010</a>, 64 newborn infants were randomised to twice‐weekly washing for the first eight weeks of life in one of four groups: Group WG: bathing with wash gel (Top‐To‐Toe Baby Gel Penaten, Johnson &amp; Johnson); Group C: bathing with clear water and afterwards topical cream (Baby Caring Facial &amp; Body Cream Penaten, Johnson &amp; Johnson); Group WG + C: bathing with wash gel and topical cream; or Group C: bathing with wash only (i.e. control). Outcome assessment was conducted at eight weeks of age. <a href="./references#CD013534-bbs2-0017" title="ISRCTN72285670. Baby Skin Care Trial: a study comparing an infant skin-cleansing product with water. www.isrctn.com/ISRCTN72285670 (first received 17 March 2009). [DOI: 10.1186/ISRCTN72285670]LavenderT ,  Bedwell C, O'BrienE , CorkMJ , TurnerM , HartA . Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial. BMC Pediatrics2011;11:35. [DOI: 10.1186/1471-2431-11-35]">Lavender 2011</a> randomised newborn infants to be washed with Johnson's Baby Top‐To‐Toe or water, at least three times a week, for the first eight weeks of life. Skin was assessed at four and eight weeks, the first during and the second at the end of the intervention period. This was a pilot trial; the full trial, <a href="./references#CD013534-bbs2-0019" title="LavenderT ,  Bedwell C, RobertsSA , HartA , TurnerMA , CarterLA , et al. Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates. Journal of Obstetric, Gynaecologic, and Neonatal Nursing2013;42(2):203‐14. [DOI: 10.1111/1552-6909.12015]">Lavender 2013</a>, randomised 307 infants to washing with commercial product or water alone at least three times a week. The intervention period lasted for four weeks only, with outcome assessment at four weeks (the end of the intervention period). <a href="./references#CD013534-bbs2-0021" title="LundC ,  Kuller J, DurandDJ . Baby's first bath: changes in skin barrier function after bathing full-term newborns with water vs liquid baby cleanser. Pediatric Dermatology2019;37:115-9. [DOI: 10.1111/pde.14037]">Lund 2020</a> randomised 100 newborn infants to be washed with Johnson's Baby Top‐To‐Toe or water, in the first hours of life. Skin was assessed before and "after" this bath. <a href="./references#CD013534-bbs2-0026" title="RushJ . Does routine newborn bathing reduce Staphylococcus aureus colonization rates? A randomized controlled trial. Birth1986;13(3):176‐80. ">Rush 1986</a> randomised healthy term newborn infants to daily washing with soap and water versus dry skin care and no bath. The outcome was measured on day 4 of bathing, or immediately before discharge. </p> </section> <section id="CD013534-sec-0063"> <h6 class="title">iv. Combined skin interventions </h6> <p><a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a> compared detailed instructions to use a combined skin intervention for parents of newborn infants involving delaying the first bath and using daily baby oil on scalp and body or chlorhexidine wash for umbilical cord bathing twice per week versus study shampoo versus standard care. The cream, wash, shampoo, and wipes used were provided to parents for a four‐week interval, with outcomes measured at the end of the treatment period. <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> was a factorial randomised trial of 2396 infants evaluating the effects of a skin barrier intervention of emollient and bath oil and early introduction of allergenic food on the development of eczema and food allergy. Those randomised to the skin barrier intervention were advised to bathe daily with bath oil and to apply emollient to the infant's face from two weeks to eight months of age. Outcomes were assessed at 12 months to three years of age. <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a> evaluated the effects of infant swimming and applying an emollient after swimming versus swimming alone in three‐ to six‐month‐old infants. Both groups participated in the swimming classes once a week for four weeks. The intervention group was instructed to apply a simple emollient all over after swimming. The final outcome was assessed at one week after the end of the intervention period. In another swimming‐related intervention, <a href="./references#CD013534-bbs2-0033" title="Zhao S,  Xie L, HuH , Xia J, ZhangW , YeN , et al. A study of neonatal swimming (water therapy) applied in clinical obstetrics. Journal of Maternal-Fetal &amp; Neonatal Medicine2005;17(1):59‐62. [DOI: 10.1080/14767050400028782]">Zhao 2005</a> evaluated the impact of daily infant swimming in the maternity hospital compared to control. Infants in the swimming group had twice‐daily, 10‐ to 15‐minute swimming sessions whilst in the maternity hospital. Outcomes were measured on discharge. </p> </section> <section id="CD013534-sec-0064"> <h6 class="title">v. Diapers </h6> <p><a href="./references#CD013534-bbs2-0003" title="BaldwinS ,  Odio MR,  Haines SL, O'ConnorRJ ,  Englehart JS, LaneAT . Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. Journal of the European Academy of Dermatology and Venereology2001;15(s1):5-11. [DOI: 10.1046/j.0926-9959.2001.00002.x]">Baldwin 2001</a> compared a new zinc oxide diaper to a commercially available diaper for prevention of diaper dermatitis. Previously well children without diaper dermatitis were randomly assigned to control diaper or zinc oxide‐based diaper for four weeks. The outcome of diaper dermatitis was measured at the end of the treatment period.  </p> </section> <section id="CD013534-sec-0065"> <h6 class="title">vi. Cleansing products</h6> <p>In <a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>, newborn infants were randomised to receive chlorhexidine liquid soap bath versus control liquid soap. Outcome was measured at 24 hours after bath. In <a href="./references#CD013534-bbs2-0013" title="Garcia Bartels N,  Massoudy L,  Scheufele R, DietzE ,  Proquitté H,  Wauer R, et al. Standardized diaper care regimen: a prospective, randomized pilot study on skin barrier function and epidermal IL-1α in newborns. Pediatric Dermatology2012;29(3):270‐6. [DOI: 10.1111/j.1525-1470.2011.01590.x]NCT01131403. Clinical analysis of the influence of using the skin care products on the diaper area in comparison with using a cotton wool cloth, moistened with clear water on the skin physiology of the newborns from the 1st day to the 4th week of life. clinicaltrials.gov/ct2/show/NCT01131403 (first received 27 May 2010). ">Garcia Bartels 2012</a>, newborn infants were randomised to washing of the diaper area with commercial wipes or water‐moistened cloths (control) for four weeks. Skin was assessed at four weeks (the end of the intervention period). In <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>, 280 newborn infants were also randomised to washing of the diaper area with a commercial wipe (Johnson's Baby Skincare Fragrance Free Wipe) or cotton wool and water for four weeks postbirth, with outcome assessed at four weeks (the end of the intervention period). <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a> was a cluster‐randomised study of 17,530 infants in rural Nepal that compared all‐over cleansing at birth with a chlorhexidine wipe versus a wipe without chlorhexidine. This was a one‐time intervention provided at birth. Outcome was measured at 28 days. </p> </section> </section> <section id="CD013534-sec-0066"> <h5 class="title">Follow‐up</h5> <p>Our specified primary and secondary outcomes were measured from one to three years, apart from adverse events, which were measured during the intervention period. The included studies evaluating emollients and the <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> study were the only studies with follow‐up long enough to meet this outcome timing. Most of the other studies followed infants up to a maximum of four weeks, which was too soon to assess whether eczema or food allergy was present. </p> </section> <section id="CD013534-sec-0067"> <h5 class="title">Comparators</h5> <p>All trials included a comparison arm that provided 'routine' skin care for their country. We did not specify the comparator, as daily practices on how to treat infant skin vary between countries and within countries according to cultural norms. We excluded any trials that had an active comparator such as an emollient. </p> </section> <section id="CD013534-sec-0068"> <h5 class="title">Outcomes</h5> <p>Of the 33 included studies, 17 studies provided data on one or more outcomes relevant to this review, of which 11 could be included in the meta‐analysis. Ten trials provided IPD, including nine studies that provided IPD for the primary outcome eczema or food allergy. <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a> provided IPD for adverse events only. Prespecified outcome timings were one to three years for both primary and secondary outcomes related to eczema and food allergy. Adverse events were measured during the intervention period. </p> <p>Eczema data were measured between one and three years of age in eight trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Two trials had eczema outcomes before one year (<a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>). A further four trials recorded some data on eczema outcomes that were not useable in the meta‐analysis (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>); however, these data were included in narrative format in the results. The primary outcome of eczema was measured by Hanifin and Rajka or by UK Working Party methods in all trials except one, which used parental report of a doctor diagnosis of eczema (<a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Three studies measured eczema severity between one and three years by clinician assessment: <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> and <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a> used the Eczema Area and Severity Index (EASI) at two years and one year, respectively, whilst <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> used the objective SCORAD (SCORing Atopic Dermatitis) (a clinical tool used to assess the extent and severity of eczema) at one year. Only <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> recorded parental report of eczema severity based on the Patient‐Orientated Eczema Measure (POEM) at two years. Nine studies measured time to onset of eczema (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). </p> <p>The primary outcome of IgE‐mediated food allergy diagnosed by oral food challenge between one and three years was measured in <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> and <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>, although only <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> provided data for oral food challenge alone, whereas both trials provided data for a composite outcome of food allergy diagnosed by oral food challenge or expert panel assessment at two or three years, respectively. Three trials provided data on parental report of doctor diagnosis of food allergy between one and three years: <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> (by one year), <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a> (by two years), and <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> (by two years). Two trials provided data on parental report of an immediate (&lt; 2 hours) reaction to a common food allergen: <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> (at two years) and <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a> (by one year). Data on allergic sensitisation to foods between one and three years were provided in <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> (at two years), <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> (at one year), and <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> (three years). Two trials provided data on allergic sensitisation to foods at eight months, <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>, and nine months, <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>, which were used in sensitivity analysis only. <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a> and <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a> provided narrative information on food allergy that could not be used in meta‐analysis but that was included in narrative format in the results. </p> <p>Ten studies provided data for the prespecified adverse events of interest (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Nine studies contributed some narrative data on non‐specific adverse events, which were not included in the meta‐analysis but are presented descriptively in the <a href="#CD013534-sec-0077">Effects of interventions</a> section (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a>; <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>; <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a>). </p> </section> <section id="CD013534-sec-0069"> <h5 class="title">Funding</h5> <p>Of the 11 trials contributing data to one or more meta‐analyses, two trials did not specify funding (<a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>); the other nine contributing trials were funded through higher‐level institutions. </p> <p>Of the six trials contributing aggregate data that were considered not relevant for inclusion in one or more meta‐analyses, three studies did not specify funding; two were supported by local hospitals; and one was commercially sponsored. </p> <p>Of the 16 trials that did not contribute any data on outcomes, two trials did not report on funding; two were sponsored by local hospitals; one was sponsored by a local hospital and the Gates Foundation; and 11 were commercially sponsored. </p> </section> </section> <section id="CD013534-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 191 studies (see <a href="./references#CD013534-sec-0124" title="">Characteristics of excluded studies</a> for selected reasons for exclusion). Overall, we excluded these studies for the following reasons.  </p> <p> <ul id="CD013534-list-0020"> <li> <p>Wrong patient population (96 studies). The aim of this review was to evaluate the prevention of eczema and food allergy in infants, therefore any population already diagnosed with eczema was excluded, along with participants over the age of 12 months. We also excluded any studies primarily evaluating preterm infants, as these infants did not have a 'normal' neonatal course; most were cared for in neonatal intensive care units, where skin care practices are inherently different. </p> </li> <li> <p>Wrong study design (62 studies). Studies were excluded mainly if they were not RCTs. </p> </li> <li> <p>Wrong comparator (18 studies). Studies were excluded if there was no standard control in the study design.  </p> </li> <li> <p>Wrong intervention (15 studies). Some interventions included oral probiotics. </p> </li> </ul> </p> <section id="CD013534-sec-0071"> <h5 class="title">Studies awaiting classification</h5> <p>We assessed four trials as awaiting classification (see <a href="./references#CD013534-sec-0125" title="">Characteristics of studies awaiting classification</a>). </p> <p><a href="./references#CD013534-bbs2-0210" title="CTRI/2014/12/005282. Can an intervention involving improvements in community-based newborn massage practice with promotion of cold-pressed sunflower oil as preferred emollient improve newborn survival in rural North India?www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2014/12/005282 (first received 11 December 2014). ISRCTN38965585. Can an intervention involving improvements in community-based newborn massage practice with promotion of cold-pressed sunflower oil as preferred emollient improve newborn survival in rural North India?www.isrctn.com/ISRCTN38965585 (first received 8 July 2014). [DOI: 10.1186/ISRCTN38965585]">ISRCTN38965585</a> is a World Health Organization (WHO)‐sponsored cluster‐randomised trial including over 40,000 infants and assessing the effects of newborn massage with cold‐pressed olive oil on newborn survival in rural India. This study was registered initially in 2014 and is marked as "recruitment complete". This study could only have contributed information for adverse events; no results are recorded at the clinical trial registry or in our search. We received no response from study authors when we contacted them via the email addresses provided. For the update of this review, we again attempted to contact the team, with no response.  </p> <p><a href="./references#CD013534-bbs2-0211" title="JPRN-UMIN000026877. Use test of skin care goods. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000026877 (first received 5 April 2017). ">JPRN‐UMIN000026877</a> is a small trial of 50 infants evaluating the efficacy of a foam body cleanser and "lotion" on infant skin; it was sponsored by a Japanese cosmetics company and is marked as "complete" at the clinical trial register. We received no response from study authors when we contacted them via the email addresses provided, and again for this update.  </p> <p><a href="./references#CD013534-bbs2-0212" title="NCT03640897. Evaluation of the safety and performance of LiNiDERM® in the prevention of infant diaper rash. clinicaltrials.gov/ct2/show/NCT03640897 (first received 21 August 2018). ">NCT03640897</a> is a commercial trial of a wipe for infants (n = 133). It does meet our criteria for efficacy outcomes; however, it could potentially contribute information for adverse events. This study has been marked as "complete" at the trial register since March 2019. No data have been published. We received no response from study authors when we contacted them through their website at <a href="https://www.labogilbert.com/" target="_blank">www.labogilbert.com/</a>. </p> <p><a href="./references#CD013534-bbs2-0213" title="NgPSM , WeeLWY , HoVPY , TanWC , BishnoiP , AlagappanU , et al. Moisturisers from birth in at-risk infants of atopic dermatitis - a pragmatic randomised controlled trial. Australasian Journal of Dermatology 2021 Aug 23 [Epub ahead of print]. [DOI: 10.1111/ajd.13703]">Ng 2021</a> is a recently published study from Singapore of twice‐daily Cetaphil Restoraderm moisturiser along with Cetaphil Restoraderm wash in 200 infants with at least two primary relatives with atopy. The primary outcome was moderate to severe eczema at 12 months. This moisturiser contains ceramides and 2 filaggrin breakdown products: arginine and sodium pyrrolidone carboxylic acid. This study was not previously registered and was published in August 2021, therefore we were unable to incorporate it into this update as the extensive analysis was complete by then and there was insufficient time to arrange a data sharing agreement. However, this study should be included in any future updates of the review. </p> </section> <section id="CD013534-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We classified 11 studies as ongoing studies (see <a href="./references#CD013534-sec-0126" title="">Characteristics of ongoing studies</a>). Specifically for the prevention of eczema in infants, <a href="./references#CD013534-bbs2-0219" title="NCT02906475. Atopic dermatitis in atopy predisposed infants. clinicaltrials.gov/ct2/show/NCT02906475 (first received 20 September 2016). ">NCT02906475</a> is an RCT of 160 infants undertaken by HIPP Pharmaceuticals to evaluate the impact of use of daily milk lotion in infants for the prevention of eczema. <a href="./references#CD013534-bbs2-0217" title="Jabbar-LopezZK , Gurung N,  Greenblatt D,  Briley A, ChalmersJR , ThomasKS , et al. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]NCT03270566. Softened water for eczema prevention pilot trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1 September 2017). ">Jabbar‐Lopez 2019</a> is a pilot RCT at King's College London of 80 infants that is evaluating whether families would be willing to be randomised to have domestic ion exchange water softener installed, with a secondary outcome of prevention of eczema in infants. <a href="./references#CD013534-bbs2-0221" title="NCT03808532. Moisturizer to prevent atopic dermatitis (ACE-AD). clinicaltrials.gov/ct2/show/NCT03808532 (first received 17 January 2019). ">NCT03808532</a> is an RCT by MYOR Corporation of 290 infants that is evaluating the effect of daily emollient for the prevention of eczema. <a href="./references#CD013534-bbs2-0216" title="EichnerB , MichaelsLAC ,  Branca K, RamseyK , MitchellJ ,  MorrisCD , et al. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients - protocol for a randomized controlled trial. Trials2020;21(1):243. [DOI: 10.1186/s13063-020-4150-5]NCT03409367. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE). clinicaltrials.gov/ct2/show/NCT03409367 (first received 24 January 2018). ">Eichner 2020</a> is an RCT of 1250 infants conducted in the USA to evaluate the impact of daily lipid‐rich emollient from birth to two years on the cumulative incidence of eczema at 24 months. <a href="./references#CD013534-bbs2-0214" title="ChiCTR2000035585. A multi-center, randomized, single-blind controlled study on the regular use of medical emollients in early birth to reduce the incidence and severity of atopic dermatitis in infants and young children. www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000035585 (first received 14 August 2020). ">ChiCTR2000035585</a> is an RCT conducted in China comparing different lengths of intervention of daily emollient for the prevention of eczema in high‐risk children (target sample size of 752 infants). <a href="./references#CD013534-bbs2-0224" title="TCTR20200630006. Effect of emollient on newborn skin from birth in the prevention of atopic eczema: a randomized control study in Thai neonates. www.thaiclinicaltrials.org/show/TCTR20200630006 (first received 30 June 2020). ">TCTR20200630006</a> is an RCT of 154 Thai infants comparing moisturiser versus control in infants with a family history of atopic disease. </p> <p>For the prevention of eczema and food allergy, <a href="./references#CD013534-bbs2-0222" title="NCT03871998. Short-term topical application to prevent atopic dermatitis (STOP AD). clinicaltrials.gov/ct2/show/NCT03871998 (first received 12 March 2019). Ni ChaoimhC , LadD , NicoC , PuppelsGJ , CaspersPJ , IrvineAD , et al. Neonatal natural moisturising factor concentrations in a high-risk cohort with parental history of atopy compared to a reference cohort. Allergy: European Journal of Allergy and Clinical Immunology2020;75 Suppl 109:91. [EMBASE: 633542472]Ni ChaoimhC , LadD , StamatasGN , OddosT , IrvineAD , O'B HourihaneJ . Parental compliance with an infant moisturization protocol in the first 2 months of life. Allergy2020;75 Suppl 109:596. [EMBASE: 633545599]">NCT03871998</a> is an RCT in Ireland of 242 infants that is evaluating the effect of twice‐daily all‐over emollient in the first two months of life on incidence of eczema at 12 months and of IgE‐mediated food allergy at 24 months. <a href="./references#CD013534-bbs2-0218" title="ACTRN12617001380381. The PEBBLES Study - testing a strategy for preventing eczema and food allergy in high risk infants. www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617001380381 (first received 28 September 2017). Lowe A, SuJ , TangM , LodgeCJ , Matheson M, AllenKJ ,  et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open2019;9(3):e024594. [DOI: 10.1136/bmjopen-2018-024594]">Lowe 2019</a> is an RCT of 760 infants undertaken in Melbourne, Australia, to evaluate the impact of a twice‐daily ceramide‐dominant emollient for the prevention of eczema and food allergy. <a href="./references#CD013534-bbs2-0223" title="NCT04398758. Moisturizer mediated Prevention of symptoms of Atopic Dermatitis in early childhood (MOPAD). clinicaltrials.gov/ct2/show/NCT04398758 (first received 21 May 2020). ">NCT04398758</a> is an RCT that is under way in Germany to evaluate twice‐daily paraffin‐based cream on infants with a family history of diagnosed eczema. The primary outcome is eczema at six months, with food sensitisation at 12 months a secondary outcome. </p> <p>For evaluation of the skin barrier in infants without recording eczema or food allergy outcomes, and so limited to contributing adverse event outcome data, <a href="./references#CD013534-bbs2-0220" title="NCT03142984. UK BABY study using a baby wash and lotion regimen (BOND). clinicaltrials.gov/ct2/show/NCT03142984 (first received 8 May 2017). ">NCT03142984</a> is a study of 160 infants assessing skin barrier effects of a new baby wash and baby lotion in the UK. <a href="./references#CD013534-bbs2-0215" title="CTRI/2020/03/023963. Topical oil for skin protection in neonates. ctri.nic.in/Clinicaltrials/showallp.php?mid1=41652&amp;EncHid=&amp;userName=Topical%20oil (first received 13 March 2020). ">CTRI/2020/03/023963</a> is a registered study exploring the impact of sesame oil on the skin barrier function of newborn infants in a hospital in India (target sample size of 60 children), </p> <p>Trialists leading the following ongoing trials are all involved in the IPD collaboration and are willing to contribute IPD to any future update of this review: <a href="./references#CD013534-bbs2-0219" title="NCT02906475. Atopic dermatitis in atopy predisposed infants. clinicaltrials.gov/ct2/show/NCT02906475 (first received 20 September 2016). ">NCT02906475</a>, <a href="./references#CD013534-bbs2-0220" title="NCT03142984. UK BABY study using a baby wash and lotion regimen (BOND). clinicaltrials.gov/ct2/show/NCT03142984 (first received 8 May 2017). ">NCT03142984</a>, <a href="./references#CD013534-bbs2-0217" title="Jabbar-LopezZK , Gurung N,  Greenblatt D,  Briley A, ChalmersJR , ThomasKS , et al. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]NCT03270566. Softened water for eczema prevention pilot trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1 September 2017). ">Jabbar‐Lopez 2019</a>, <a href="./references#CD013534-bbs2-0222" title="NCT03871998. Short-term topical application to prevent atopic dermatitis (STOP AD). clinicaltrials.gov/ct2/show/NCT03871998 (first received 12 March 2019). Ni ChaoimhC , LadD , NicoC , PuppelsGJ , CaspersPJ , IrvineAD , et al. Neonatal natural moisturising factor concentrations in a high-risk cohort with parental history of atopy compared to a reference cohort. Allergy: European Journal of Allergy and Clinical Immunology2020;75 Suppl 109:91. [EMBASE: 633542472]Ni ChaoimhC , LadD , StamatasGN , OddosT , IrvineAD , O'B HourihaneJ . Parental compliance with an infant moisturization protocol in the first 2 months of life. Allergy2020;75 Suppl 109:596. [EMBASE: 633545599]">NCT03871998</a>, <a href="./references#CD013534-bbs2-0218" title="ACTRN12617001380381. The PEBBLES Study - testing a strategy for preventing eczema and food allergy in high risk infants. www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617001380381 (first received 28 September 2017). Lowe A, SuJ , TangM , LodgeCJ , Matheson M, AllenKJ ,  et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open2019;9(3):e024594. [DOI: 10.1136/bmjopen-2018-024594]">Lowe 2019</a>, and <a href="./references#CD013534-bbs2-0216" title="EichnerB , MichaelsLAC ,  Branca K, RamseyK , MitchellJ ,  MorrisCD , et al. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients - protocol for a randomized controlled trial. Trials2020;21(1):243. [DOI: 10.1186/s13063-020-4150-5]NCT03409367. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE). clinicaltrials.gov/ct2/show/NCT03409367 (first received 24 January 2018). ">Eichner 2020</a>. </p> </section> </section> </section> <section id="CD013534-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias using the Cochrane RoB 2 tool for trials providing outcome data on one or more of eczema, food allergy, slippage accidents, skin infections, stinging or allergic reactions, serious adverse events, time to eczema onset, parent report of immediate reaction to a common allergenic food, and allergic sensitisation (<a href="./references#CD013534-bbs2-0277" title="HigginsJP , SavovicJ , PageMJ , SterneJA , ROB2 development group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 5 February 2019).">Higgins 2018</a>). Detailed risk of bias assessment data, with consensus responses to each RoB 2 signalling question, are available at <a href="./references#CD013534-bbs2-0249" title="Cro S, Kelleher M, CorneliusV , BoyleR . Skin care interventions for preventing eczema and food allergy: RoB 2 assessments (Version 1) [Data set]. Zenodo. [DOI: 10.5281/zenodo.4288759]">Cro 2020b</a>. Risk of bias assessments by analysis are also summarised in the risk of bias tables. Risk of bias assessments were not performed for trials providing qualitative narrative information. </p> <section id="CD013534-sec-0074"> <h4 class="title">Risk of bias summary by domain</h4> <p>Most studies (12/17) were at low risk of bias for the randomisation process; we rated five studies as some concerns for risk of bias, as insufficient information on allocation concealment or balance in baseline characteristics was provided (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>). </p> <p>Most studies (12/17) providing outcome data were judged to be at low risk of bias for deviations from intended interventions for all outcomes, as whilst it was not possible to blind participants or carers in the individual studies due to the nature of the intervention under study, no evidence indicates that deviations arose because of the trial context. Control group rates of skin care application were consistent with those of other trials and observational studies, which have reported that up to 75% of individuals apply a skin care intervention (<a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Additionally, analyses were appropriately performed according to the intention‐to‐treat principle to identify the effect of assignment to the intervention. </p> <p>We assessed three studies as at some concerns of bias for deviations from intended interventions for all outcomes (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>), as they provided no information to permit an assessment of whether deviations arose because of trial context. In two other studies, analysis populations were unclear, therefore we rated these studies as having high risk of bias (<a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>). </p> <p>For missing data on our outcomes of interest, studies were predominantly at low risk of bias or at some concerns if they included a non‐negligible quantity of missing data, and if sensitivity analysis using the individual participant revealed that trial conclusions changed (point estimate changed by at least 20% of the complete‐case estimate). However, across most outcomes, whilst missingness could have depended on the true value, we judged it unlikely that missingness in the outcome depended on its true value due to trial circumstances and the fact that rates of missingness did not vary considerably by intervention groups. The one exception to this was a single trial that provided outcome data on food allergy as assessed by oral food challenge and was rated as having high risk of bias for missing data (see <a href="./references#CD013534-tblf-0063" title="">Risk of bias table for Analysis 1.33</a>) (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Data were missing for 398/1394 (29%) of randomised participants. Results varied in missing data sensitivity analyses performed using the IPD, and it was judged potentially likely that missingness depended on the value of the outcome (because there was a difference between treatment groups in the proportion of participants who underwent oral food challenge), and recorded reasons for missingness included decline in oral food challenge and unwillingness to participate, which could have depended on the outcome. </p> <p>For measurement of the outcome, outcomes reported by carers (e.g. adverse events, report of reaction, POEM, eczema for one study) were judged at some concerns for risk of bias, as carers were unblinded due to the nature of the intervention. However, whilst knowledge of the intervention could have influenced the measurement, it was judged unlikely to have impacted measurement. For other outcome measurements, if no information was available on the blinding status of assessors, these were rated as some concerns. One trial supplied no information on how eczema was measured or by whom it was measured and was rated as having high risk of bias for this outcome. </p> </section> <section id="CD013534-sec-0075"> <h4 class="title">Selection of the reported result</h4> <p>Of the 17 studies providing data on one or more of our outcomes assessed for risk of bias, 10 were rated at low risk of bias for selection of reported results; these studies supplied IPD (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). For each of these trials, for each outcome, we performed the required analysis using the supplied trial data set in keeping with a prespecified statistical analysis plan that was finalised before unblinded outcome data were available for analysis (<a href="./references#CD013534-bbs2-0248" title="CroS , BoyleR , KelleherM , TranL , CorneliusV . Skin care interventions for preventing eczema and food allergy: a statistical analysis plan for a systematic review and individual participant data meta-analysis. zenodo.org/record/3610604#.XiGKU8j7SUk (accessed 16 January 2020). [DOI: 10.5281/zenodo.3610604]">Cro 2020a</a>). </p> <p>Seven trials contributing some aggregated outcome data were rated as some concerns for selection of reported results (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>; <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>). Of these studies, only <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a> was included in the meta‐analysis. All seven trials provided no information on whether a prespecified statical analysis plan, finalised before unblinding, was followed. </p> </section> <section id="CD013534-sec-0076"> <h4 class="title">Overall risk of bias</h4> <p>In summary, we assessed most of the evidence included in this review as low risk or some concern of risk of bias. Over all RoB 2 domains, 3/17 studies were rated as low risk of bias across all included outcomes (<a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>); eight were rated as some concerns for risk of bias across all included outcomes (<a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>; <a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>); and one was at high risk of bias for its sole included outcome (<a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>). Two trials were predominantly rated as some concerns of risk of bias across all included outcomes due to measurement of the outcome or missing data  (5/6 and 4/6 outcomes for <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> and <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>, respectively), but also included outcomes at low risk of bias (1/6 and 2/6 outcomes for <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> and <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>, respectively). We assessed one study as at high risk of bias for eczema and as at some concerns for risk of bias for the skin infection outcome overall (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>). Another study was at high risk of bias for allergic sensitisation and some concerns for risk of bias for the eczema outcome overall (<a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>). Finally, one study was at low risk of bias for 2/7 outcomes; some concerns for 4/7 outcomes due to unblinded measurement; and high risk of bias for food allergy due to missing data (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). </p> </section> </section> <section id="CD013534-sec-0077"> <h3 class="title" id="CD013534-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD013534-tbl-0001"><b>Summary of findings 1</b> Skin care intervention compared to standard skin care or no skin care intervention for the prevention of eczema and food allergy</a> </p> <section id="CD013534-sec-0078"> <h4 class="title">Primary outcomes</h4> <p>Primary and secondary outcome results are presented for comparison 1: skin care intervention versus no treatment or standard care only. We did not evaluate comparison 2: skin care intervention B versus no treatment or standard care only because our search did not identify any eligible studies of skin care interventions type B. Results are summarised in <a href="./full#CD013534-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013534-sec-0079"> <h5 class="title">Eczema </h5> <p>Individual participant data on eczema diagnosis by age one to three years were available from seven studies including 4800 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Eczema was measured using the Hanifin and Rajka criteria (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>), or the UK Working Party refinement of these criteria (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), or other modifications of the Hanifin and Rajka criteria in six trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), and eczema was doctor diagnosed in one trial (<a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Eczema was diagnosed cumulatively up to 12 months in three trials (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>); up to 24 months in three trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>); and up to both 12 months and 36 months in one trial (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Pooled IPD available from 3075 participants in these studies showed no benefit of skin care intervention (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; <a href="./references#CD013534-fig-0006" title="">Analysis 1.1</a>). However, the 95% CI for the pooled RR indicates that we cannot rule out potential benefit or harm, extending from 0.81 to 1.31. Results showed moderate statistical heterogeneity between studies for this outcome (I² = 41%, P = 0.12). This was driven by one trial with an RR favouring standard care (RR 1.57, 95% CI 1.10 to 2.23) (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), and may be due to the type of intervention (bathing with oil and emollient applied to the face only) or by timing of outcome assessment, or both. When this study was excluded, pooled IPD available from 2004 participants in the remaining six studies continued to show no benefit of skin care intervention (RR 0.95, 95% CI 0.81 to 1.12; I² = 0%; <a href="./references#CD013534-fig-0017" title="">Analysis 1.12</a>). When three‐year data instead of one‐year data were used from this study (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), there was also no evidence for a benefit of skin care intervention and no statistical heterogeneity (RR 1.00, 95% CI 0.88 to 1.14; I² = 0%; <a href="./references#CD013534-fig-0010" title="">Analysis 1.5</a>). </p> <p>We conducted a series of preplanned sensitivity analyses (see <a href="#CD013534-tbl-0005">Table 4</a>). Sensitivity analysis including aggregate data from one additional study that did not supply IPD involving 63 randomised participants, of which 60 completed the study (<a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>), did not change the pooled result (RR 0.97, 95% CI 0.75 to 1.25; <a href="./references#CD013534-fig-0007" title="">Analysis 1.2</a>). When only the six studies that used the Hanifin and Rajka criteria (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>), or the UK Working Party refinement of them (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), or other modifications of the Hanifin and Rajka criteria to assess eczema were included, the pooled result remained consistent (RR 1.02, 95% CI 0.78 to 1.34; <a href="./references#CD013534-fig-0008" title="">Analysis 1.3</a>). The pooled result also remained consistent in sensitivity analyses that included data from all four arms of <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> (RR 1.03, 95% CI 0.81 to 1.31; <a href="./references#CD013534-fig-0009" title="">Analysis 1.4</a>); using three‐year in place of the one‐year eczema outcome for <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> (RR 1.00, 95% CI 0.88 to 1.14; <a href="./references#CD013534-fig-0010" title="">Analysis 1.5</a>); including only studies at low risk of bias (RR 0.97, 95% CI 0.81 to 1.17; <a href="./references#CD013534-fig-0011" title="">Analysis 1.6</a>); excluding non‐prospectively acquired data (RR 1.08, 95% CI 0.84 to 1.37; <a href="./references#CD013534-fig-0012" title="">Analysis 1.7</a>); incorporating studies assessing eczema by six months to three years (RR 0.89, 95% CI 0.70 to 1.14; <a href="./references#CD013534-fig-0013" title="">Analysis 1.8</a>); and considering eczema only after the intervention period (i.e. at one year or beyond) (RR 1.00, 95% CI 0.87 to 1.16; <a href="./references#CD013534-fig-0014" title="">Analysis 1.9</a>).  </p> <div class="table" id="CD013534-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for eczema </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> <p><b>standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary:</b> </p> <p><b>eczema by 1 to 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1489</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1586</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.03</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.81 to 1.31</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>eczema by 1 to 3 years including aggregate data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 to 1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years using UK Working Party Criteria only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 to 1.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years including all 4 arms from the PreventADALL trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 to 1.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years (using PreventADALL 36‐month outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 to 1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years, low risk of bias data only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 to 1.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years, excluding non‐prospectively acquired data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 to 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 6 months to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 to 1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema after the intervention period (at  1 year or beyond (up to 3 years))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 to 1.16</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>. <br/><sup>d</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>. <br/><sup>e</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>f</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>g</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </div> <p>Four additional studies randomising a total of 314 participants provided aggregate data on eczema at four weeks, <a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>, six months, <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a>; <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>, and nine months, <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>, that were not eligible for meta‐analysis because IPD were not supplied, and data were only reported from the short follow‐up period. <a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a> reported eczema in 0/35 (0%) participants randomised to skin care intervention and 2/35 (5.7%) randomised to standard care over a four‐week follow‐up period. At six months, <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a> reported eczema in 9.8% of the intervention arm versus 18.3% of the control arm (60 participants were randomised to each treatment group, but the analysis population was not clear); after follow‐up of 24 months, seven new cases of atopic dermatitis were observed in the intervention group and six new cases in the control group. <a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a> reported 5/35 (14%) versus 6/32 (19%) cases of eczema in the intervention and control arms, respectively.  At nine months, <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a> reported 0/26 (0%) versus 4/27 (15%) cases of eczema in the intervention and control arms, respectively. </p> <p>Subgroup analysis did not suggest any differences in treatment effects by intervention type or intervention duration. For basic emollients (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), there was a pooled RR of 1.04 (95% CI 0.66 to 1.65), and for complex emollients (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>), there was a pooled RR of 1.01 (95% CI 0.75 to 1.37) (<a href="./references#CD013534-fig-0015" title="">Analysis 1.10</a>). Only one study reported a prescribed intervention period of less than six months (<a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>), with an RR of 1.01 (95% CI 0.45 to 2.26; <a href="./references#CD013534-fig-0016" title="">Analysis 1.11</a>). For the six studies with an intervention period of six months or more (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), there was a pooled RR of 1.02 (95% CI 0.78 to 1.34) (<a href="./references#CD013534-fig-0016" title="">Analysis 1.11</a>). One study initiated the intervention after the first week of life (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), with an RR of 1.57 (95% CI 1.10 to 2.23), which differed significantly from studies that initiated the intervention during the first week of life (RR 0.95, 95% CI 0.81 to 1.12; <a href="./references#CD013534-fig-0017" title="">Analysis 1.12</a>). Another clear difference in this study was that the intervention was emollient applied to the face only, with a daily bath using a bath oil.  </p> <p>The interaction effect between treatments and actual age of treatment initiation (&lt; 4 days, ≥ 4 days) for eczema by one to three years could be estimated for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>), which randomised a total of 1474 participants. Pooled IPD available from 1284 participants in these two studies showed no impact of age of treatment initiation on treatment effect (RR 1.05, 95% CI 0.64 to 1.73; <a href="./references#CD013534-fig-0018" title="">Analysis 1.13</a>). In one additional study randomising 118 participants (<a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>), the interaction between treatment and actual age of treatment initiation for eczema by eight months could be estimated for 99 participants. When data from this study were incorporated, pooled IPD available from 1383 participants continued to show no impact of age of treatment initiation (RR 1.59, 95% CI 0.56 to 4.51; <a href="./references#CD013534-fig-0019" title="">Analysis 1.14</a>).  </p> <p>The interaction effect between treatment and <i>FLG</i> genotype on eczema by one to three years could be estimated for three trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Pooled individual data available from 1716 participants in these studies showed no impact of having the 1/2 <i>FLG</i> mutations on treatment effect (RR 1.08, 95% CI 0.69 to 1.70; <a href="./references#CD013534-fig-0020" title="">Analysis 1.15</a>). In one additional study randomising 124 participants (<a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>), the interaction between treatment and <i>FLG</i> mutations for eczema by six months could be estimated for 63 participants. When data from this study were incorporated, pooled IPD available from 1779 participants continued to show an uncertain impact of <i>FLG</i> mutations on treatment effect (RR 1.03, 95% CI 0.66 to 1.61; <a href="./references#CD013534-fig-0021" title="">Analysis 1.16</a>).  </p> <p>The interaction effect between treatment and family history of atopic disease on eczema by one to three years could be estimated for three trials (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>), which randomised 3172 participants. Based on available data from 1663 participants, the pooled RR of eczema by two years for having one or more family members in the skin care intervention group versus zero did not indicate a notable interaction (RR 0.95, 95% CI 0.35 to 2.61; <a href="./references#CD013534-fig-0024" title="">Analysis 1.19</a>). </p> <p>The interaction effect between treatment and <i>FLG</i> genotype or family history of atopic disease on eczema by one to three years could be estimated for one trial (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Based on available data from 1065 participants in <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>, the RR of eczema by one year for having 1/2 <i>FLG </i>mutations or family history of atopic disease in the skin care intervention group versus zero mutations and no family history was RR 0.62 (95% CI 0.16 to 2.44; <a href="./references#CD013534-fig-0025" title="">Analysis 1.20</a>). The wide 95% CI indicates uncertainty surrounding the direction and magnitude of any effect of <i>FLG</i> or family history of atopic disease on treatment effect from this one study.  </p> <p>The interaction effect between treatment and the chromosome 11 intergenic variant rs2212434 on eczema by one to three years could be estimated for two trials (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Pooled individual data available from 1807 participants in these studies showed no impact of C:T or T:T genotype (where T is the risk allele) versus C:C genotype on the treatment effect (RR 1.31, 95% CI 0.85 to 2.03; <a href="./references#CD013534-fig-0022" title="">Analysis 1.17</a>) The wide 95% CI indicates uncertainty surrounding the direction and magnitude of any effect of chromosome 11 variants on the treatment effect from these two studies. </p> <p>There is evidence of a multiplicative effect of <i>FLG</i> null genotype and variants at the chromosome 11q13.5 locus on eczema risk (<a href="./references#CD013534-bbs2-0299" title="O'ReganGM , CampbellLE , CordellHJ , IrvineAD , Irwin McleanWH , BrownSJ . Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations. Journal of Allergy and Clinical Immunology2010;125(1):170-4. [PMID: 20109745]">O'Regan 2010</a>). The interaction effect between treatment and <i>FLG</i> genotype and the chromosome 11 variant on eczema by one to three years was available for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Based on available data on 1644 participants, the RR for having eczema by one to three years in those with one or two <i>FLG</i> mutation(s) and/or C:T or T:T genotype at chromosome 11 locus in the skin care intervention group versus no <i>FLG</i> mutation and no chromosome 11 variant was 1.24 (95% CI 0.72 to 2.12; <a href="./references#CD013534-fig-0023" title="">Analysis 1.18</a>).  </p> <p>The complier average causal effect (CACE) for an individual using skin care intervention for three or more days a week could be estimated for three trials providing adequate compliance and eczema outcome data (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). The pooled CACE for an individual using skin care intervention for three or more days a week from 1440 participants in these studies was on average more in favour of the skin care intervention (RR 0.65, 95% CI 0.29 to 1.45; <a href="./references#CD013534-fig-0026" title="">Analysis 1.21</a>) compared with the pooled intention‐to‐treat effect for these same three studies (RR 0.93, 95% CI 0.77 to 1.12; <a href="./references#CD013534-fig-0032" title="">Analysis 1.27</a>). However, the 95% CI for the CACE estimate was considerably wider than for the intention‐to‐treat effect and was consistent with the intention‐to‐treat effect of no difference, a decreased or an increased risk ratio, therefore we could not infer any difference in treatment effects for a complier. Additional CACE estimates for alternative definitions of a complier are displayed in <a href="#CD013534-tbl-0006">Table 5</a>, and similarly do not reveal an impact of compliance on treatment effect. </p> <div class="table" id="CD013534-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Complier average causal effect (CACE) analyses for eczema</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Complier </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N standard care </b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>CACE</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Intention‐to‐treat</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary CACE:</b> </p> <p><b>≥ 3 days of use over intervention period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>705</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>735</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.65</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 to 1.45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 to 1.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity CACE:</p> <p>≥ 5 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 to 2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 to 2.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 5 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 to 1.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 to 2.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </div> <p>Trial sequential analysis shows that a target sample size of 5534 would be necessary to demonstrate a minimum relative risk reduction of 30% (assuming a control rate of 15% versus skin care intervention 10.5%) with 90% power (<a href="#CD013534-fig-0002">Figure 2</a>). However, based on the data accumulated to date and included within the primary eczema meta‐analysis (3075 participants), the Z value falls on the boundary of the inner wedge and is well within the two‐sided significance testing boundaries, indicating that a conclusion can be made: the intervention effect is not greater than 30%. A target sample size of 13,072 would be necessary to demonstrate a minimum relative risk reduction of 20% (assuming a control rate of 15% versus skin care intervention 12%) with 90% power (<a href="#CD013534-fig-0003">Figure 3</a>). The meta‐analysis is currently inconclusive for an effect size of 20 because it has not yet crossed the upper or lower boundary for statistical significance or non‐superiority. </p> <div class="figure" id="CD013534-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Trial sequential analysis for eczema (RR of 30%)." data-id="CD013534-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis for eczema (RR of 30%).</p> </div> </div> </div> <div class="figure" id="CD013534-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Trial sequential analysis for eczema (RR of 20%)." data-id="CD013534-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis for eczema (RR of 20%).</p> </div> </div> </div> </section> <section id="CD013534-sec-0080"> <h5 class="title">Food allergy</h5> <p>Individual participant data on IgE‐mediated food allergy, confirmed by oral food challenge, by age one to three years were recorded in one study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Data on oral food challenge, conducted at two years, were available for 976 participants in one study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), and favoured standard care (RR 2.53, 95% CI 0.99 to 6.49; <a href="./references#CD013534-fig-0038" title="">Analysis 1.33</a>). The 95% CI for the RR is wide, and is consistent with both no effect or small to large harm of skin care intervention in this one study. Data were available for food allergy evaluated by a combination of oral food challenge and investigator assessment based on clinical history or allergy tests, or both, for 2030 participants in two studies and favoured standard care (RR 1.45, 95% CI 0.98 to 2.15; <a href="./references#CD013534-fig-0039" title="">Analysis 1.34</a>) (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). The width of the 95% CI for the RR was reduced, but still included both no difference and small to large harm of skin care intervention. These data are also shown in <a href="#CD013534-tbl-0007">Table 6</a>. </p> <div class="table" id="CD013534-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for food allergy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> <p><b>standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary:</b> </p> <p><b>food allergy (oral food challenge) by 1 to 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>482</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99 to 6.49</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>food allergy (oral food challenge + panel assessment) by 1 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food allergy (parent report of doctor diagnosis) by 1 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 to 1.31</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>.<b> </b><br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </div> <p>For food allergy measured by a parental report of a doctor diagnosis, IPD were available for three studies including 2170 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Food allergy diagnosis was cumulative up to 12 months for one trial (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>), and up to 24 months for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Pooled IPD available from 1614 participants in these studies showed no effect of skin care intervention (RR 1.02, 95% CI 0.80 to 1.31; I² = 0; <a href="./references#CD013534-fig-0040" title="">Analysis 1.35</a>). </p> <p>One additional trial randomising 53 participants reported some narrative information on food allergy for only the control group that was not suitable for inclusion in meta‐analysis (<a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>). It was narratively reported that <i>"</i>none of the 4 IAD [infantile atopic dermatitis] infants developed cow’s milk protein allergy or any other food allergy". </p> <p>As only one study reported the primary food allergy outcome (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), and the two studies that reported IgE‐mediated food allergy confirmed by oral food challenge or via an investigator assessment based on clinical history and/or skin prick tests fell within the same groups for each of the planned subgroup analysis (intervention type: basic emollients, intervention period: ≥ 6 months; and intervention duration: long) (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), we did not conduct planned subgroup analysis at the study level for food allergy. </p> <p>Access to IPD did allow us to assess the interaction between actual age of treatment initiation and treatment. Based on data available for 976participants in <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>, the RR of food allergy for starting skin care treatment at four or more days of age, in comparison to initiation of skin care treatment less than four days, was 0.49 (95% CI 0.07 to 3.40). The wide 95% CI indicates uncertainty surrounding the direction and magnitude of any effect of age of treatment initiation. </p> <p>The interaction effect between treatment and <i>FLG</i> genotype on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge only) was available for one trial (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), but was not estimable. The interaction effect between treatment and <i>FLG</i> genotype on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge or via an investigator assessment based on clinical history or skin prick tests data, or both) by one to three years could be estimated for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Based on individual data from 1517 participants, the RR of food allergy by three years for having one or two <i>FLG</i> null mutations in the skin care intervention group versus no <i>FLG</i> mutations was RR 1.29 (95% CI 0.41 to 4.08; <a href="./references#CD013534-fig-0041" title="">Analysis 1.36</a>). </p> <p>The interaction effect between treatment and the chromosome 11 variant on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge only) was available for one trial (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), but was not estimable. The interaction effect between treatment and the chromosome 11 variant on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge or via an investigator assessment based on clinical history or skin prick tests data, or both) by one to three years could be estimated for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Based on available data from 1650 participants, the RR of food allergy by three years for having C:T or T:T<i> </i>genotype in the skin care intervention group versus C:C mutation was RR 1.59 (95% CI 0.63 to 4.01; <a href="./references#CD013534-fig-0042" title="">Analysis 1.37</a>). The wide 95% CIs indicate uncertainty surrounding the direction and magnitude of any effect of the chromosome 11 variant mutations on treatment effect from these studies. </p> <p>The interaction effect between treatment and the combination of <i>FLG</i> genotype and the chromosome 11 variant on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge only) was available for one trial (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), but was not estimable.  The interaction effect between treatment and the combination of <i>FLG</i> genotype and the chromosome 11 variant on food allergy (provided by IgE‐mediated food allergy confirmed by oral food challenge or via an investigator assessment based on clinical history or skin prick tests data, or both) by one to three years could be estimated for two trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Based on available data from 1492 participants, the RR of food allergy by three years in those with one or two <i>FLG</i> mutations and/or C:T or T:T genotype at the chromosome 11 locus versus no <i>FLG</i> null mutations and C:C genotype was 1.67 (95% CI 0.57 to 4.93; <a href="./references#CD013534-fig-0043" title="">Analysis 1.38</a>). </p> <p>The CACE for an individual using a skin care intervention for three or more days a week could be estimated for one study providing adequate compliance and food allergy outcome data (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). The CACE on food allergy assessed (confirmed by oral food challenge or via an investigator assessment based on clinical history or skin prick tests data, or both) for an individual using a skin care intervention for three or more days a week based on 1115 participants was accompanied by a considerable level of uncertainty, as reflected by very wide 95% CI (RR 4.06, 95% CI 0.59 to 27.68; <a href="./references#CD013534-fig-0044" title="">Analysis 1.39</a>). Whilst the point estimate for the RR was more in favour of standard care compared with the intention‐to‐treat effect of RR 2.53 (95% CI 0.99 to 6.49) (<a href="./references#CD013534-fig-0038" title="">Analysis 1.33</a>), the 95% CI for the CACE estimate is considerably wider than for the intention‐to‐treat effect and is consistent with the intention‐to‐treat effect of no difference. We therefore cannot infer any difference in treatment effect for a complier. Additional CACE estimates for alternative definitions of a complier are displayed in <a href="#CD013534-tbl-0008">Table 7</a>, and similarly do not demonstrate an impact of compliance on the treatment effect due to a large amount of uncertainty in estimation.  </p> <div class="table" id="CD013534-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Complier average causal effect (CACE) analyses for food allergy (oral food challenge or panel assessment)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Complier </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N standard care </b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>CACE</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intention‐to‐treat</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary CACE:</b> </p> <p><b>≥ 3 days of use over intervention period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>547</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>568</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.06</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 to 27.68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>≥ 5 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 to 57.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 to 293.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 6.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 5 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 to 7.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 to 20.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>One study is included across all presented analyses: <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>. </p> </div> </div> <p>Trial sequential analysis shows that a target sample size of 7602 would be necessary to demonstrate a minimum relative risk reduction of 30% (assuming a control rate of 5% versus skin care intervention 3.5%) with 90% power (<a href="#CD013534-fig-0004">Figure 4</a>). A target sample size of 18,063 would be necessary to demonstrate a minimum relative risk reduction of 20% (assuming a control rate of 5% versus skin care intervention 4%) with 90% power (<a href="#CD013534-fig-0005">Figure 5</a>). Based on the data accumulated to date included within the primary food allergy meta‐analysis (976 participants), the meta‐analysis is inconclusive for a relative effect size of 30 or smaller, because it has not yet crossed the upper or lower boundary for statistical significance or non‐superiority. </p> <div class="figure" id="CD013534-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial sequential analysis for food allergy (RR of 30%)." data-id="CD013534-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis for food allergy (RR of 30%).</p> </div> </div> </div> <div class="figure" id="CD013534-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis for food allergy (RR of 20%)." data-id="CD013534-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis for food allergy (RR of 20%).</p> </div> </div> </div> </section> </section> <section id="CD013534-sec-0081"> <h4 class="title">Secondary outcomes</h4> <section id="CD013534-sec-0082"> <h5 class="title">Adverse effects</h5> <p>Our adverse events of interest for which we separately reported meta‐analysis below were skin infections, stinging or allergic reactions, slippages, and serious adverse events recorded over the study intervention period. Ten trials reported some data on one or more of these specific adverse events, seven trials of which could be included in one or more meta‐analyses. </p> <p>An additional nine trials randomising 18,869 participants (one trial randomised 17,530 participants) provided a short general qualitative narrative on adverse events not eligible for inclusion in the meta‐analysis (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a>; <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>; <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a>). Of these nine trials, six trials randomising 18,593 participants  (9412 control, 9181 intervention) narratively reported no intervention‐related adverse events (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0018" title="ISRCTN86207019. Baby skin care research programme: Baby Wipes study. www.isrctn.com/ISRCTN86207019 (first received 17 February 2010). [DOI: 10.1186/ISRCTN86207019]LavenderT ,  Furber C, CampbellM , VictorS , RobertsI ,  Bedwell C, et al. Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. BMC Pediatrics2012;12:59. [DOI: 10.1186/1471-2431-12-59]LavenderT ,  Furber C, CorkM , CampbellM , VictorS . Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;1:Fa43-4. [DOI: 10.1136/archdischild.2011.300164.91]">Lavender 2012</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>; <a href="./references#CD013534-bbs2-0031" title="NCT00109616. Community trial of newborn skin and umbilical cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/ct2/show/NCT00109616 (first received 2 May 2005). Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  KatzJ , LeClerqSC , et al. Impact of newborn skin-cleansing with chlorhexidine on neonatal mortality in Southern Nepal: a community-based, cluster-randomized trial. Pediatrics2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]">Tielsch 2007</a>). Of the remaining three trials, <a href="./references#CD013534-bbs2-0027" title="Sankaranarayanan K,  Mondkar JA,  Chauhan MM,  Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in neonates: an open randomized controlled study of coconut versus mineral oil. Indian Pediatrics2005;42(9):877‐84. [PMID: 16208048]">Sankaranarayanan 2005</a> (randomised 112 term babies to groups of 38 coconut oil, 37 mineral oil, and 37 placebo) reported "3 in the coconut oil group, 3 in the mineral oil group and 2 in the placebo group developed mild rash that did not require discontinuation of application"; <a href="./references#CD013534-bbs2-0012" title="Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,  ReisshauerA , et al. Effect of baby swimming and baby lotion on the skin barrier of infants aged 3-6 months. Journal of the German Society of Dermatology2011;9(12):1018‐26. [DOI: 10.1111/j.1610-0387.2011.07710.x]">Garcia Bartels 2011</a> (randomised 44; 20 lotion and 24 no lotion) reported "the overall occurrence of adverse events (AEs) was lower in group L <i>(lotion)</i> (n = 18) than in group WL <i>(without lotion)</i> (n = 33, Table 3)"; and <a href="./references#CD013534-bbs2-0025" title="IRCT201102265912N1. The effect of massage with sunflower oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201102265912N1 (first received 8 January 2012). Raisi Dehkordi Z. A comparative study of the effect of massage with sunflower oil or sesame oil on infants' crying and sleep times: a randomized control trial. European Psychiatry2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]">Raisi Dehkordi 2010</a> (randomised 120) reported "some adverse events in the oil massage groups; however they were mild rash, which required no cessation". </p> <section id="CD013534-sec-0083"> <h6 class="title">Skin infections</h6> <p>Individual participant data on skin infections were available from six studies (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), including a total of 4209 randomised participants. Pooled IPD available from 2728 participants in these studies were in favour of standard care (RR 1.33, 95% CI 1.01 to 1.75; <a href="./references#CD013534-fig-0050" title="">Analysis 1.45</a>), with I² = 0 (P = 0.95).  </p> <p>One additional trial that randomised 70 participants (35 to each group) reported weekly infection rates over four weeks of 0 (0%), 3 (8.6%), 7 (20%), and 5 (14.3%) in the control group versus 0 (0%), 0 (0%), 1 (2.9%), and 0 (0%) in the skin care group (<a href="./references#CD013534-bbs2-0002" title="Amer M, Amer A. Neonatal skin care. A four-week follow up randomized controlled trial. European Journal of Pediatric Dermatology2015;25(2):93-9. [DOI: 10.26326/2281-9649.25.2.1106]Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what should we do? A four-week follow-up randomized controlled trial at Zagazig University Hospitals. International Journal of Dermatology2017;56(11):1198‐203. [DOI: 10.1111/ijd.13735]">Amer 2017</a>). </p> </section> <section id="CD013534-sec-0084"> <h6 class="title">Stinging or allergic reactions</h6> <p>Individual participant  data on stinging or allergic reactions to moisturisers were available from four studies (<a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>), including a total of 349 randomised participants. Pooled IPD available from 343 participants in these studies were in favour of standard care (RR 2.24, 95% CI 0.67 to 7.43; <a href="./references#CD013534-fig-0051" title="">Analysis 1.46</a>), with I² = 0 (P = 0.99), but with some uncertainty about the true effect, the 95% CI including no difference and a benefit of skin care intervention. </p> <p>One study randomising 120 participants to Johnson's Baby Top‐To‐Toe wash (Group 1, n = 60), Sebamed Baby Liquid Cleanser (Group 2, n = 60), and lukewarm tap water (Group 3, n = 60) reported "in group I, 1/60 subjects had mild rashes and redness on the neck and arms that appeared around 4 days after use. The irritation appeared 2‐3 hours after bathing and lasted for a few minutes. In group II, 2/60 subjects had irritation in the first week. These were mild rashes on the back and leg and lasted for 1‐ 2 days. For group II, 1/60 subjects had mild rashes and dryness 3 days after starting use of the product. No irritation was noted with any of the three compounds in the second week" (<a href="./references#CD013534-bbs2-0009" title="Dizon MV,  Galzote C, Estanislao R, MathewN ,  Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatrics2010;47(11):959‐63. [DOI: 10.1007/s13312-010-0161-8]">Dizon 2010</a>).  It was also reported that "no statistically significant irritation was visible to the clinician for all three groups of the study". </p> <p>One additional study randomised 93 participants to receive the first bath with chlorhexidine (n = 44) or neutral liquid soap in the control group (n = 49) (<a href="./references#CD013534-bbs2-0007" title="Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,  Cunha ML. Effect of the first bath with chlorhexidine on skin colonization with Staphylococcus aureus in normal healthy term newborns. Scandinavian Journal of Infectious Diseases2008;40(8):615-20. [DOI: 10.1080/00365540801932447]">Da Cunha 2008</a>). No adverse effects were reported for the use of chlorhexidine, including skin irritation. </p> </section> <section id="CD013534-sec-0085"> <h6 class="title">Slippage accidents</h6> <p>Individual participant data on slippage accidents were available from four studies (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), involving a total of 3994 randomised participants. Two studies recorded no slippage events in both treatment groups (<a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Pooled IPD analysis from 2538 participants in these studies showed that the treatment effect favoured standard care (RR 1.42, 95% CI 0.67 to 2.99; <a href="./references#CD013534-fig-0052" title="">Analysis 1.47</a>), with I² = 0 (P = 0.68), but with some uncertainty about the true effect, the 95% CI including no difference and a benefit of skin care intervention (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>). </p> <p><a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> provided data on slippage accidents and was a 2 x 2 factorial trial. Because significant interaction was noted between the two interventions in this trial (food intervention and skin care intervention), we only included in our analysis data from the skin care intervention group versus the control group, as was in line with our prespecified statistical analysis plan (<a href="./references#CD013534-bbs2-0248" title="CroS , BoyleR , KelleherM , TranL , CorneliusV . Skin care interventions for preventing eczema and food allergy: a statistical analysis plan for a systematic review and individual participant data meta-analysis. zenodo.org/record/3610604#.XiGKU8j7SUk (accessed 16 January 2020). [DOI: 10.5281/zenodo.3610604]">Cro 2020a</a>). One accident connected with bathing was reported for a participant in the 'food and skin care' intervention group (1/583, 0.2%); however the 'food and skin care' group was not included in the analysis as a significant interaction between skin care and early introduction of food allergens was identified. </p> </section> <section id="CD013534-sec-0086"> <h6 class="title">Serious adverse events</h6> <p>Individual participant data on serious adverse events were available from three studies including a total of 2591 randomised participants (<a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Pooled IPD available from 1367 participants in these studies favoured standard care (RR 1.80, 95% CI 0.45 to 7.18; <a href="./references#CD013534-fig-0053" title="">Analysis 1.48</a>), but with some uncertainty about the true effect, the 95% CI including no difference and a benefit of skin care intervention. The evidence showed some heterogeneity (I² = 51, P = 0.13); however, only three trials were included in this comparison, each of which had wide confidence intervals for the effect size, including no difference and a benefit of standard care and a benefit of skin care intervention due to small numbers of events. A description of reported serious adverse events is provided in <a href="#CD013534-tbl-0009">Table 8</a>. </p> <div class="table" id="CD013534-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Skin care</b> </p> <p><b>(N events)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control </b> </p> <p><b>(N events)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total</b> </p> <p><b>(N events)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jaundice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral lung infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure (benign myoclonic jerks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchiolitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p> <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure (non‐febrile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchiolitis (respiratory syncytial virus or other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Croup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Foreign body aspiration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery (operation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flu/diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injury or accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unspecified reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD013534-sec-0087"> <h5 class="title">Eczema severity </h5> <p>Individual participant data on eczema severity as assessed by a clinician at one to three years were available from three studies including 1528 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). Eczema severity was measured using the EASI at 24 months for <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; the EASI at 12 months for <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; and the objective SCORAD at 12 months for <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>. When no eczema was present, two studies had recorded an eczema severity rating of 0 (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). For one study, we imputed an eczema severity rating of 0 for the purpose of analysis when no eczema was reported (<a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>).  </p> <p>We first assessed the risk of moderate/severe/very severe eczema versus clear/mild eczema. Two studies did not record any incidences of moderate/severe/very severe eczema in either treatment group amongst a total of 108 participants (58 skin care intervention versus 50 standard care) (<a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). In the third study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), data on eczema severity, measured by a clinician at two years, were available for 1120 participants, and showed no difference between treatment groups (RR 0.92, 95% CI 0.37 to 2.27; <a href="./references#CD013534-fig-0054" title="">Analysis 1.49</a>). The 95% CI for the RR is wide, indicating no difference or small to large harm, and benefit of the skin care intervention for moderate/severe/very severe eczema cannot be ruled out based on this one study. </p> <p>We subsequently assessed the pooled standardised mean treatment group difference for clinician‐assessed eczema severity. Pooled IPD available from 1228 participants in the three studies providing participant data on clinician‐assessed eczema severity showed no difference between treatment groups (standardised mean difference (SMD) −0.02, 95% CI −0.17 to 0.12; <a href="./references#CD013534-fig-0055" title="">Analysis 1.50</a>), with I² = 7% (P = 0.34) (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). When the SMD was re‐expressed on the EASI, this was equivalent to a mean difference (MD) of −0.035 (95% CI −0.296 to 0.209), using the pooled standard deviation (SD) of 1.74 for EASI as observed in the largest study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). </p> <p>An additional study randomising 63 participants (31 intervention, 32 control) that did not provide IPD narratively reported that 60 infants completed the study (29 intervention, 31 control), and the severity of eczema measured using the SCORAD in the control group was significantly greater than in the intervention group: "(22.6 +/‐ 12.9 vs 17.6 +/‐ 5.3 respectively, U = 348, P &lt; 0.058)" (<a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>). <a href="./references#CD013534-bbs2-0004" title="Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Journal of Investigative Dermatology2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]Bellemere G, BoyerG , De Belilovsky C,  Baudouin C. Prevention of atopic dermatitis using emollients for 6 months - follow-up for 24 months. Pediatric Dermatology2019;36:S9. [DOI: 10.1111/pde.13846]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention biological data 1. Pediatric Dermatology2017;34:S106-7. [DOI: 10.1111/pde.13196]Bellemere G, BoyerG , De Belilovsky C,  Moga A,  Fontanie M,  Baudouin C. Early atopic dermatitis: prevention study. Pediatric Dermatology2018;35:S4‐5. [DOI: 10.1111/pde.13502]Bellemere G, BoyerG , de Belilovsky C,  Moga A, FontaineM . Early atopic dermatitis: prevention biologic data. Journal of the American Academy of Dermatology2018;79(3):AB115. [DOI: 10.1016/j.jaad.2018.05.487]">Bellemere 2018</a> reported that amongst 120 randomised participants (60 intervention, 60 control), the frequency of atopic dermatitis during the first six months of life was 9.8% in the prevention group, 18.3% in the control group, and 6.7% in the no‐risk group. Mean SCORAD scores were 24.1 and 23.3 in the at‐risk groups. </p> </section> <section id="CD013534-sec-0088"> <h5 class="title">Parent‐assessed eczema severity</h5> <p>Individual participant data on eczema severity as assessed by a parent were available from one study including 1394 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Eczema severity was measured using the POEM at 24 months. We first evaluated the risk of moderate/severe/very severe eczema versus clear/mild eczema as assessed by the parent. Data on eczema severity as assessed by a parent at two years were available for 1171 participants, and showed no difference between treatment groups (RR 1.17, 95% CI 0.82 to 1.67; <a href="./references#CD013534-fig-0056" title="">Analysis 1.51</a> ). The width of the 95% CI for the RR indicates that we cannot rule out no difference or small to large favouring of standard care or skin care intervention for moderate/severe/very severe eczema based on this one study. </p> <p>We subsequently assessed the MD for parent‐assessed eczema severity for the only study with available data (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Individual participant data available from 1171 participants showed no difference between treatment groups (MD 0.07, 95% CI −0.38 to 0.52; <a href="./references#CD013534-fig-0057" title="">Analysis 1.52</a>). </p> </section> <section id="CD013534-sec-0089"> <h5 class="title">Time to onset of eczema</h5> <p>Individual participant data on time to eczema onset were available from nine studies including 5042 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). Eczema was measured using the Hanifin and Rajka criteria (<a href="./references#CD013534-bbs2-0273" title="HanifinJM , RajkaG . Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica1980;60 Suppl 92:44-7.">Hanifin 1980</a>), or the UK Working Party refinement of them (<a href="./references#CD013534-bbs2-0349" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology1994;131(3):383-96.">Williams 1994</a>), or other modifications of the Hanifin and Rajka criteria in six studies (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>); was doctor diagnosed in two studies (<a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>); and was assessed by first parent report of a clinical diagnosis in one study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>). Eczema onset was assessed up to six months in one study (<a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>); up to 8 months (32 weeks) in one study (<a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>); up to 12 months in four studies (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>); and up to 24 months in three studies (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>). For each trial, data were censored at the trial‐specific last measured time point for individuals not experiencing eczema. </p> <p>Pooled IPD available from 3349 participants in these nine studies showed no benefit of skin care intervention (hazard ratio (HR) 0.86, 95% CI 0.65 to 1.14; <a href="./references#CD013534-fig-0058" title="">Analysis 1.53</a>). However, the 95% CI for the pooled HR indicates that we cannot rule out potential benefit or harm, extending from 0.65 to 1.14. The median time to eczema onset across the included studies in the control group was six months. The pooled HR corresponds to a median time to eczema onset of 6.98 months in the skin care intervention group. Results show moderate statistical heterogeneity between studies for this outcome (I² = 53%, P = 0.03). Post hoc subgroup analysis conducted to explore heterogeneity showed a significant interaction effect (P = 0.03) of trial follow‐up (&lt; 1 year versus ≥ 1 year). The pooled HR from the two studies with follow‐up of less than a year was 0.55 (95% CI 0.35 to 0.87) (I² = 0%, P = 0.67) (<a href="./references#CD013534-fig-0059" title="">Analysis 1.54</a>). However, as this result was based on a total of only 224 participants from two studies that followed up participants for only six or eight months, there is uncertainty as to whether the skin care intervention delays eczema. The pooled HR from the seven studies with follow‐up of at least one year was 1.00 (95% CI 0.75 to 1.33; I² = 44%; <a href="./references#CD013534-fig-0059" title="">Analysis 1.54</a>). Remaining heterogeneity amongst studies with follow‐up of at least one year was driven by one trial (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). When <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> was excluded, the pooled HR with follow‐up of at least one year was 0.91 (95% CI 0.78 to 1.07) (I² = 0%, P = 0.67), which continues to show no benefit of skin care intervention. This heterogeneity may be driven by type of intervention (bathing and oil and emollient applied to the face only) or by timing of intervention initiation (from two weeks), or both.  </p> <p>One additional study that did not provide IPD, with a follow‐up period of nine months, reported no diagnoses of eczema in the skin care intervention group, and four (14.8%) atopic dermatitis diagnoses in the control group, for whom "the mean age of the 4 infants at the onset of IAD was 5.5 ± 0.55 months" (<a href="./references#CD013534-bbs2-0030" title="TCTR20161208001. The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161208001 (first received 4 December 2016). Thitthiwong P, KoopitakkajornT . The good skin care practices and emollient using since early infancy as the primary prevention of infantile atopic dermatitis in infants at risk: a randomized controlled trial. Siriraj Medical Journal2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]">Thitthiwong 2019</a>).  </p> </section> <section id="CD013534-sec-0090"> <h5 class="title">Parent report of immediate reaction to food allergen</h5> <p>Individual participant data on parental report of an immediate reaction (within two hours) to a known common food allergen at one to three years were available from two studies including 1448 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). In one study, no immediate reactions were reported in either treatment group from a total of 41/54 participants who were followed up to one year (<a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>). In the other study, data were available for 1171/1394 participants who were followed up to two years (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>); reactions were reported in 118/574 infants (21%) in the skin care intervention group and 96/597 infants (16%) in the standard care group, favouring standard care (RR 1.27, 95% CI 1.00 to 1.61; <a href="./references#CD013534-fig-0060" title="">Analysis 1.55</a>). </p> <p>For one trial (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), we were able to examine parental reports of an immediate reaction (within two hours) separately for milk, egg, and peanut. Reactions to milk were reported for 61/575 (11%) of the skin care intervention group and 46/598 (8%) of the standard care group, favouring standard care on average, but with some uncertainty regarding the true effect, with the 95% CI including no difference (RR 1.38, 95% CI 0.95 to 2.00; <a href="./references#CD013534-fig-0061" title="">Analysis 1.56</a>). Reactions to egg were reported for 44/575 (8%) of the skin care intervention group and 41/598 (7%) of the standard care group, favouring standard care on average, but with some uncertainty regarding the true effect, with the 95% CI including no difference and a benefit of skin care intervention (RR 1.12, 95% CI 0.74 to 1.68; <a href="./references#CD013534-fig-0062" title="">Analysis 1.57</a>). Reactions to peanuts were reported for 8/574 (1.4%) of the skin care intervention group and 10/598 (2%) of the standard care group, favouring skin care intervention on average, but with some uncertainty regarding the true effect, with the 95% CI including no difference and a benefit of standard care (RR 0.84, 95% CI 0.33 to 2.10; <a href="./references#CD013534-fig-0063" title="">Analysis 1.58</a>). </p> </section> <section id="CD013534-sec-0091"> <h5 class="title">Allergic sensitisation to foods or inhalants</h5> <p>Allergic sensitisation data on foods or inhalants at one to three years were available from two studies including 1474 randomised participants (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>). In one study (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), data were available for 988/1394 participants who were followed up at two years; sensitisation was reported for 88/490 (18%) of the skin care intervention group and 74/498 (15%) of the standard care group. In the second study (<a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>), data were available for 70/80 participants who were followed up at one year; sensitisation was reported for 6/34 (18%) of the skin care intervention group and 8/36 (22%) of the standard care group. Pooled IPD available from 1058 participants in these studies showed no evidence of a difference between groups, but there is uncertainty regarding the true effect, with the 95% CI including a benefit of skin care intervention and no difference (RR 1.09, 95% CI 0.72 to 1.66; <a href="./references#CD013534-fig-0064" title="">Analysis 1.59</a>). </p> <p>For allergic sensitisation to food only, data were available for 985/1394 participants in <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> who were followed up at two years; sensitisation was reported for 58/487 (12%) of the skin care intervention group and 44/498 (9%) of the standard care group. In the second study (<a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>), data were available for 70/80 participants who were followed up at one year; sensitisation was reported for 3/34 (9%) of the skin care intervention group and 7/36 (19%) of the standard care group. In the third study (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), data were available for 739/1171 participants who were followed up at three years; food sensitisation was reported for 18/341 (5.3%) of the skin care intervention group and 21/398 (5.3%) of the standard care group. Pooled IPD available from 1794 participants in these three studies showed no difference between groups. The 95% CI for the pooled RR indicates that we cannot rule out potential benefit or harm of skin care intervention and no difference (RR 1.05, 95% CI 0.64 to 1.71; <a href="./references#CD013534-fig-0065" title="">Analysis 1.60</a>). There was a moderate level of statistical heterogeneity across the three included trials (I² = 44%), which could not be explained. We pooled results separately for milk, egg, and peanut across the three trials providing allergic sensitisation data on foods at one to three years. Pooled results for milk were based on estimates from <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> and <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> only (RR 1.16, 95% CI 0.55 to 2.43; <a href="./references#CD013534-fig-0066" title="">Analysis 1.61</a>). Pooled results included all three studies for egg (RR 0.92, 95% CI 0.42 to 2.00; <a href="./references#CD013534-fig-0067" title="">Analysis 1.62</a>) and for peanut (RR 1.08, 95% CI 0.68 to 1.71; <a href="./references#CD013534-fig-0068" title="">Analysis 1.63</a>). Milk and peanut analysis also showed a low level of heterogeneity, although the egg analysis revealed moderate levels of heterogeneity across the included trials.  </p> <p>Two additional studies reported allergic sensitisation to foods at eight and nine months (<a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>). When data from these two studies were included in sensitivity analyses, the pooled treatment effect was RR 1.08 (95% CI 0.92 to 1.27; <a href="./references#CD013534-fig-0070" title="">Analysis 1.65</a>). Pooled results for milk were RR 0.84 (95% CI 0.59 to 1.21; <a href="./references#CD013534-fig-0071" title="">Analysis 1.66</a>); for egg RR 1.11 (95% CI 0.94 to 1.30; <a href="./references#CD013534-fig-0072" title="">Analysis 1.67</a>); and for peanut RR 1.08 (95% CI 0.68 to 1.71; <a href="./references#CD013534-fig-0073" title="">Analysis 1.68</a>). </p> <p>One additional study that did not provide IPD, with a follow‐up period of six months, reported eczema onset for "5/35 of the intervention group and 6/32 of the control group. And eczema onset ratio among infants who reacted positive to a prick test were 5/1 vs. 6/8" (<a href="./references#CD013534-bbs2-0016" title="Kataoka Y, YoshidaN ,  Nishino H,  Maeda N,  Sarumaru T,  Kijima A, et al. Can skin care from neonatal period prevent the onset of atopic dermatitis?Allergo Journal2010;19:338-9. [DOI: 10.1007/s40629-019-00114-5]">Kataoka 2010</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013534-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013534-sec-0092"></div> <section id="CD013534-sec-0093"> <h3 class="title" id="CD013534-sec-0093">Summary of main results</h3> <p>A summary of the main results is shown in <a href="./full#CD013534-tbl-0001">summary of findings Table 1</a>. </p> <p>Our key results as presented here were based on 10 trials providing individual participant data (IPD). These studies assessed skin care interventions that aim to promote hydration or barrier function: eight studies assessed emollients; one study assessed combined skin interventions, including emollients; and one study assessed topical oils, although this study only provided IPD for adverse events. </p> <p>For our primary outcome of eczema, we identified data from 3075 participants in seven randomised controlled trials (RCTs) and found that skin care interventions probably do not influence the development of eczema by age one to three years in healthy term infants when compared with standard care. The certainty of the evidence was moderate. One trial, <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>, showed an increase in eczema in the intervention group at age one year, leading to some statistical heterogeneity in the main eczema analysis. This was a factorial randomised trial with skin care interventions and early allergenic food introduction. Due to significant interaction between interventions, only the skin care and control arms of the trial could be utilised in the primary analysis. The skin care intervention was a combination of daily facial emollient with daily baths with paraffin‐based bath oil, which differs somewhat to the interventions evaluated in the other trials providing data towards the primary analysis. This difference in intervention may explain the statistical heterogeneity seen in the main eczema analysis, with daily baths potentially having an adverse effect on skin barrier function and risk of eczema development compared with direct emollient application. Our preplanned subgroup analyses showed that the following factors did not influence the effect of intervention on risk of developing eczema: family history of atopy or <i>FLG</i> mutation, classification of intervention type, duration of intervention, and age. In this update we included chromosome 11 analysis, which was newly available data; however, there was similarly no effect of the intervention on eczema dependent on genetic status. We also found that the skin care interventions used probably do not change time to onset of eczema when compared with standard care (based on 3349 participants in nine trials; moderate‐certainty evidence). This is thought to be important in the interaction between eczema and food allergy because increased length of time with eczema is associated with increased likelihood of food sensitisation (<a href="./references#CD013534-bbs2-0334" title="TsilochristouO , du ToitG , SayrePH , RobertsG , LawsonK , SeverML ,  et al. Association of Staphylococcus aureus colonization with food allergy occurs independently of eczema severity. Journal of Allergy and Clinical Immunology2019;144(2):494-503. [PMID: 31160034]">Tsilochristou 2019</a>). Overall, the evidence from this review demonstrates with moderate certainty that the skin care interventions used in these RCTs do not impact the development of eczema (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>).  </p> <p>For our co‐primary outcome of food allergy, we found that skin care interventions using emollients may increase the risk of developing an immunoglobulin (Ig)E‐mediated food allergy when compared with standard care. Two trials (2081 participants) had food allergy diagnosed by oral food challenge as an outcome. Only one trial reported this separately (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), and both trials reported a combined outcome of food allergy by oral food challenge or investigator assessment (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Both analyses suggested that skin care interventions may increase the risk of food allergy; however, the certainty of the evidence is low, thus we are uncertain as to whether skin care interventions influence risk of food allergy by age one to three years when compared with standard care. </p> <p>The evidence for allergic sensitisation to food was of low certainty due to statistical heterogeneity and imprecision, with no difference in allergic sensitisation to food by age one to three years between treatment groups in pooled analysis of three trials (1797 participants). </p> <p>Data from one trial (1171 participants) suggest that when compared with standard care, skin care interventions may slightly increase the risk of parent‐reported immediate reaction to a common food allergen at two years, but this association was seen only for parent‐reported immediate reaction to cow's milk, which is thought to be an unreliable measure of IgE‐mediated cow's milk allergy due to commercially influenced over‐reporting of cow's milk allergy in infants (<a href="./references#CD013534-bbs2-0295" title="MunblitD , PerkinMR , PalmerDJ , AllenKJ , BoyleRJ . Assessment of evidence about common infant symptoms and cow's milk allergy. JAMA Pediatrics2020;174(6):599-608. [DOI: 10.1001/jamapediatrics.2020.0153] [PMID: 32282040]">Munblit 2020</a>). Hence, we also judged the certainty of this evidence to be low. </p> <p>Complier average causal effect (CACE) analysis was utilised to assess whether compliance with the assigned intervention influenced outcomes. For both &gt; 3 days per week and &gt; 5 days per week, although the CACE favoured the intervention for the eczema outcome, the CI ranged from large benefit to moderate harm, therefore we were unable to demonstrate whether increased adherence to the assigned interventions was associated with different outcomes. Insufficient evidence meant that we were unable to ascertain whether treatment adherence affected the risk of developing food allergy with any confidence. </p> <p>Our key adverse events of interest were local infection, stinging or allergic reactions to moisturisers, and slippage accidents. We found that compared to standard care, skin care interventions probably increase the risk of skin infection in an analysis that included IPD from 2728 infants participating in six trials (moderate‐certainty evidence). There may be an increase in stinging and allergic reactions (four trials including 343 participants) and slippage accidents (four trials including 2538 participants) with the intervention; however, the certainty of these findings was low due to very small numbers of events, yielding very wide confidence intervals that included the possibility of no effect or reduced risk. </p> </section> <section id="CD013534-sec-0094"> <h3 class="title" id="CD013534-sec-0094">Overall completeness and applicability of evidence</h3> <p>Only 17 of 33 included studies reported outcomes relevant to this review. </p> <p>Of these 17 studies, seven reported our primary outcome cumulative incidence of eczema by one to three years, and three of these studies measured eczema severity between one and three years by clinician assessment, with one of these studies also reporting parent report of eczema severity. Nine studies measured time to onset of eczema. Two studies reported parent report of immediate food allergy, and two studies reported allergic sensitisation to food or inhalant allergen. Ten studies reported adverse event data for our prespecified adverse events of interest. </p> <p>Only 10 trials provided IPD analysis. Most of the other identified trials included types of skin barrier interventions other than emollients, such as change in bath routine, but they did not provide follow‐up long enough after intervention to allow measurement of our predefined primary outcomes, and they were limited to contributing some narrative data on safety outcomes. As a result, the impact of non‐emollient interventions on the development of eczema or food allergy, rather than their short‐term impact on skin barrier physiology or safety outcomes, is unknown. </p> <p>All of the trials reporting eczema as an outcome used an emollient either on its own, or within a combination of skin care interventions, as the intervention and commenced within the first month of life. Eczema was largely evaluated by a blinded trained assessor using widely accepted tools such as Hanifin and Rajka or UK Working Party criteria for diagnosis. We can therefore be confident in the diagnosis of eczema in these studies. Interventions mainly focused on emollients, with each study using a different emollient with different constituents. Trials also had variable regimens and durations of emollient therapy. The emollients used were a combination of so‐called simple emollients and more complex emollients that contained lipids. Emollient regimens varied in intensity from twice‐daily all‐over body emollient to once daily on cheeks in combination with other skin care interventions. Skin care for infants varies by country and culture, and there is no standard recommendation. Our comparison of control (standard skin care or no skin care intervention) may thus have varied between studies. </p> <p>We analysed data based on assignment to intervention rather than on adherence to intervention. Compliance with daily emollient, when reported, was low but may have been higher in smaller pilot studies, in which potentially greater input from the research team could have aided compliance. Complier average causal effect was utilised to assess whether compliance with the assigned intervention influenced outcomes. However, we were unable to identify whether or not adherence to skin care interventions influences risk of eczema. </p> <p>The prospective portion of this meta‐analysis, planned in 2017, ensured that the two largest trials in the series had aligned outcomes and used similar methods of outcome evaluation (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). Meta‐analysis of these two studies and another five studies providing IPD on the development of eczema by one to three years allowed us to assess both study factors and individual participant factors that may influence results. When we evaluated study factors such as type of emollient used and duration of intervention and individual factors such as age, <i>FLG</i> genotype, chromosome 11 risk variant, or family history of atopy, we found no evidence for an interaction between these factors and the intervention on eczema risk. </p> <p>Ongoing studies are randomising newborn healthy infants to a skin care intervention, half of which are assessing emollients. <a href="./references#CD013534-bbs2-0222" title="NCT03871998. Short-term topical application to prevent atopic dermatitis (STOP AD). clinicaltrials.gov/ct2/show/NCT03871998 (first received 12 March 2019). Ni ChaoimhC , LadD , NicoC , PuppelsGJ , CaspersPJ , IrvineAD , et al. Neonatal natural moisturising factor concentrations in a high-risk cohort with parental history of atopy compared to a reference cohort. Allergy: European Journal of Allergy and Clinical Immunology2020;75 Suppl 109:91. [EMBASE: 633542472]Ni ChaoimhC , LadD , StamatasGN , OddosT , IrvineAD , O'B HourihaneJ . Parental compliance with an infant moisturization protocol in the first 2 months of life. Allergy2020;75 Suppl 109:596. [EMBASE: 633545599]">NCT03871998</a> is designed to address whether the emollient intervention applied from day one or two of life for a short (two‐month) time period influences eczema and IgE‐mediated food allergy development. <a href="./references#CD013534-bbs2-0218" title="ACTRN12617001380381. The PEBBLES Study - testing a strategy for preventing eczema and food allergy in high risk infants. www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617001380381 (first received 28 September 2017). Lowe A, SuJ , TangM , LodgeCJ , Matheson M, AllenKJ ,  et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open2019;9(3):e024594. [DOI: 10.1136/bmjopen-2018-024594]">Lowe 2019</a> and <a href="./references#CD013534-bbs2-0216" title="EichnerB , MichaelsLAC ,  Branca K, RamseyK , MitchellJ ,  MorrisCD , et al. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients - protocol for a randomized controlled trial. Trials2020;21(1):243. [DOI: 10.1186/s13063-020-4150-5]NCT03409367. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE). clinicaltrials.gov/ct2/show/NCT03409367 (first received 24 January 2018). ">Eichner 2020</a> are evaluating daily complex emollients, and are expected to report in 2022. It is possible that the use of more complex emollient interventions may have different effects on risk of eczema. </p> <p>We identified 16 eligible studies that did not have outcome measures relevant to this review (i.e. they did not record eczema or food allergy at one to three years or at any time, and they did not comment on adverse events). Infants in these trials were followed up to a maximum of four weeks, which was too soon to assess whether eczema or food allergy was present. These trials mainly involved different timings and mechanisms of bathing infants, along with different types of bathing products. Follow‐up was four weeks or less, and outcomes were skin physiology, such as transepidermal water loss. It is possible that had these infants been followed up for longer, and had eczema outcome been measured, these skin care practices would have been shown to have an effect on eczema. Furthermore, although "skin care intervention type B: any skin care interventions that aimed to protect the skin barrier from irritation such as water softeners" was prespecified in our search, it could not be assessed, as no suitable trials were found. A trial of water softeners is currently ongoing (<a href="./references#CD013534-bbs2-0217" title="Jabbar-LopezZK , Gurung N,  Greenblatt D,  Briley A, ChalmersJR , ThomasKS , et al. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]NCT03270566. Softened water for eczema prevention pilot trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1 September 2017). ">Jabbar‐Lopez 2019</a>). </p> <p>Evidence for the effects of skin care interventions in infants on risk of food allergy has increased due to this update. We were able to analyse data from two trials (2081 participants) reporting food allergy diagnosed by oral food challenge, although only one of these trials reported oral food challenge outcomes separately. Both trials reported a combined outcome of food allergy by oral food challenge or investigator assessment. Data from more trials reporting food allergy are needed in order to increase the certainty of evidence around effects of skin care interventions on food allergy development. </p> </section> <section id="CD013534-sec-0095"> <h3 class="title" id="CD013534-sec-0095">Quality of the evidence</h3> <p>Our confidence in the findings for eczema was moderate. Sensitivity analysis including only studies with low risk of bias was consistent with the primary analysis. We downgraded the certainty of evidence for eczema due to statistical heterogeneity that could not be explained. For the primary eczema outcome, the source of this heterogeneity was one trial that found increased eczema in the intervention group compared with the control group at age one year, but not at age three years (<a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). One potential cause of this heterogeneity was the nature of the intervention. <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> used a bathing intervention, whilst other trials contributing to the primary eczema analysis used direct application of a moisturiser to the infant's skin. However, for the outcome time to onset of eczema, we downgraded the certainty of evidence due to statistical heterogeneity, and heterogeneity in this analysis was due to more than one trial.  </p> <p>Our confidence in the findings for food allergy was low, and reliant on a small number of studies reporting robust food allergy outcomes. We downgraded the certainty of evidence for food allergy due to imprecision, with small numbers of studies and events and wide confidence intervals encompassing both a harmful effect and no effect. We also downgraded the primary food allergy outcome, due to risk of bias related to missing outcome data. In the only trial that reported oral food challenge outcomes separately (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>), participants who were invited for an oral food challenge due to suspected food allergy frequently declined to attend an oral food challenge, and the proportion that did attend differed between intervention group (29%) and control group (17%), suggesting a high risk of bias related to missing outcome data. Although the findings were similar if all those with missing outcome data were assumed to not have food allergy, they differed if participants were assumed to have food allergy. However, findings for food allergy assessed by the combined outcome of oral food challenge and investigator assessment also suggested that skin care interventions may increase risk of food allergy (<a href="./references#CD013534-fig-0039" title="">Analysis 1.34</a>). We also downgraded the secondary food allergy outcome, allergic sensitisation to a food allergen, due to statistical heterogeneity that could not be explained. </p> <p>Our confidence in the findings for adverse events was moderate or low. We downgraded the certainty of evidence for skin infection due to imprecision, with wide confidence intervals including a harmful effect and no effect. We downgraded the certainty of evidence for slippages and stinging/allergic reactions to moisturisers due to severe imprecision, with small numbers of events and wide confidence intervals that included both a harmful effect and a beneficial effect. We assessed risk of bias for all studies included in the adverse events analyses except one as some concerns for the specific adverse events assessed; this was due to the nature of adverse events being self‐recalled by carers, who could not be blinded because of the type of intervention under study. </p> </section> <section id="CD013534-sec-0096"> <h3 class="title" id="CD013534-sec-0096">Potential biases in the review process</h3> <p>The meta‐analysis collaboration group for this review, SCiPAD (Skin Barrier Interventions for Prevention of Allergic Disease), was formed in 2017 through collaboration between the two largest trials, <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> and <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>. The purpose of the prospective collaboration was to increase the alignment of outcomes measured in the two individual trials and to enhance the power of individual trials to identify effects of the interventions on the outcome of food allergy, which is less prevalent than eczema. Other trial groups were invited to join the collaboration between 2017 and 2020, and their data formed the basis of the prospective portion of the meta‐analysis. Prospective meta‐analysis allows for alignment of outcomes before completion of the trial, so that comparisons and analysis are more readily conducted between trials. Within this collaborative group, trials mainly involved emollients as an intervention and eczema as an outcome. We attempted to reduce any availability bias by conducting a sensitive search, which identified over 6000 potentially eligible studies, and by contacting authors of eligible studies to request their collaboration in the IPD meta‐analysis; however, follow‐up for most studies was too short for inclusion. </p> <p>We classified collaborating trials when trial outcome data were not analysed and known to study authors before February 2017 as contributing 'prospectively acquired data'. Data from some of these trials became known to the investigators or to the public before the statistical analysis plan (SAP) for this meta‐analysis was locked, so that, in theory, findings could have influenced the design of the statistical analysis plan. Development of the SAP was led by a statistician (SC) with no detailed knowledge of eligible trial publications at the time of finalisation of the SAP, and the principles of the SAP and the review protocol were aligned with the February 2017 PROSPERO registration of the prospective meta‐analysis (<a href="./references#CD013534-bbs2-0238" title="BoyleR , WilliamsH , AskieL , Lodrup-CarlsenK , MontgomeryA , ChalmersJ , et al. Prospectively planned meta-analysis of skin barrier studies for the prevention of eczema and associated health conditions. www.crd.york.ac.uk/prospero/display_record.php?RecordID=56965 (first received 10 February 2017).">Boyle 2017</a>). The SAP was signed off before any unblinding of individual participant data sets received from individual trials. Our close collaboration with trial investigators meant that they were involved in protocol and SAP development and in interpretation of meta‐analysis findings. A strength of this approach is that collaborating trialists had the opportunity to review our analyses of their data sets before stage 2 of the IPD meta‐analysis and to correct any misinterpretation of data coding. Review authors MK and RJB were very involved in the <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a> trial, with RJB the principal investigator for food allergy, and MK involved in food allergy diagnosis; these two review authors were therefore not involved in data extraction or risk of bias assessment for this trial, other than as investigators commenting on meta‐analysis findings.  </p> <p>Use of IPD in this review allowed us to (i) fit a consistent analysis model to trial data sets for each outcome to ensure that we compared treatment effects adjusted for the same covariates across trials; (ii) fully explore the risk of bias due to missing data by conducting additional sensitivity analyses that had not previously been reported; (iii) obtain more reliable and powerful subgroup analyses including estimation of treatment interactions with participant characteristics that had not previously been reported; and (iv) evaluate the relationship between compliance with the intervention and outcomes of interest. However, the method of sharing IPD can result in availability bias. We attempted to limit this by offering all trials administrative assistance in working with their individual institutions for data agreement development and sign‐off and for data sharing and extraction. Overall, trials with relevant outcomes from which we did not manage to access IPD were generally small (fewer than 100 participants) or were industry funded, and researchers were concerned about the commercial impact of data sharing. Only one trial, with 60 participants, had primary outcome data eligible for inclusion in the meta‐analysis and did not supply IPD; sensitivity analysis including aggregate data from this one trial showed similar findings to the main analysis. One industry‐funded trial was involved in the SCiPAD collaboration (<a href="./references#CD013534-bbs2-0219" title="NCT02906475. Atopic dermatitis in atopy predisposed infants. clinicaltrials.gov/ct2/show/NCT02906475 (first received 20 September 2016). ">NCT02906475</a> ); however, this trial is ongoing, and results are expected in 2022. </p> <p>Overall, the close relationship between trialists and systematic reviewers in this project carries risk of availability bias and academic bias towards individual clinical trial findings, which is mitigated only in part by the prospectively planned nature of the meta‐analysis for most studies contributing data.  </p> <p>The interventions used in the included trials varied in their composition, and there is no standard classification system for emollients (<a href="./references#CD013534-bbs2-0330" title="SurberC , KottnerJ . Skin care products: what do they promise, what do they deliver. Journal of Tissue Viability2017;26(1):29-36.">Surber 2017</a>). This led to difficulty in classification of the intervention for the purpose of subgroup analysis, as different emollients have overlapping constituents, which may have differential effects on the skin barrier or on skin health. We took advice from a member of our collaboration (MC) with expertise in emollient formulation and effects on skin barrier, who classified the interventions used before seeing the meta‐analysis results. These were used for the subgroup analysis of 'basic' versus 'complex' skin care interventions, which showed no evidence of an interaction. We acknowledge that other groups may have classified the interventions differently. Similarly, although we planned to stratify interventions as skin care intervention A: those that primarily aim to enhance the skin barrier through direct application of emollient or moisturiser, and skin care intervention B: those that aim to protect the skin barrier from damage, we did not find any trial results where intervention B had been used. <a href="./references#CD013534-bbs2-0217" title="Jabbar-LopezZK , Gurung N,  Greenblatt D,  Briley A, ChalmersJR , ThomasKS , et al. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]NCT03270566. Softened water for eczema prevention pilot trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1 September 2017). ">Jabbar‐Lopez 2019</a> would be classified as an intervention B, but is still ongoing. Similarly, there is no standard recommended skin care for infants, with practices varying by country and by culture, therefore the comparison of control, taken as standard skin care or no skin care intervention, may have varied between studies. </p> <p>Several trials did not contribute data to the meta‐analysis, or contributed only narrative data on non‐specific adverse events. We had some difficulty in deciding whether these trials should be included based on the type of intervention and the type of comparator evaluated. For example, we excluded trials that compared one way of bathing to another (<a href="./references#CD013534-bbs2-0051" title="Bryanton J, WalshD , BarrettM , Gaudet D. Tub bathing versus traditional sponge bathing for the newborn. Journal of Obstetric, Gynecologic, and Neonatal Nursing2004;33(6):704‐12. [DOI: 10.1177/0884217504270651]">Bryanton 2004</a>), but we included a trial that used a different product in the bath compared to the control group bath, because this might influence skin barrier function (<a href="./references#CD013534-bbs2-0021" title="LundC ,  Kuller J, DurandDJ . Baby's first bath: changes in skin barrier function after bathing full-term newborns with water vs liquid baby cleanser. Pediatric Dermatology2019;37:115-9. [DOI: 10.1111/pde.14037]">Lund 2020</a>). We concentrated on a normal healthy term population so that our findings were generalisable and were not impacted by the unique structure of preterm skin and the different skin care practices to which preterm infants are exposed.  </p> </section> <section id="CD013534-sec-0097"> <h3 class="title" id="CD013534-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>This is an update of the first Cochrane Review of skin barrier intervention in term infants. A previous Cochrane Review looked at topical emollients for preventing infection in preterm infants (<a href="./references#CD013534-bbs2-0057" title="Cleminson J, McGuire W. Topical emollient for preventing infection in preterm infants. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD001150. [DOI: 10.1002/14651858.CD001150.pub3]">Cleminson 2016</a>). That review concluded that there was no evidence that emollients prevent invasive infection in preterm infants in high‐, middle‐, or low‐income countries. <a href="./references#CD013534-bbs2-0057" title="Cleminson J, McGuire W. Topical emollient for preventing infection in preterm infants. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD001150. [DOI: 10.1002/14651858.CD001150.pub3]">Cleminson 2016</a> also evaluated topical oils (mainly vegetable oils), finding some evidence that preterm infants treated with topical vegetable oils had increased growth compared to those given control treatment, although long‐term growth was not measured. <a href="./references#CD013534-bbs2-0057" title="Cleminson J, McGuire W. Topical emollient for preventing infection in preterm infants. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD001150. [DOI: 10.1002/14651858.CD001150.pub3]">Cleminson 2016</a> had invasive infection as a primary outcome. The review did not discuss or report on cutaneous infection, so it is unclear whether this was not seen as an adverse effect of the interventions studied, or if it just was not measured. If skin care interventions increase risk of cutaneous infection in term infants, but not in preterm infants, the reason for this difference is unclear. Preterm infants have more permeable skin than term infants and have specific vulnerability to serious bacterial infection. It is possible that hand hygiene for those who apply emollients or oils to the skin of preterm infants may be more thorough than hand hygiene for those who apply emollients or oils to the skin of healthy term infants. If this were the case, then differences in effects on risk of cutaneous infection could potentially be explained by differences in hand hygiene practice. </p> <p>A previous Cochrane overview of interventions for the primary prevention of eczema in children identified systematic reviews of trials evaluating dietary interventions such as maternal dietary antigen avoidance, exclusive breastfeeding for a defined period of time, omega‐3 and omega‐6 fatty acid supplementation, hydrolysed protein formula, soya formula, and prebiotics and probiotics. The overview did not identify trials of skin care interventions or an intervention that effectively prevents the onset of eczema (<a href="./references#CD013534-bbs2-0083" title="Foisy M, BoyleRJ , ChalmersJR , SimpsonEL , Williams HC. Overview of reviews: the prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews. Evidence-Based Child Health: A Cochrane Review Journal2011;6(5):1322-39. [DOI: 10.1002/ebch.827]">Foisy 2011</a>). </p> <p>A systematic review of interventions for the prevention of food allergy was undertaken by a European Academy of Allergy and Clinical Immunology committee to inform an update of their guidance on food allergy prevention (<a href="./references#CD013534-bbs2-0256" title="De SilvaD ,  Halken S,  SinghC ,  Muraro A,  Angier E,  Arasi S, et al. Preventing food allergy in infancy and childhood: systematic review of randomised controlled trials. Paediatric Allergy and Immunology2020;31(7):813-26. [DOI: 10.1111/pai.13273]">De Silva 2020</a>). This systematic review included <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> in its section on emollients for food allergy prevention, as other studies reporting eligible food allergy outcomes had not been published at the time this systematic review was conducted. Review authors concluded that emollients may not reduce risk of food allergy (low‐certainty evidence). Our review included the larger and more recently completed trials using oral food challenge for outcome assessment (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>), and did not include food challenge outcomes from <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a> in the primary food allergy analysis because oral food challenge was not used for food allergy assessment in this trial. We rated the evidence for this outcome as low certainty and found that skin care interventions may increase risk of food allergy. However, this was not supported by the findings for parent report of doctor diagnosis of food allergy or for allergic sensitisation to foods, where we found skin care interventions such as emollients may not change these outcomes. </p> <p>Two pilot studies, <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a> and <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>, were reported as showing significant reductions in eczema risk. Larger, more definitive trials published subsequently found no reduction in eczema, and our meta‐analysis results are consistent with the findings from these larger trials (<a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>). The reason for the difference in findings between small pilot studies and larger trials is not clear, but differences in adherence to treatment, methods and timing of outcome assessment, and study population may all be relevant.  </p> <p>Finally, a previous Cochrane Review has evaluated emollients as treatment for already established eczema (<a href="./references#CD013534-bbs2-0341" title="Van ZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenAP , ArentsBW . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012119. [DOI: 10.1002/14651858.CD012119.pub2]">Van Zuuren 2017</a>). That review concluded that although the evidence was weak, emollients reduce disease severity compared to no treatment ‐ reducing flares, prolonging time between flares, and decreasing the need for topical corticosteroids. Our new review concerns the primary prevention of eczema and does not directly impact the well‐established and well‐accepted intervention of emollients for people who already have eczema. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013534-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013534-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for eczema (RR of 30%)." data-id="CD013534-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Trial sequential analysis for eczema (RR of 30%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for eczema (RR of 20%)." data-id="CD013534-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Trial sequential analysis for eczema (RR of 20%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for food allergy (RR of 30%)." data-id="CD013534-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial sequential analysis for food allergy (RR of 30%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for food allergy (RR of 20%)." data-id="CD013534-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial sequential analysis for food allergy (RR of 20%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 1: Eczema by 1 to 3 years" data-id="CD013534-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 1: Eczema by 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 2: Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data" data-id="CD013534-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 2: Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 3: Sensitivity analysis: Eczema by 1 to 3 years (UKWP only)" data-id="CD013534-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 3: Sensitivity analysis: Eczema by 1 to 3 years (UKWP only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 4: Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)" data-id="CD013534-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 4: Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 5: Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36‐month outcome)" data-id="CD013534-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 5: Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36‐month outcome) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 6: Sensitivity analysis: Eczema by 1 to 3 years ‐ low risk of bias" data-id="CD013534-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 6: Sensitivity analysis: Eczema by 1 to 3 years ‐ low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 7: Sensitivity analysis: Eczema by 1 to 3 years ‐ excluding non‐prospectively acquired data" data-id="CD013534-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 7: Sensitivity analysis: Eczema by 1 to 3 years ‐ excluding non‐prospectively acquired data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 8: Sensitivity analysis: Eczema by 6 months to 3 years" data-id="CD013534-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 8: Sensitivity analysis: Eczema by 6 months to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 9: Sensitivity analysis: Eczema after the intervention period (at 1 year or beyond ‐ up to 3 years) " data-id="CD013534-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 9: Sensitivity analysis: Eczema after the intervention period (at 1 year or beyond ‐ up to 3 years)  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 10: Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type" data-id="CD013534-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 10: Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 11: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration " data-id="CD013534-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 11: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 12: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing" data-id="CD013534-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 12: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 13: Participant‐level treatment interaction: Eczema by 1 to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age" data-id="CD013534-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 13: Participant‐level treatment interaction: Eczema by 1 to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 14: Participant‐level treatment interaction: Eczema by 6 months to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age" data-id="CD013534-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 14: Participant‐level treatment interaction: Eczema by 6 months to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 15: Participant‐level treatment interaction: Eczema by 1 to 3 years by FLG genotype (0 mutations versus 1/2 mutations)" data-id="CD013534-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 15: Participant‐level treatment interaction: Eczema by 1 to 3 years by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 16: Participant‐level treatment interaction: Eczema by 6 months to 3 years by FLG genotype (0 mutations versus 1/2 mutations)" data-id="CD013534-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 16: Participant‐level treatment interaction: Eczema by 6 months to 3 years by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 17: Participant‐level treatment interaction: Eczema by 1 to 3 years by chromosome 11 status (C:C versus C:T or T:T)" data-id="CD013534-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 17: Participant‐level treatment interaction: Eczema by 1 to 3 years by chromosome 11 status (C:C versus C:T or T:T) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 18: Participant‐level treatment interaction: Eczema by 1 to 3 years by FLG mutation and chromosome 11 status (no FLG and C:C versus FLG mutation and/or chromosome 11 C:T or T:T)" data-id="CD013534-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 18: Participant‐level treatment interaction: Eczema by 1 to 3 years by <i>FLG</i> mutation and chromosome 11 status (no <i>FLG</i> and C:C versus <i>FLG</i> mutation and/or chromosome 11 C:T or T:T) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 19: Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease " data-id="CD013534-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 19: Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 20: Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease and/or FLG genotype (0 mutations versus 1/2 mutations)" data-id="CD013534-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 20: Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease and/or <i>FLG</i> genotype (0 mutations versus 1/2 mutations) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 21: CACE: Eczema by 1 to 3 years for use over intervention period ≥ 3 days a week" data-id="CD013534-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 21: CACE: Eczema by 1 to 3 years for use over intervention period ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 22: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period ≥ 5 days a week" data-id="CD013534-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 22: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 23: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period 7 days  a week " data-id="CD013534-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 23: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period 7 days  a week  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 24: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 3 days a week" data-id="CD013534-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 24: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 25: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 5 days a week" data-id="CD013534-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 25: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 26: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months 7 days a week" data-id="CD013534-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 26: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months 7 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 27: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 3 days a week" data-id="CD013534-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 27: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 28: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 5 days a week" data-id="CD013534-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 28: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 29: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period 7 days a week" data-id="CD013534-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 29: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period 7 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 30: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 3 days a week" data-id="CD013534-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 30: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 31: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 5 days a week" data-id="CD013534-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 31: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 32: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months 7 days a week" data-id="CD013534-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 32: Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months 7 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 33: Food allergy by 1 to 3 years" data-id="CD013534-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 33: Food allergy by 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 34: Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment)" data-id="CD013534-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 34: Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 35: Sensitivity analysis: Food allergy by 1 to 3 years (parent report of doctor diagnosis)" data-id="CD013534-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 35: Sensitivity analysis: Food allergy by 1 to 3 years (parent report of doctor diagnosis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 36: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by FLG genotype (0 mutations versus 1/2 mutations)" data-id="CD013534-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 36: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 37: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by chromosome 11 status (C:C versus C:T or T:T)" data-id="CD013534-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 37: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by chromosome 11 status (C:C versus C:T or T:T) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 38: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by FLG mutation and chromosome 11 status (no FLG and C:C versus FLG mutation and/or chromosome 11 C:T or T:T)" data-id="CD013534-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 38: Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by <i>FLG</i> mutation and chromosome 11 status (no <i>FLG</i> and C:C versus <i>FLG</i> mutation and/or chromosome 11 C:T or T:T) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 39: CACE: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 3 days a week" data-id="CD013534-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 39: CACE: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 40: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 5 days a week" data-id="CD013534-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 40: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 41: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period 7 days a week" data-id="CD013534-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 41: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period 7 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 42: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months ≥ 3 days a week" data-id="CD013534-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 42: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months ≥ 3 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 43: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months  ≥ 5 days a week" data-id="CD013534-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 43: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months  ≥ 5 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 44: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months 7 days a week" data-id="CD013534-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 44: CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months 7 days a week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 45: Adverse event: skin infection" data-id="CD013534-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 45: Adverse event: skin infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 46: Adverse event: stinging or allergic reaction to moisturisers" data-id="CD013534-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 46: Adverse event: stinging or allergic reaction to moisturisers </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 47: Adverse event: slippage accidents" data-id="CD013534-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 47: Adverse event: slippage accidents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 48: Serious adverse events" data-id="CD013534-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 48: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 49: Clinician‐assessed eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)" data-id="CD013534-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 49: Clinician‐assessed eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 50: Clinician‐assessed eczema severity at 1 to 3 years (standardised mean difference)" data-id="CD013534-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 50: Clinician‐assessed eczema severity at 1 to 3 years (standardised mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 51: Parent‐reported eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)" data-id="CD013534-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 51: Parent‐reported eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 52: Parent‐reported eczema severity at 1 to 3 years (mean difference)" data-id="CD013534-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 52: Parent‐reported eczema severity at 1 to 3 years (mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 53: Time to onset of eczema" data-id="CD013534-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 53: Time to onset of eczema </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 54: Subgroup analysis: Time to onset of eczema (&lt; 1‐year follow‐up versus ≥ 1‐year follow‐up)" data-id="CD013534-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 54: Subgroup analysis: Time to onset of eczema (&lt; 1‐year follow‐up versus ≥ 1‐year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 55: Parent report of immediate (&lt; 2 hours) reaction to a known common food allergen" data-id="CD013534-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 55: Parent report of immediate (&lt; 2 hours) reaction to a known common food allergen </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 56: Parent report of immediate (&lt; 2 hours) reaction to milk" data-id="CD013534-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 56: Parent report of immediate (&lt; 2 hours) reaction to milk </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 57: Parent report of immediate (&lt; 2 hours) reaction to egg" data-id="CD013534-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 57: Parent report of immediate (&lt; 2 hours) reaction to egg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 58: Parent report of immediate (&lt; 2 hours) reaction to peanut" data-id="CD013534-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 58: Parent report of immediate (&lt; 2 hours) reaction to peanut </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.59" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 59: Allergic sensitisation to common foods or inhalants at 1 to 3 years" data-id="CD013534-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.59.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.59.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 59: Allergic sensitisation to common foods or inhalants at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.59.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.60" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 60: Allergic sensitisation to common foods at 1 to 3 years" data-id="CD013534-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.60.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.60.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 60: Allergic sensitisation to common foods at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.60.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.61" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 61: Allergic sensitisation to milk at 1 to 3 years" data-id="CD013534-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.61.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.61.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 61: Allergic sensitisation to milk at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.61.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.62" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 62: Allergic sensitisation to egg at 1 to 3 years" data-id="CD013534-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.62.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.62.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 62: Allergic sensitisation to egg at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.62.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.63" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 63: Allergic sensitisation to peanut at 1 to 3 years" data-id="CD013534-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.63.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.63.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.63</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 63: Allergic sensitisation to peanut at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.63.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.64" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 64: Allergic sensitisation to inhalants at 1 to 3 years" data-id="CD013534-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.64.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.64.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.64</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 64: Allergic sensitisation to inhalants at 1 to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.64.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.65" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 65: Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years" data-id="CD013534-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.65.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.65.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.65</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 65: Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.65.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.66" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 66: Sensitivity analysis: Allergic sensitisation to milk at 6 months to 3 years" data-id="CD013534-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.66.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.66.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.66</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 66: Sensitivity analysis: Allergic sensitisation to milk at 6 months to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.66.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.67" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 67: Sensitivity analysis: Allergic sensitisation to egg at 6 months to 3 years" data-id="CD013534-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.67.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.67.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.67</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 67: Sensitivity analysis: Allergic sensitisation to egg at 6 months to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.67.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013534-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/urn:x-wiley:14651858:media:CD013534:CD013534-CMP-001.68" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 68: Sensitivity analysis: Allergic sensitisation to peanut at 6 months to 3 years" data-id="CD013534-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.68.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_t/tCD013534-CMP-001.68.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.68</div> <div class="figure-caption"> <p>Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 68: Sensitivity analysis: Allergic sensitisation to peanut at 6 months to 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/media/CDSR/CD013534/image_n/nCD013534-CMP-001.68.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013534-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Skin care intervention compared to standard skin care or no skin care intervention for the prevention of eczema and food allergy</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Patient or population: infants age 12 months or younger</b> </p> <p><b>Setting: prevention</b> </p> <p><b>Intervention: skin care intervention</b> </p> <p><b>Comparison: standard skin care or no skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> <br/> <br/> <br/> <br/> <br/>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema diagnosis by 1 to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000 (122 to 197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (0.81 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3075 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a sensitivity analysis that included studies that measured eczema using Hanifin and Rajka, or UK Working Party methods only, total N = 2919 (6), the pooled treatment effect for eczema by 1 to 2 years was RR 1.02, 95% CI 0.78 to 1.34.  In a separate sensitivity analysis including studies rated as low risk of bias only, total N = 1739 (3), the pooled treatment effect for eczema by 1 to 2 years was RR 0.97, 95% CI 0.81 to 1.17. In sensitivity analysis using a 3‐year eczema outcome instead of a 1‐year eczema outcome from 1 trial, the pooled treatment effect for eczema by 1 to 3 years was RR 1.00, 95% CI 0.88 to 1.14. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IgE‐mediated food allergy (oral food challenge) by 1 to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000 (50 to 335)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (0.99 to 6.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>976 (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a sensitivity analysis that examined IgE‐mediated food allergy as measured by oral food challenge or based on a panel assessment of clinical history and/or allergic sensitisation by 1 to 3 years, total N = 2081 (2), the pooled treatment effect was RR 1.45, 95% CI 0.98 to 2.15. For parent report of a doctor diagnosis of food allergy at 1 to 3 years, total N = 1614 (3), the pooled treatment effect was RR 1.02, 95% CI 0.80 to 1.31. No low risk of bias sensitivity analysis was possible. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slippages (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000 (14 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.42 (0.67 to 2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2538 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin infection (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000 (51 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33 (1.01 to 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2728 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stinging/allergic reactions to moisturisers (over the intervention period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000 (27 to 298) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.24 (0.67 to 7.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 343 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to onset of eczema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27.9 months (21.1 to 36.9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.86 (0.65 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3349 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent report of immediate reaction to common food allergen (at 2 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000 (160 to 258)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (1.00 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1171 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic sensitisation to a food allergen (at 1 to 3 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000 (58 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05 (0.64 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1794 (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI, confidence interval; HR, hazard ratio; IgE, immunoglobulin E; RR risk ratio</p> <p><sup>a</sup>Downgraded one level for heterogeneity driven by one trial (PreventADALL) contributing 21.8% of the weight of the analysis; a clear explanation for this heterogeneity could not be identified. PreventADALL used a bathing intervention, whereas the other trials used direct emollient application to the skin; PreventADALL also initiated treatment later than the other trials. There was no significant heterogeneity in a sensitivity analysis using the 3‐year outcome instead of the 1‐year outcome from the PreventADALL study (Analysis 1.5).<br/><sup>b</sup>Downgraded one level for overall risk of bias due to missing outcome data (29%) and one level for imprecision due to small numbers of events from a single study, with wide confidence intervals including both a harmful effect and no effect. There was increased information for the sensitivity analysis of food allergy diagnosed by oral food challenge or investigator assessment, where overall risk of bias was assessed as 'some concerns' and confidence intervals were narrower. <br/><sup>c</sup>Downgraded by two levels for imprecision due to small numbers of events, with wide confidence intervals including both a harmful effect and a beneficial effect.<br/><sup>d</sup>Downgraded by one level for imprecision due to wide confidence intervals including both a harmful effect and no effect.<br/><sup>e</sup>Downgraded one level for heterogeneity driven by more than one trial, for which a plausible explanation could not be identified.<br/><sup>f</sup>Downgraded two levels for imprecision due to small numbers of events from a single study, with wide confidence intervals including both a harmful effect and no effect.<br/><sup>g</sup>Downgraded one level for heterogeneity, for which a plausible explanation could not be identified, and one level for imprecision due to wide confidence intervals including both a harmful and a beneficial effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Skin care intervention compared to standard skin care or no skin care intervention for the prevention of eczema and food allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adolescence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A period in development, roughly between ages 10 and 19 years, between onset of puberty and acceptance of adult identity and behaviour </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic (atopic) march</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Typical pattern of onset of allergic disease from eczema, to food allergy, to asthma and allergic rhinitis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhinitis is a group of symptoms affecting the nose, typically by sneezing, itching, or congestion. Allergic rhinitis occurs when these symptoms are due to environmental allergies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic sensitisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demonstrated by a positive skin prick test of specific IgE to a known allergen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute, potentially life‐threatening immediate reaction to an allergen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angio‐oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pronounced swelling of the deep dermis, subcutaneous or submucosal tissue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atopic dermatitis</p> <p>(atopic eczema)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema with IgE sensitisation, either by IgE antibody or by skin prick test, is classified as atopic eczema. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genetic predisposition to develop allergic diseases such as eczema, food allergy, asthma, and allergic rhinitis, which is often associated with the production of IgE antibodies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceramides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lipid (fatty) molecules found in the lipid bilayer of the intercellular matrix</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complex chronic skin condition characterised by itch, a form of dermatitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gene encoding for filaggrin, a filament‐binding protein in the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A period of worsening of eczema signs and symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Can be IgE‐mediated or non‐IgE‐mediated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food sensitisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Production of IgE to a food, in the form of a positive skin prick test or immunoglobulin E; may not equate to food allergy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Humectant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or product that draws water towards it</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunoglobulin E (IgE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class of antibody that plays a key role in allergic disease. Signs and symptoms of IgE‐mediated disease include urticaria, angio‐oedema, wheeze, and anaphylaxis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A baby in the first year of life</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhalant allergen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergen that typically enters the immune system via the respiratory tract and is airborne, such as house dust mite or pollen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intergenic locus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A stretch of DNA sequences located between genes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mast cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Granular basophil cell present in connective tissue that releases histamine and other mediators in allergic reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A baby in the first 28 days of life</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observable characteristics from an interaction between genes and the environment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In statistics, refers to the number of cases of a disease, present in a particular population at a given time </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined by the World Health Organization as individuals' perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transepidermal water loss (TEWL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive measurement of water loss across the epidermis used as a measure of skin barrier function </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urticaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash that is a transient erythematous itchy swelling of skin</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]"><b>Chalmers 2020</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]"><b>Cooke 2015</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). "><b>Dissanayake 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]"><b>Horimukai 2014</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]"><b>Lowe 2018a</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]"><b>Migacheva 2018</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). "><b>McClanahan 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]"><b>Simpson 2014</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]"><b>Skjerven 2020</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gestational age: mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (1.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1134 (47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight: mean grams (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3405 (452)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3048 (322)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3054 (363)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3356 (442)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3577 (480)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal delivery: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 (83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age intervention began: mean days (SD)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All &lt; 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Family history atopy: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1394 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 (83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1814 (78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) (1/2 mutations): n (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1394</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>549</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>118</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>80</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>124</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2396</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis (continued)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b><a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). "><b>NCT03376243</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]"><b>Yonezawa 2018</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gestational age: mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4 (1.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight: mean grams (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3547 (497)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3017 (362)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal delivery: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age intervention began: mean days (SD)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Family history atopy: n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filaggrin (<i>FLG</i>) (1/2 mutations): n (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics of participants included in meta‐analysis (continued)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for eczema </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> <p><b>standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary:</b> </p> <p><b>eczema by 1 to 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1489</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1586</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.03</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.81 to 1.31</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>eczema by 1 to 3 years including aggregate data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 to 1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years using UK Working Party Criteria only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 to 1.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years including all 4 arms from the PreventADALL trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 to 1.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years (using PreventADALL 36‐month outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 to 1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years, low risk of bias data only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 to 1.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 1 to 3 years, excluding non‐prospectively acquired data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 to 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema by 6 months to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 to 1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema after the intervention period (at  1 year or beyond (up to 3 years))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 to 1.16</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0023" title="Migacheva N,  Zhestkov A. Combined approach to primary prevention of atopic dermatitis. Allergy2018;73:331. [DOI: 10.1111/all.13537]">Migacheva 2018</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>. <br/><sup>d</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>. <br/><sup>e</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>f</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0015" title="Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,  Nozaki M,  et al. Application of moisturizer to neonates prevents development of atopic dermatitis. Journal of Allergy and Clinical Immunology2014;134(4):824‐30.e6. [DOI: 10.1016/j.jaci.2014.07.060]JPRN-UMIN000004544. Effect of emollients on the prevention of infantile eczema and atopic dermatitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first received 1 November 2010). Morita K. Application of moisturizer to neonates prevents development of atopic dermatitis. World Allergy Organization Journal2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-A252]Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H, et al. Primary prevention of atopic dermatitis by skin care with emollient: a randomized controlled study (OP02). British Journal of Dermatology2014;170(6):e9. [DOI: 10.1111/bjd.13064]">Horimukai 2014</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0022" title="McClanahanD , WongA ,  Kezic S,  Samrao A,  Hajar T, HillE , et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy of Dermatology &amp; Venereology2019;33(11):2807-94. [DOI: 10.1111/jdv.15786]NCT01375205. Comparing Cetaphil Restoraderm System versus standard skin care in infants. clinicaltrials.gov/ct2/show/NCT01375205 (first received 17 June 2011). ">McClanahan 2019</a>; <a href="./references#CD013534-bbs2-0028" title="ChalmersJR , SimpsonEL , ChenYY ,  CorkMJ , BrownSJ , ThomasKS , et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). British Journal of Dermatology2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]Glatz M, JoJ , KennedyEA , PolleyEC , SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Allergy2017;72:311. [DOI: 10.1111/all.13251]Glatz M, PolleyEC ,  Schmid-Grendelmeier P, SimpsonEL , KongHH . Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis. Swiss Medical Weekly2017;147(Suppl 228):53S. Glatz M, PolleyEC , SimpsonEL , KongHH . Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Journal of Investigative Dermatology2015;135:S31. [DOI: 10.1038/jid.2015.69]GlatzM , JoJH , KennedyEA , PolleyEC ,  Segre JA,  SimpsonEL , et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLOS ONE2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]ISRCTN84854178. Feasibility study of barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN84854178 (first received 8 January 2010). NCT01291940. The effects of emollient therapy on the skin barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received 9 February 2011). SimpsonE , ChalmersJR , IrvineAD , CorkMJ , McLeanWHI , WilliamsHC . Barrier enhancement for eczema prevention; the BEEP feasibility study. Allergo Journal2010;19(5):340. [DOI: 10.1007/BF03362342]SimpsonEL , ChalmersJR ,  Hanifin JM, FrenchME ,  Lubianski T,  Samrao A, et al. Barrier enhancement for eczema prevention - the BEEP feasibility study. Journal of Investigative Dermatology2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]SimpsonEL , ChalmersJR ,  Hanifin JM, ThomasKS , CorkMJ , McLeanWH , et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology2014;134(4):818‐23. [DOI: 10.1016/j.jaci.2014.08.005]">Simpson 2014</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>g</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for eczema </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Complier average causal effect (CACE) analyses for eczema</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Complier </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N standard care </b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>CACE</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Intention‐to‐treat</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary CACE:</b> </p> <p><b>≥ 3 days of use over intervention period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>705</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>735</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.65</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 to 1.45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 to 1.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity CACE:</p> <p>≥ 5 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 to 2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 to 2.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 5 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 to 1.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 to 2.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.15</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. <br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0024" title="NCT03376243. EARLYEMOLLIENT - Feasibility of early emollient use in children with atopic eczema. clinicaltrials.gov/ct2/show/NCT03376243 (first received 18 December 2017). ">NCT03376243</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Complier average causal effect (CACE) analyses for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for food allergy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> <p><b>standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary:</b> </p> <p><b>food allergy (oral food challenge) by 1 to 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>482</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99 to 6.49</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>food allergy (oral food challenge + panel assessment) by 1 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food allergy (parent report of doctor diagnosis) by 1 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 to 1.31</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>. <br/><sup>b</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a>.<b> </b><br/><sup>c</sup><a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>; <a href="./references#CD013534-bbs2-0008" title="Dissanayake E,  Tani Y,  Nagai K, SaharaM ,  Mitsuishi C,  Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. International Archives of Allergy &amp; Immunology2019;180(3):202-11. [DOI: 10.1159/000501636]Dissanayake E,  Tani Y, SaharaM ,  Mitsuishi C,  Nagai K, SatoY , et al. Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial randomized non-treatment controlled trial. Allergy2018;73(105):692-3. [DOI: 10.1111/all.13539]JPRN-UMIN000010838. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 x 2 factorial, randomized, non-treatment controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010838 (first received 31 May 2013). ">Dissanayake 2019</a>; <a href="./references#CD013534-bbs2-0032" title="JPRN-UMIN000013260. Effects of moisturizing skin care from the neonatal stage for improving skin barrier function and preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013260 (first received 1 March 2014). Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants: a randomized controlled trial. Journal of Dermatology2018;45(1):24‐30. [DOI: 10.1111/1346-8138.14080]Yonezawa K, Haruna M. Short-term skin problems in infants aged 0-3 months affect food allergies or atopic dermatitis until 2 years of age, among infants of the general population. Allergy, Asthma &amp; Clinical Immunology2019;15(74):1552. [DOI: 10.1186/s13223-019-0385-7]">Yonezawa 2018</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for food allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Complier average causal effect (CACE) analyses for food allergy (oral food challenge or panel assessment)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Complier </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N trials</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N skin care intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N standard care </b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>CACE</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intention‐to‐treat</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% confidence interval</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pooled risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>95% confidence interval</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary CACE:</b> </p> <p><b>≥ 3 days of use over intervention period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>547</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>568</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.06</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 to 27.68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity:</p> <p>≥ 5 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 to 57.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over intervention period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 to 293.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 6.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 5 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 to 7.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 days of use over <i>first 3 months</i> of intervention period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 to 20.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 to 2.13</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>One study is included across all presented analyses: <a href="./references#CD013534-bbs2-0005" title="ChalmersJR ,  Haines RH, BradshawL , MontgomeryAA , ThomasKS , BrownSJ , et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet2020;395(10228):962-72. [DOI: 10.1016/S0140-6736(19)32984-8]ChalmersJR ,  Haines RH, MitchellEJ , ThomasKS , BrownSJ ,  Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]ChalmersJR , ThomasKS , MontgomeryA ,  Sach T, BoyleRJ ,  Ridd MJ, et al. A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial) (PP01). British Journal of Dermatology2014;170(6):e32. [DOI: 10.1111/bjd.13064]ISRCTN21528841. Barrier enhancement for eczema prevention. www.isrctn.com/ISRCTN21528841 (first received 25 July 2014). [DOI: 10.1186/ISRCTN21528841]">Chalmers 2020</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Complier average causal effect (CACE) analyses for food allergy (oral food challenge or panel assessment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013534-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Skin care</b> </p> <p><b>(N events)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control </b> </p> <p><b>(N events)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total</b> </p> <p><b>(N events)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> <a href="./references#CD013534-bbs2-0006" title="CookeA , CorkM , VictorS , CampbellM , DanbyS ,  Chittock J, et al. A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. British Journal of Dermatology2015;173:153. [DOI: 10.1111/bjd.13819]CookeA , CorkMJ , VictorS , CampbellM , DanbyS ,  Chittock J, et al. Olive oil, sunflower oil or no oil for baby dry skin or massage: a pilot, assessor-blinded, randomized controlled trial (the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-Venereologica2016;96(3):323-30. [DOI: 10.2340/00015555-2279]ISRCTN37373893. The use of oil in baby skincare trial. www.isrctn.com/ISRCTN37373893 (first received 22 August 2013). [DOI: 10.1186/ISRCTN37373893]">Cooke 2015</a> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jaundice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral lung infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure (benign myoclonic jerks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> <a href="./references#CD013534-bbs2-0020" title="ACTRN12609000727246. Prevention of eczema by a barrier lipid equilibrium strategy (PEBBLES) pilot study - testing the compliance and safety of a strategy for improving infant skin function. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000727246 (first received 19 August 2009). ACTRN12613000472774. The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium Strategy. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364115 (first received 23 April 2013). ACTRN12617001380381. The PEBBLES study – testing a strategy for preventing eczema and food allergy in high risk infants. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373506 (first received 20 September 2017). LoweA , SuJ , AllenK ,  Abramson M,  Cranswick N, RobertsonC , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study NCD. Pediatric Dermatology2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]LoweA . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: the PEBBLES pilot study NCD. Journal of Investigative Dermatology2017;137:S72. [DOI: 10.1016/j.jid.2017.02.436]LoweAJ , SuJC , AllenKJ ,  Abramson MJ,  Cranswick N, RobertsonCF , et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. British Journal of Dermatology2018;178(1):e19‐21. [DOI: 10.1111/bjd.15747]">Lowe 2018a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchiolitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p> <a href="./references#CD013534-bbs2-0029" title="Carlsen L, RehbinderEM , SkjervenHO , Hauger Carlsen M,  Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy2018;73(10):2063-70. [DOI: 10.1111/all.13468]Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlancM ,  Granum B, HaugenG ,  et al. Department of Error: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial (Lancet (2020) 395(10228) (951-61) (S0140673619329836)). Lancet2020;395(10228):e53. [DOI: 10.1016/S0140-6736(20)30422-0]Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlancM ,  Granum B, HaugenG , et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet2020;395(10228):951‐61. [DOI: 10.1016/S0140-6736(19)32983-6]">Skjerven 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure (non‐febrile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchiolitis (respiratory syncytial virus or other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Croup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Foreign body aspiration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery (operation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flu/diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injury or accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unspecified reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/full#CD013534-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013534-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Skin care intervention versus standard skin care or no skin care intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Eczema by 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.75, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Sensitivity analysis: Eczema by 1 to 3 years (UKWP only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36‐month outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Sensitivity analysis: Eczema by 1 to 3 years ‐ low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Sensitivity analysis: Eczema by 1 to 3 years ‐ excluding non‐prospectively acquired data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Sensitivity analysis: Eczema by 6 months to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Sensitivity analysis: Eczema after the intervention period (at 1 year or beyond ‐ up to 3 years)  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Basic emolient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Complex emolient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Intervention prescribed for &lt;6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.45, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Intervention prescribed for ≥6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Intervention prescribed to start in first week of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Intervention prescribed to start after first week of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.10, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Participant‐level treatment interaction: Eczema by 1 to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Participant‐level treatment interaction: Eczema by 6 months to 3 years for treatment initiation &lt; 4 days versus ≥ 4 days of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.56, 4.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Participant‐level treatment interaction: Eczema by 1 to 3 years by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.69, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Participant‐level treatment interaction: Eczema by 6 months to 3 years by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.66, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Participant‐level treatment interaction: Eczema by 1 to 3 years by chromosome 11 status (C:C versus C:T or T:T) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.85, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Participant‐level treatment interaction: Eczema by 1 to 3 years by <i>FLG</i> mutation and chromosome 11 status (no <i>FLG</i> and C:C versus <i>FLG</i> mutation and/or chromosome 11 C:T or T:T) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.72, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.35, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Participant‐level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first‐degree relative with history of allergic disease and/or <i>FLG</i> genotype (0 mutations versus 1/2 mutations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.16, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 CACE: Eczema by 1 to 3 years for use over intervention period ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.29, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 CACE sensitivity: Eczema by 1 to 3 years for use over intervention period ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 CACE sensitivity: Eczema by 1 to 3 years for use over intervention period 7 days  a week  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.23, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.46, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months 7 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.34, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period 7 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months 7 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Food allergy by 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.98, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Sensitivity analysis: Food allergy by 1 to 3 years (parent report of doctor diagnosis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by <i>FLG</i> genotype (0 mutations versus 1/2 mutations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.41, 4.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by chromosome 11 status (C:C versus C:T or T:T) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.63, 4.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Participant‐level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment) by <i>FLG</i> mutation and chromosome 11 status (no <i>FLG</i> and C:C versus <i>FLG</i> mutation and/or chromosome 11 C:T or T:T) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.57, 4.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 CACE: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period 7 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months ≥ 3 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months  ≥ 5 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 CACE sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months 7 days a week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Adverse event: skin infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.01, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Adverse event: stinging or allergic reaction to moisturisers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.67, 7.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Adverse event: slippage accidents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.67, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.45, 7.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 Clinician‐assessed eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.50 Clinician‐assessed eczema severity at 1 to 3 years (standardised mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.17, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.51 Parent‐reported eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.52 Parent‐reported eczema severity at 1 to 3 years (mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.53 Time to onset of eczema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.54 Subgroup analysis: Time to onset of eczema (&lt; 1‐year follow‐up versus ≥ 1‐year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.54.1 Follow‐up ≥ 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.54.2 Follow‐up &lt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.55 Parent report of immediate (&lt; 2 hours) reaction to a known common food allergen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.56 Parent report of immediate (&lt; 2 hours) reaction to milk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.57 Parent report of immediate (&lt; 2 hours) reaction to egg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.58 Parent report of immediate (&lt; 2 hours) reaction to peanut <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.59 Allergic sensitisation to common foods or inhalants at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.72, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.60 Allergic sensitisation to common foods at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.61 Allergic sensitisation to milk at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.55, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.62 Allergic sensitisation to egg at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.42, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.63 Allergic sensitisation to peanut at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.68, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.64 Allergic sensitisation to inhalants at 1 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.76, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.65 Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.92, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.66 Sensitivity analysis: Allergic sensitisation to milk at 6 months to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.67 Sensitivity analysis: Allergic sensitisation to egg at 6 months to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.94, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.68 Sensitivity analysis: Allergic sensitisation to peanut at 6 months to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.68, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Skin care intervention versus standard skin care or no skin care intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#CD013534-tbl-0010">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Eczema by 1 to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Eczema by 1 to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Migacheva 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information given on randomization process.Baseline characteristics (russian language table) do not suggest a problem with with imbalance in a small number of key baseline characteristics, but only limited baseline aggregate data provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial not registered so intended intervention unclear and it's not clear whether the patients were analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>It's unclear how many participants were included in the analysis. No information available on the number of participants with missing data. The circumstances of the trial make it unlikely that missingness depends on outcome. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema assessed by a trained investigator but no information on blinding status.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not a registered trial, therefore unclear if outcomes are reported as initially planned.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This study was unregistered and reported in an abstract only, not clear regarding blinding of outcomes or missing data and analysis population. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Sensitivity analysis: Eczema by 1 to 3 years (UKWP only)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Sensitivity analysis: Eczema by 1 to 3 years (UKWP only)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36‐month outcome)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36‐month outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Sensitivity analysis: Eczema by 1 to 3 years ‐ low risk of bias</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Sensitivity analysis: Eczema by 1 to 3 years ‐ low risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Sensitivity analysis: Eczema by 1 to 3 years ‐ excluding non‐prospectively acquired data</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Sensitivity analysis: Eczema by 1 to 3 years ‐ excluding non‐prospectively acquired data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Sensitivity analysis: Eczema by 6 months to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Horimukai 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomised trial, no information provided on allocation concealment. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Control rates of skin care in line with those observed in other trials and observational studies (e.g. up to ~75 % in Rendell at al. 2011). Quote: “Because the IRB recommended permitting application of petroleum jelly when the parents thought it necessary, we calculated the amount of these 2 types of moisturizers used by each group based on their diaries. The mean daily amount of emulsion‐type moisturizer used by the intervention group was 7.86 6 4.34 g (0 g for the control group, excluding the 2 infants placed in the wrong group). The mean daily amount of petroleum jelly applied to the control group was 0.101 6 0.286 g (mean frequency of use, 0.235 d/wk). Petroleum jelly (20 g per bottle) was prescribed to all neonates born at the NCCHD, but we had no information about how much was used by the intervention group. Nevertheless, only a few of the parents occasionally used a small, almost ignorable, amount of the jelly on their infants.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>79/118=84% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.66 [0.42, 1.05], or if everyone missing is assumed to have eczema RR=0.79, [0.63, 0.99]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The primary outcome measure was the cumulative rate of incidence of AD, eczema, or both by temporal observation. The diagnostic criteria for infantile eczema, AD, or both (AD/eczema) were developed based on a modification of the United Kingdom Working Party’s criteria and were applied by a dermatology specialist" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Simpson 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Infants were randomized at a 1:1 ratio using random block sizes to either the intervention or control group with a central, Web‐based, computer generated, Internet randomization service." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “Eight (13.3%) parents in the control group reported using emollients in a way that mirrored the intervention (ie, regular generalized application of emollient for reasons other than the treatment of cradle cap, nappy rash, or eczema).” The IPD shows regular use of emollient (≥ 3 days a week) by 50/55 intervention individuals and only 3/53 control participants with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>108/124=87% have outcome. Sensitivity analysis using the IPD reveals findings do not change significantly if everyone missing is assumed to not have eczema  RR=0.53 [0.29 to 0.99] but or if all missing are assumed to have eczema RR= 0.71 [0.46 to 1.10] (point estimate of RR &gt;20% of the complete case estimate and upper bound of 95% CI shifted above 1). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was determined by an investigator. Outcome assessors were blind to treatment allocation.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Sensitivity analysis: Eczema by 6 months to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.1 Basic emolient</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.2 Complex emolient</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration </span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.1 Intervention prescribed for &lt;6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.2 Intervention prescribed for ≥6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.12.1 Intervention prescribed to start in first week of life</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in <a href="./references#CD013534-bbs2-0312" title="RendellME , Baig-LewisSF , Berry TM, DennyME , SimpsonBM , BrownPA , et al. Do early skin care practices alter the risk of atopic dermatitis? A case-control study. Pediatric Dermatology2011;28(5):593-5.">Rendell 2011</a>). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1210/1394 = 87% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.93, 95% 0.76 to 1.15,  or if all assumed to have eczema, RR=0.99, 95% CI 0.86 to 1.15. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial data set provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>455/549=83% have outcome. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema (RR 1.24 95% CI[0.84, 1.83]) or they do have eczema (RR 1.00 95% CI[0.79, 1.27]). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>74/80 = 93% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.61 [0.26 to 1.40] or if all assumed to have eczema, RR=0.67 [0.34 to 1.33]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias for all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011.). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up was 40% for eczema by 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all missing are assumed to not have eczema:  RR=0.53 [0.20, 1.35], but conclusions do change if all missing were assumed to have eczema RR=0.93 [0.65, 1.34] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>49/54=91% have outcome. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=0.73, 95% 0.24 to 2.23 but conclusions do change when all missing are assumed to have eczema RR=1.24, 95% CI 0.55 to 2.78 (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UKWP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>156/227 = 69% have outcome. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to not have eczema: RR=0.68 [0.29, 1.61] or if all missing are assumed to have eczema RR=1.40 [0.98, 2.00] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.12.2 Intervention prescribed to start after first week of life</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, RR=1.42 [1.00 to 2.02] but conclusions change if all missing are  assumed to have eczema, RR=2.03 [1.56 to 2.63] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK Working party criteria and HF at 12 months. Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing outcome data (results varied in sensitivity analysis), low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.33 Food allergy by 1 to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>996/1394 have outcome =71% of randomised participants. Sensitivity analysis using the IPD data shows conclusions do not change significantly if all missing are assumed to not have food allergy, RR=2.46, 95% CI 0.96 to 6.30. But conclusions vary when all missing are assumed to have food allergy RR=1.09, 95% CI 0.93 to 1.28. The overall proportion of missing data is similar in the two treatment groups. However there is a difference between treatment groups in the proportion of participants who underwent oral food challenge. Of those invited to oral food challenge due to suspected food allergy, only 39 of 133 (29%) in the intervention group and 21 of 125 (17%) in the control group underwent oral food challenge. This suggests that missingness is likely to have depended on the outcome. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing data (29% and results varied in sensitivity analysis) which could have depended on the outcome, but low risk of bias in all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.33 Food allergy by 1 to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.34 Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1115/1394 have outcome = 80% of randomised participants. Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to not have food allergy, RR=1.42, 95% CI 0.90 to 2.26, but when all missing are assumed to have food allergy RR=1.17, 95% CI 0.97 to 1.40 (Point estimate varies by ≥20% complete case estimate.) Missingness could have depended on outcome, but not likely as panel assessment based on skin prick testing and history incorporated. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (results varied in sensitivity analysis). Missingness could have depended on outcome, but not likely as panel assessment based on skin prick testing and history incorporated. Low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arose because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 267/446 = 60% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 82.6%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have food allergy, RR=1.22 [0.59 to 2.51]. Conclusions change if all missing are assumed to have food allergy, RR=1.72 [1.34, 2.20] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study design did not allow for masking of study participants to the interventions. To limit the risk of observer bias, study personnel who did the clinical follow‐up investigations did not have access to the randomisation lists. Furthermore, parents were firmly instructed not to apply any type of emollient bath additives or leave‐on emollients within 24 h before each follow‐up investigation and all clinical assessments and investigations were done and recorded without knowledge of the group allocation." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided and IPD meta‐analysis SAP followed</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns because of potential bias due to missing outcome data. All other domains classed as low risk of bias. </p> <p> </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.34 Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.45 Adverse event: skin infection</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin infections were prompted for at all visits.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin infections were reported by parents on the 3, 6 and 12 month questionnaires. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Cooke 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was 1:1:1 via a central telephone‐based service" and "Allocation was concealed from the participant and independent research midwife until the point of allocation".  Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “The weekly ranges of adherence for treatment use were 79% to 93% of participants for the olive oil group, 83% to 94% for the sunflower oil group and 100% for the no oil group” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “All measurements were taken by the investigator who remained blind to the treatment allocation. Changes in the skin were observed and recorded by the investigator at baseline and follow‐up (erythema, dryness and scaling, need for medical products/attention) between 48 h and 4 weeks.” </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all 5 domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits and an event recorded for 74/80=92.5%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits (week 6, month 6 and month 12). Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context.: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events self‐recalled by all participants and prompted for at visits.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events self‐recalled by all participants and prompted for at visits (2, 6 and 12mo) and telephone follow‐up calls (18 and 24 mo). Outcome assessors were reporters who were aware of the allocation (parents). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Simpson 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Infants were randomized at a 1:1 ratio using random block sizes to either the intervention or control group with a central, Web‐based, computer generated, Internet randomization service." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “Eight (13.3%) parents in the control group reported using emollients in a way that mirrored the intervention (ie, regular generalized application of emollient for reasons other than the treatment of cradle cap, nappy rash, or eczema).” The IPD shows regular use of emollient (≥ 3 days a week) by 50/55 intervention individuals and only 3/53 control participants with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin infections were prompted for at all patient visits.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin infections were prompted for at 10days, 6 weeks, 12 weeks, 18 weeks and 24 weeks. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Adverse events were recorded in weekly electronic diaries up to week 26, in electronic questionnaires every 3 months, and in specific forms by personnel at the discretion of the study personnell." Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.45 Adverse event: skin infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.46 Adverse event: stinging or allergic reaction to moisturisers</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Cooke 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was 1:1:1 via a central telephone‐based service" and "Allocation was concealed from the participant and independent research midwife until the point of allocation".  Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “The weekly ranges of adherence for treatment use were 79% to 93% of participants for the olive oil group, 83% to 94% for the sunflower oil group and 100% for the no oil group." </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: " All measurements were taken by the investigator who remained blind to the treatment allocation. Changes in the skin were observed and recorded by the investigator at baseline and follow‐up (erythema, dryness and scaling, need for medical products/ attention) between 48 h and 4 weeks." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits and an event recorded for 74/80=92.5%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits (week 6, month 6 and month 12). Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arise because of the trial context: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events self‐recalled by all participants and prompted for at visits.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events self‐recalled by all participants and prompted for at visits (2, 6 and 12mo) and telephone follow‐up calls (18 and 24 mo). Outcome assessors were reporters who were aware of the allocation (parents). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin reactions prompted for at all visits and when participants left the study early (e.g. due to eczema). Note: a number of participants dropped out of the trial early due to loss to follow‐up (n=5, 9%) or when they had eczema (n=10, 18%, with median follow‐up 18 weeks, IQR 12 to 30 weeks). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin reactions prompted for at all visits and when participants left the study early (e.g. due to eczema). Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.46 Adverse event: stinging or allergic reaction to moisturisers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.47 Adverse event: slippage accidents</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Slippage accidents were prompted for at all visits.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Slippage incidents and skin infections were reported by parents on the 3, 6 and 12 month questionnaires. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains </p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arise because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits and an event recorded for 74/80=92.5%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits (week 6, month 6 and month 12). Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Simpson 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Infants were randomized at a 1:1 ratio using random block sizes to either the intervention or control group with a central, Web‐based, computer generated, Internet randomization service." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “Eight (13.3%) parents in the control group reported using emollients in a way that mirrored the intervention (ie, regular generalized application of emollient for reasons other than the treatment of cradle cap, nappy rash, or eczema).” The IPD shows regular use of emollient (≥ 3 days a week) by 50/55 intervention individuals and only 3/53 control participants with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>AE's were prompted for at all patient visits, including accidents.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>AE's were prompted for at all follow‐ups (10days, 6 weeks, 12 weeks, 18 weeks and 24 weeks), including accidents. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p> Quote: "Adverse events were recorded in weekly electronic diaries up to week 26, in electronic questionnaires every 3 months, and in specific forms by personnel at the discretion of the study personnell." Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.47 Adverse event: slippage accidents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.48 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Cooke 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was 1:1:1 via a central telephone‐based service" and "Allocation was concealed from the participant and independent research midwife until the point of allocation".  Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “The weekly ranges of adherence for treatment use were 79% to 93% of participants for the olive oil group, 83% to 94% for the sunflower oil group and 100% for the no oil group.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: " All measurements were taken by the investigator who remained blind to the treatment allocation. Changes in the skin were observed and recorded by the investigator at baseline and follow‐up (erythema, dryness and scaling, need for medical products/attention) between 48 h and 4 weeks." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events prompted for at visits and an event recorded for 74/80=92.5%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation, but assessment of serious adverse events not likely to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events collected for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation, but assessment of serious adverse events not likely to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.48 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.53 Time to onset of eczema</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1236/1394 =89% have outcome. Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to have eczema, HR=0.94, 95% 0.79 to 1.12 or when all missing are assumed to have eczema, HR=0.92, 95% CI 0.79 to 1.11. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was parent report of doctor diagnosis of eczema and parents unblinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome missing for 21.5% (not all people with eczema outcome have time of eczema onset). Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema by 12months HR=1.27 [0.83 to 1.95], or to have eczema onsets by 12 months: HR= 1.16 [0.76 to 1.78]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Horimukai 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomised trial, no information provided on allocation concealment. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Control rates of skin care in line with those observed in other trials and observational studies (e.g. up to ~75 % in Rendell at al. 2011). Quote: “Because the IRB recommended permitting application of petroleum jelly when the parents thought it necessary, we calculated the amount of these 2 types of moisturizers used by each group based on their diaries. The mean daily amount of emulsion‐type moisturizer used by the intervention group was 7.86 6 4.34 g (0 g for the control group, excluding the 2 infants placed in the wrong group). The mean daily amount of petroleum jelly applied to the control group was 0.101 6 0.286 g (mean frequency of use, 0.235 d/wk). Petroleum jelly (20 g per bottle) was prescribed to all neonates born at the NCCHD, but we had no information about how much was used by the intervention group. Nevertheless, only a few of the parents occasionally used a small, almost ignorable, amount of the jelly on their infants.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on time to eczema available for 116/118=98%, assuming censoring at random for 37/118=31% participants who dropped out of the trial prior to 9 months with no eczema outcome recorded prior to drop out. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone censored is assumed to not have eczema by 9 months, HR=0.59 [0.33, 1.07], or if everyone missing is assumed to have eczema by 9 months 0.61, [0.39, 0.97]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Modification of the UKWP criteria used to record eczema up to 32 weeks and blinded assessment. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 79/80=99%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria used by blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context.: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on time to eczema available for 100% (assuming censoring at random for 40/100 participants who dropped out of the trial prior to 2 years with no eczema outcome recorded prior to drop out).  Loss to follow‐up was 40% for eczema at 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all censored before two years are assumed to not have eczema, 0.49 [0.17 to 1.40]. But conclusions do change if all censored before two years are assumed to have eczema, 0.91 [0.52 to 1.57]  by the end of trial follow‐up (point estimate of RR HR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (40% censored before 2 years and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>5/54 (9%) participants are censored prior to 12 months due to loss to follow‐up/eczema status unknown. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to have eczema, HR=1.27, 0.46 to 3.53 (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UK WP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (9% and result varied in sensitivity analysis) but low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Simpson 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Infants were randomized at a 1:1 ratio using random block sizes to either the intervention or control group with a central, Web‐based, computer generated, Internet randomization service." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “Eight (13.3%) parents in the control group reported using emollients in a way that mirrored the intervention (ie, regular generalized application of emollient for reasons other than the treatment of cradle cap, nappy rash, or eczema).” The IPD shows regular use of emollient (≥ 3 days a week) by 50/55 intervention individuals and only 3/53 control participants with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome is missing for 13% of randomised participants. Sensitivity analysis using the IPD reveals findings do not change significantly if everyone missing is assumed to not have eczema  HR 0.48 [0.23 to 0.98] but if all are assumed to have eczema at 3 or 6 months HR = 0.65 [0.36 to 1.15] (point estimate of HR &gt;20% of the complete case estimate).  Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was determined by an investigator. Outcome assessors were blind to treatment allocation. This only failed in 4% of cases. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (13% and results varied in sensitivity analysis), but low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%.  Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, HR=1.46 [1.00 to 2.12] but conclusions change if all missing are  assumed to have eczema, HR=2.20 [1.66 to 2.93] (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK WP +Hanifin and Rajka criteria and blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (10% and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema outcome available for 156/227 randomised = 69% participants. Sensitivity analysis of IPD reveals conclusions change if all missing do not have eczema: 0.63 [0.23, 1.73] or if all missing are assumed to have eczema at 12 or 24 months: 1.60 [1.03 to 2.47] (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on the outcome, but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (31% and results varied in sensitivity analysis) and how outcome reported by unblinded assessors (parents) but low risk of bias for other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.53 Time to onset of eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.54 Subgroup analysis: Time to onset of eczema (&lt; 1‐year follow‐up versus ≥ 1‐year follow‐up)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.54.1 Follow‐up ≥ 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1236/1394 =89% have outcome. Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to have eczema, HR=0.94, 95% 0.79 to 1.12 or when all missing are assumed to have eczema, HR=0.92, 95% CI 0.79 to 1.11. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was parent report of doctor diagnosis of eczema and parents unblinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome missing for 21.5% (not all people with eczema outcome have time of eczema onset). Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing eczema outcome are assumed to not have eczema by 12months HR=1.27 [0.83 to 1.95], or to have eczema onsets by 12 months: HR= 1.16 [0.76 to 1.78]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria and blinded assessor used. Quote: "AD diagnosis was further confirmed blindly" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 79/80=99%.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>UK working party criteria used by blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>McClanahan 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was completed via a computer‐generated randomization list issued by a statistician with block sizes of 10 and concealed from the recruitment coordinator until randomization." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context.: "At 2, 6 and 12 months, the intervention group had 87%, 72.4% and 66.7% high adherence, respectively, vs. 45.2%, 45.8% and 45.5% in the control group, respectively." The control group rates are high but similar to those reported in another study by the same group (e.g. up to ~75 % in Rendell et al. 2011). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on time to eczema available for 100% (assuming censoring at random for 40/100 participants who dropped out of the trial prior to 2 years with no eczema outcome recorded prior to drop out).  Loss to follow‐up was 40% for eczema at 2 years and incident eczema was captured through voluntary contacting of investigators. Sensitivity analysis of IPD reveals conclusions do not change if all censored before two years are assumed to not have eczema, 0.49 [0.17 to 1.40]. But conclusions do change if all censored before two years are assumed to have eczema, 0.91 [0.52 to 1.57]  by the end of trial follow‐up (point estimate of RR HR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>U.K. Working Party Criteria adapted to identify incident cases, some as young as 2 weeks. Some uncertainty about validity of this tool at this age. Incident cases not followed further after first diagnosis. Low risk of bias as this is our pre‐defined preferred tool. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (40% censored before 2 years and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>5/54 (9%) participants are censored prior to 12 months due to loss to follow‐up/eczema status unknown. Sensitivity analysis of IPD reveals conclusions change if all missing are assumed to have eczema, HR=1.27, 0.46 to 3.53 (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "assessor‐blind." UK WP criteria used. Patients were followed up until they had eczema or 12 months or were lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (9% and result varied in sensitivity analysis) but low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by only 1 control participant and 262/599 = 44% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 89.8%.  Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have eczema, HR=1.46 [1.00 to 2.12] but conclusions change if all missing are  assumed to have eczema, HR=2.20 [1.66 to 2.93] (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Used UK WP +Hanifin and Rajka criteria and blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (10% and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Yonezawa 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Randomization was performed individually according to central registration after measuring the skin barrier function at baseline.” Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participant carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to ~75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 63/69 (91%) intervention participants 52/87 (60%) control participants with outcomes recorded). Quote: “The frequency of bathing (mean +/‐ standard deviation [SD], 0.81 +/‐ 0.22 vs 0.99 +/‐ 0.06 times/day, P &lt; 0.001) and soap use was lower (mean +/‐ SD, 0.50 +/‐ 0.09 vs 0.98 +/‐ 0.05 times/ day, P &lt; 0.001), and that of lotion use was higher (1.30 +/‐ 0.67 vs 0.48 +/‐ 0.39 times/day, P &lt; 0.001) in the intervention group than in the control group during the study period.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema outcome available for 156/227 randomised = 69% participants. Sensitivity analysis of IPD reveals conclusions change if all missing do not have eczema: 0.63 [0.23, 1.73] or if all missing are assumed to have eczema at 12 or 24 months: 1.60 [1.03 to 2.47] (point estimate of HR &gt;20% of the complete case estimate). Missingness could have depended on the outcome, but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was collected from parents using a self‐reported questionnaire. Outcome assessors were reporters who were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (31% and results varied in sensitivity analysis) and how outcome reported by unblinded assessors (parents) but low risk of bias for other domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.54.2 Follow‐up &lt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horimukai 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomised trial, no information provided on allocation concealment. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Control rates of skin care in line with those observed in other trials and observational studies (e.g. up to ~75 % in Rendell at al. 2011). Quote: “Because the IRB recommended permitting application of petroleum jelly when the parents thought it necessary, we calculated the amount of these 2 types of moisturizers used by each group based on their diaries. The mean daily amount of emulsion‐type moisturizer used by the intervention group was 7.86 6 4.34 g (0 g for the control group, excluding the 2 infants placed in the wrong group). The mean daily amount of petroleum jelly applied to the control group was 0.101 6 0.286 g (mean frequency of use, 0.235 d/wk). Petroleum jelly (20 g per bottle) was prescribed to all neonates born at the NCCHD, but we had no information about how much was used by the intervention group. Nevertheless, only a few of the parents occasionally used a small, almost ignorable, amount of the jelly on their infants.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on time to eczema available for 116/118=98%, assuming censoring at random for 37/118=31% participants who dropped out of the trial prior to 9 months with no eczema outcome recorded prior to drop out. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone censored is assumed to not have eczema by 9 months, HR=0.59 [0.33, 1.07], or if everyone missing is assumed to have eczema by 9 months 0.61, [0.39, 0.97]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Modification of the UKWP criteria used to record eczema up to 32 weeks and blinded assessment. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Simpson 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Infants were randomized at a 1:1 ratio using random block sizes to either the intervention or control group with a central, Web‐based, computer generated, Internet randomization service." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote “Eight (13.3%) parents in the control group reported using emollients in a way that mirrored the intervention (ie, regular generalized application of emollient for reasons other than the treatment of cradle cap, nappy rash, or eczema).” The IPD shows regular use of emollient (≥ 3 days a week) by 50/55 intervention individuals and only 3/53 control participants with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome is missing for 13% of randomised participants. Sensitivity analysis using the IPD reveals findings do not change significantly if everyone missing is assumed to not have eczema  HR 0.48 [0.23 to 0.98] but if all are assumed to have eczema at 3 or 6 months HR = 0.65 [0.36 to 1.15] (point estimate of HR &gt;20% of the complete case estimate).  Missingness could have depended on outcome, but this is not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eczema was determined by an investigator. Outcome assessors were blind to treatment allocation. This only failed in 4% of cases. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (13% and results varied in sensitivity analysis), but low risk of bias for all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.54 Subgroup analysis: Time to onset of eczema (&lt; 1‐year follow‐up versus ≥ 1‐year follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.55 Parent report of immediate (&lt; 2 hours) reaction to a known common food allergen</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 1171/1394=84%. Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to assumed not to have reaction: RR = 1.24 [0.97 to 1.59] or if everyone missing is assumed to have reaction RR=1.20 [1.02 to 1.40]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation. Low risk of bias for all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>NCT03376243</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. e.g. up to ~75 % in Rendell et al. 2011. The IPD shows daily use of emollient over intervention period by 7/27 (26%) control and 19/22 (86%) intervention participants with eczema outcomes recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data available for 41/54 = 76%.  Zero events observed, therefore results differ in sensitivity analysis. Missingness could depend on outcome but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were reporters who were aware of the allocation.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (24%) and how outcome reporters (parents) were unblinded, but low risk of bias for other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.55 Parent report of immediate (&lt; 2 hours) reaction to a known common food allergen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.59 Allergic sensitisation to common foods or inhalants at 1 to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 988/1394=71%. Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to not have any allergic sensitisation, RR=1.21, 95% CI 0.90 to 1.61, or if everyone missing is assumed to have any allergic sensitisation, RR=1.06, 95% CI 0.94 to 1.21. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 70/80=88% of randomised participants at 12 months. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have allergic sensitisation, 0.68 [0.27 to 1.71] but conclusions change  if all missing the outcome are assumed to have allergic sensitisation, 1.04 [0.53 to 2.01] (point estimate of RR &gt;20% of the complete case estimate).  Missingness could have depended on outcome, but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin prick tests used by blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (12% and result varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.59 Allergic sensitisation to common foods or inhalants at 1 to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.60 Allergic sensitisation to common foods at 1 to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to not have allergic sensitisation to any foods, RR=1.34, 95% 0.92 to 1.96, or if all missing are assumed to have allergic sensitisation to foods, RR=1.08, 95% CI 0.94 to 1.24. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 70/80=88% of randomised participants at 12 months. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have allergic sensitisation to any food inhalant, 0.40 [0.11 to 1.38] but conclusions change  if all missing the outcome are assumed to have allergic sensitisation, 0.89 [0.42 to 1.90] (point estimate of RR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin prick tests used by blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (12% and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Number of participants that were compliant in each arm for allergic sensitisation at 36months ‐ the IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by 0 control participant and 211/343 = 62% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 63.4%. Sensitivity analysis using IPD reveals conclusions do not change significantly if everyone missing is assumed to not have allergic sensitisation to food, RR=0.87, [0.48, 1.59]. Conclusions change if all missing are assumed to have allergic sensitisation to food, RR=1.20 [1.04, 1.39] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study design did not allow for masking of study participants to the interventions. To limit the risk of observer bias, study personnel who did the clinical follow‐up investigations did not have access to the randomisation lists. Furthermore, parents were firmly instructed not to apply any type of emollient bath additives or leave‐on emollients within 24 h before each follow‐up investigation and all clinical assessments and investigations were done and recorded without knowledge of the group allocation." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided and IPD meta‐analysis SAP followed</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to potential bias due to missing outcome data. All other domains classed as low risk of bias. </p> <p> </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.60 Allergic sensitisation to common foods at 1 to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.65 Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Chalmers 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation schedule was created by the CTU using computer‐generated pseudo‐random code with permuted blocks of randomly varying size. The sequence was known only to the programmer until database lock." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies (e.g. up to 75 % in Rendell et al. 2011). Quote: “Of families in the emollient group with complete questionnaire data on adherence at each time point, 466 (88%) of 532 had satisfactory adherence at 3 months, 427 (82%) of 519 at 6 months, and 375 (74%) of 506 at 12 months.” “No emollient was supplied to the control group, but self‐directed use of emollients at least three times per week to most of the body (contamination) occurred in 18% (82 of 457) at 3 months, 17% (62 of 372) at 6 months, and 15% (49 of 324) at 12 months.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sensitivity analysis using the IPD data shows conclusions do not change if all missing are assumed to not have allergic sensitisation to any foods, RR=1.34, 95% 0.92 to 1.96, or if all missing are assumed to have allergic sensitisation to foods, RR=1.08, 95% CI 0.94 to 1.24. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Research nurses doing skin examinations, skin prick testing, food challenges, or making food allergy decisions, and the statistician, were masked to treatment allocation during the study." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Dissanayake 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation performed using minimization at a central location. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Quote: “we did not prohibit the application of moisturizers in the no‐intervention group. As this could mask the effect of the moisturizer used as an intervention, we looked at the effect of any emollient (irrespective of the formal intervention assigned) on the development of AD. We did not observe any difference in incidence between children who received any type of emollient vs. those who did not (data not shown).” “Approximately 80% of the parents/guardians in the emollient groups reported that they applied the emollient at least twice a day. Adjusting for emollient application rate did not lead to a significant difference in the rate of AD development among the groups. The effect of emollient application was also investigated in all babies who received emollient (groups 1 and 3) versus those who did not (groups 2 and 4), but this too did not show any difference in the incidence of AD.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome is available for 458/549 randomised individuals = 83%. Sensitivity analysis using the IPD shows conclusions do not change significantly if all individuals missing allergic sensitisation outcome are assumed to not have allergic sensitisation to food RR=1.19 [0.99, 1.42] or to all have allergic sensitisation to food, RR=1.05 [0.93, 1.20]. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An objective method of measurement used: IgE.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Horimukai 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomised trial, no information provided on allocation concealment. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. Control rates of skin care in line with those observed in other trials and observational studies (e.g. up to ~75 % in Rendell at al. 2011). Quote: “Because the IRB recommended permitting application of petroleum jelly when the parents thought it necessary, we calculated the amount of these 2 types of moisturizers used by each group based on their diaries. The mean daily amount of emulsion‐type moisturizer used by the intervention group was 7.86 6 4.34 g (0 g for the control group, excluding the 2 infants placed in the wrong group). The mean daily amount of petroleum jelly applied to the control group was 0.101 6 0.286 g (mean frequency of use, 0.235 d/wk). Petroleum jelly (20 g per bottle) was prescribed to all neonates born at the NCCHD, but we had no information about how much was used by the intervention group. Nevertheless, only a few of the parents occasionally used a small, almost ignorable, amount of the jelly on their infants.” </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for any allergic sensitisation is available for 92/118 randomised = 78%. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have sensitisation for any food RR=1.00, 95% CI 0.66 to 1.50. If all missing are assumed to have sensitisation for any food RR=0.91, 95% CI 0.70 to 1.17. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome obtained using an objective method of measurement and blinded assessment: IgE levels using a blood test ('DLC chip' ). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk fo bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lowe 2018a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote from trial protocol: "A computer generated random allocation list in blocks of variable length (4‐12) will be used. This list will be held by The RCH Pharmacy Department, which will be independent from the participant recruitment or testing. At all times, the allocation list will be concealed from the study coordinator and the other study investigators, who will manage participant recruitment." Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not possible to blind participants’ carers, but there is no evidence that deviations arised because of the trial context. The control group rates of skin care application were consistent with other trials and observational studies e.g. up to 75 % in Rendell et al. 2011. The IPD shows regular use of emollient (≥ 3 days a week) by 11/36 (31%) control participants and 30/38 (79%) with eczema outcome recorded). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 70/80=88% of randomised participants at 12 months. Sensitivity analysis using the IPD reveals conclusions do not change significantly if everyone missing is assumed to not have allergic sensitisation to any food inhalant, 0.40 [0.11 to 1.38] but conclusions change  if all missing the outcome are assumed to have allergic sensitisation, 0.89 [0.42 to 1.90] (point estimate of RR &gt;20% of the complete case estimate). Missingness could have depended on outcome, but not likely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Skin prick tests used by blinded assessor.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided by investigators and IPD meta‐analysis SAP followed.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to missing data (12% and results varied in sensitivity analysis) but low risk of bias in all other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Skjerven 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: “we used computer‐generated cluster randomisation based on 92 geographical living area blocks as well as eight 3‐month time blocks. All infants born in the same 3‐month period and belonging to the same postal code or city area were allocated to the same intervention group”. Baseline variables by treatment group do not suggest a problem with randomisation, characteristics well balanced (IPD available). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Number of participants that were compliant in each arm for allergic sensitisation at 36months ‐ the IPD shows regular use of emollient (ceridal cream) (≥ 3 days a week averaged over intervention period) by 0 control participant and 211/343 = 62% intervention arm. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome available for 63.4%. Sensitivity analysis using IPD reveals conclusions do not change significantly if everyone missing is assumed to not have allergic sensitisation to food, RR=0.87, [0.48, 1.59]. Conclusions change if all missing are assumed to have allergic sensitisation to food, RR=1.20 [1.04, 1.39] (point estimate of RR &gt;20% of the complete case estimate). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study design did not allow for masking of study participants to the interventions. To limit the risk of observer bias, study personnel who did the clinical follow‐up investigations did not have access to the randomisation lists. Furthermore, parents were firmly instructed not to apply any type of emollient bath additives or leave‐on emollients within 24 h before each follow‐up investigation and all clinical assessments and investigations were done and recorded without knowledge of the group allocation." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Full trial dataset provided and IPD meta‐analysis SAP followed</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to potential bias due to missing outcome data. All other domains classed as low risk of bias. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.65 Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013534.pub3/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013534.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013534-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013534-note-0028">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013534-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013534-note-0023">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013534-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013534-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013534-note-0025">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD013534-note-0026">Română</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013534-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013534\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013534\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013534\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013534\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013534\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013534.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013534.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013534.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013534.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013534.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728778428"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013534.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728778432"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013534.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eccc53a6cf56f',t:'MTc0MDcyODc3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 